annual reportmarch shareholder start imagine dramatically world change virus impact billion people nation measure year dominate uncertaintyyet pandemic help clarify priority reinforce value familiar yard sign fade message resonant covid profound new appreciation gratitude doctor nurse hospital staff serve line care everyday heroism essential worker world critical healthcare infrastructure running expectation company drive positive change behalf everyoneno matter liveare higher alex gorsky serve important reminder chairman chief executive officer central good health collective prosperity security society fundamental level world large essential person broadlybased healthcare company family town nation earth health covid touch directly unique perspective indirectly individual life leave unchanged global health profound pandemicand gain share responsibility lead call understand universal truth safe untileveryone safe soon dna sequence covid virus build time like available role clear early january impossible guess exactly nascent pandemic unfold success johnson johnson invest guarantee johnson apply good science johnson public health threat centuryand question power develop safe effective contribute breadth depth efficient vaccine large company expertise global effort number people world combat covid chairman letter ambitious urgent goal drive forward excellence execution set follow science confidence place patient physician potential vaccine available notforprofit basis customer consumer today result pandemic emergency use superb sustained delivery commitment makeand exception work clock innovative model publicprivate partnership cidcidcidwhile development covid vaccine new height purposedriven collaboration month incredible triumph face success challenge science significant continually affirm commitment safety achievement pharmaceutical business scientific integrity transparency exactly continue outperform industry year officially begin development therapeutic area region process able share positive topline mark consecutive year result phase ensemble clinical trial market adjust operational growthall company singledose covid vaccine keep pipeline submission approval shortly base totality scientific track achieve great patient evidence receive emergency use authorization enrollment clinical trial compare food drug administration receive approval subcutaneous singledose covid vaccine immediately formulation multiple myeloma drug darzalex begin ship dose daratumumab ahead schedule pdufa date new formulation take monumental achievement endure multihour intravenous treatment point pride decade come subcutaneous delivery execute remarkable successful development minute focus educate healthcare covid vaccine practitioner successfully launch incredible accomplishment year product virtual environmentreaffirme like company strong commercial capability thank resilience dedication cid consumer health business meet exceed goal year agile resourcefulness colleague recognize quickly adapt fulfil world johnson increase demand product liketylenol johnson survive listerine million home worldwide record approximately yearoveryear company pivot great growth ecommerce consumer health agility deliver notable team refuse let challenge deter launch ambitious healthy financial performance live mission holistic approach health tumultuous year continue wellnessadvance sustainable innovation invest sustainable transformative packaging provide enhance transparency ingredient product innovation longterm support proactive selfcare encourage new consumer behaviorha welcome period upheaval reminder company accomplish found broad base diversify tackle wide range unmet healthcare solution create stability investor health need increase shareholder dividend consecutive year cid strike testament power worldclass execution see core strength power performance rebound medical device business year one serve covid pandemic cause stakeholder market environment individual delay healthcare treatmentfrom unwavere focus execution innovation routine exam important elective surgery people emergency room visit medical device business continue prioritize patient customer need maintain product reliability chairmans letterand advance innovation quickly identify selexipag injection intravenous use treat urgent need focus effort support pulmonary arterial hypertension darzalex patient train million healthcare faspro treatment newly diagnose professional virtual platform conduct patient light chain amyloidosis live remote case support securing hope receive approval year ponesimod provide personal protective equipment ppe multiple sclerosis ppm treatment bring industry partner schizophrenia development expand coverage emerge site care potentially change live patient effort develop new family year come capability strengthen customer relationship set great cidcidcidour medical device business strong performance progress achieve accelerate key pipeline milestone year cid focus sustainability effort area continue invest innovation believe great impact advance critical program franchise advance health humanity healthcare include expansion company johnson johnson understand hip knee portfolio highgrowth climate health affect human health market segment enhancement industry longstanding commitment leadingtecni family intraocular lense environmental health set new climate goal introduction ofechelon endopath track year staple line reinforcement launch end honor cerenovus stroke solution remain recognized global corporate leader incredibly excite great potential climate action water security award endtoend digital surgery ecosystem alist rating carbon disclosure simultaneously develop differentiate projectthe year row tackle robotic program recently achieve climate change second year row significant milestone thefda clearance work water security velys roboticassiste solution design use attune total knee system lifeenhance innovation industry start unlock thing think speak volume potential benefit robotic digital performance prospect company technologiesand fitting investment innovation midst company help pioneer sterile year uncertainty johnson johnson surgery year ago poise lead invest alltime high billion research way bring differentiate cuttingedge new development million solution stcentury operating room billion acquisition continue fortify pipeline ensure able cidcidcidin consumer health display great agility continue change trajectory human health finding way ensure supply long pandemic year family worldwide essential product highlight science innovation pandemic innovation stop brand launch nearly new cidcidcidvaccine development area product deepen commitment worldclass scientist utilize expertise create inclusive sustainable health pharmaceutical business initiate solution meet need consumer fda file ourbcma cart therapy timely example launch nicorette ciltacabtagene autoleucel ciltacel quickmist smarttrack united kingdom treatment relapse refractory multiple world digitally connect smoking myeloma patient receive cessation option tool develop prior class therapy file approval behavioral scientist connect smoker amivantamab treatment patient support app help track metastatic nonsmall cell lung cancer personalize program epidermal growth factor receptor exon insertion mutation disease progress platinumbase chemotherapy additionally file approval uptravi chairmans letter cid innovation happen cid look possibly ignore laboratory want recognize event summer force usas impactful work supply chain colleague individual company country drive improvement efficiency confront reality systemic racism past year gartner research honor johnson society turmoil street cities johnson number rank america bring light industry supply chain index overdue recognition inequality spot rank simultaneously exacerbate rank healthcare supply chain disproportionate impact covid cite commitment continuous community color improvement put innovation practice particularly response real change happen galvanize covid pandemic moment dialogue require sustain longterm commitment want powered people purpose impact meaningful lasting meeting commitment stakeholder start place recognition racism balance act time stability public health crisis johnson johnson prosperity fierce headwind face choose focus eliminate health inequity deeply people color million race hold beliefs testand deal constant health equity platform launch november disruption feel like fulltime jobim dramatically high mortality rate community incredibly proud employee truly color covid pandemic living credo value face recent example disparity access daunting challenge onceina quality healthcare resultant outcome century pandemic excuse patient family community delay action determination well health johnson johnson reach work include use datum well understand root cause inequality cid pandemic tough day encourage information share effective employee globe work tirelessly train method medical center clinic provide uninterrupted access medicine local level help grassroot leader product use spectrum frontline worker well prepare expertise support healthcare system risk position care lift overwhelmed surge case community hospitalization billion life touch day deliver achieve true diversity clinical trial hire againeven professional office boardroom time effort personal life change way demand investment day bring new opportunity unparalleled resilience creativity inclusive know decade experience science technology innovation cid johnson johnson family company depend collaboration drive diversity johnson johnson foundation rally idea approach opinion individual support healthcare professional including well company well citizen million initiative provide doctor world community nurse work line pandemic ppe mental health resource critical form support select number johnson johnson employee serve strong nearly license healthcare professional rank take advantage company newly announce benefit week pay leave volunteer hardesthit hospital community health center chairman letterin closing time shift old saying adversity build focus healthcare away character reveal question effectiveness cost covid pandemic show accomplish follow moral compass sustainability resiliency value credo witness unprecedented level collaboration public idea company right customer patient healthcare professional private partnership past employee shareholder good monthslet use new model world pretty revolutionary concept supercharge effort combat general robert wood johnson value word doubt idea urgent public health challenge fight health humanity hard work resonant require turn collective desire address disparity care show world plague underserved community look like lead purposeespecially measurable meaningful action moment great crisis despite disruption navigate year confident forge onward fill optimism future industry company lesson learn covid ultimately accelerate progress healthier equitable future alland johnson johnson moment ensure continue play pivotal role achieve covid pandemic consequential moment world history wakeup critical profoundly grateful opportunity lead company exceptional employee importance public health national economic societal sincerely security action consider postpandemic future opportunity decide bring alex gorsky chairman chief executive officer new world johnson johnson leave owe life livelihood ravage virus enormous personal sacrifice great good choose wisely note forwardlooke statement letter contain forwardlooke statement relate thing future operate financial performance product development market position business strategy reader caution rely statement base current expectation future event important information statement include risk uncertainty factor cause actual result vary materially assumption expectation projection express forwardlooke statement reader review enclose annual report fiscal year end january include section caption cautionary note forward look statement item risk factor johnson johnson undertake update forwardlooke statement result new information future event development chairmans letter united states securities exchange commission washington annual report pursuant section security exchange act forthefiscalyearendedjanuary transition report pursuant section security exchange act transition period commissionfilenumber johnson johnson exactnameofregistrantasspecifiedinitscharter newjersey stateofincorporation irsemployeridentificationno onejohnsonjohnsonplaza newbrunswicknewjersey addressofprincipalexecutiveoffice zipcode onejohnsonjohnsonplaza newbrunswicknewjersey addressofprincipalexecutiveoffices registrantstelephonenumberincludingareacode securitiesregisteredpursuanttosectionboftheact titleofeachclass tradingsymbol nameofeachexchangeonwhichregistered commonstockparvalue jnj newyorkstockexchange notesduejanuary jnj newyorkstockexchange notesduemay jnjc newyorkstockexchange notesduenovember jnjbp newyorkstockexchange notesduenovember jnj newyorkstockexchange notesduemay jnj newyorkstockexchange indicatebycheckmarkiftheregistrantisawellknownseasonedissuerasdefinedinruleofthesecurities act yes indicatebycheckmarkiftheregistrantisnotrequiredtofilereportspursuanttosectionorsectiondoftheexchange act yes indicatebycheckmarkwhethertheregistranthasfiledallreportsrequiredtobefiledbysectionordoftheexchange actduringtheprecedingmonthsorforsuchshorterperiodthattheregistrantwasrequiredtofilesuchreportsandhas beensubjecttosuchfilingrequirementsforthepastdays yes indicatebycheckmarkwhethertheregistranthassubmittedelectronicallyeveryinteractivedatafilerequiredtobesubmitte pursuanttoruleofregulationstduringtheprecedingmonthsorforsuchshorterperiodthattheregistrantwas requiredtosubmitsuchfile yes indicatebycheckmarkwhethertheregistrantisalargeacceleratedfileranacceleratedfileranonacceleratedfilerasmaller reportingcompanyoremerginggrowthcompanyseethedefinitionsoflargeacceleratedfileracceleratedfilersmaller reportingcompanyandemerginggrowthcompanyinruleboftheexchangeact largeacceleratedfiler acceleratedfiler nonacceleratedfiler smallerreportingcompany emerginggrowthcompany ifanemerginggrowthcompanyindicatebycheckmarkiftheregistranthaselectednottousetheextendedtransitionperiod forcomplyingwithanyneworrevisedfinancialaccountingstandardsprovidedpursuanttosectionaoftheexchange act indicatebycheckmarkwhethertheregistranthasfiledareportonandattestationtoitsmanagementsassessmentofthe effectivenessofitsinternalcontroloverfinancialreportingundersectionbofthesarbanesoxleyactusc bbytheregisteredpublicaccountingfirmthatpreparedorissueditsauditreport yes indicatebycheckmarkwhethertheregistrantisashellcompanyasdefinedinruleboftheexchange act yes theaggregatemarketvalueofthecommonstockheldbynonaffiliatescomputedbyreferencetothepriceatwhichthe commonstockwaslastsoldasofthelastbusinessdayoftheregistrantsmostrecentlycompletedsecondfiscalquarter wasapproximatelybillion onfebruarythereweresharesofcommonstockoutstanding documentsincorporatedbyreference partsiandiii portionsofregistrantsproxystatementforitsannualmeetingofshareholdersfiledwithin daysafterthecloseoftheregistrantsfiscalyeartheproxystatementareincorporatedby referencetothisreportonformkthisreportitem parti business general segmentsofbusiness geographicareas rawmaterial patent trademark seasonality competition environment regulation employeesandhumancapitalmanagement availableinformation riskfactor unresolvedstaffcomment property legalproceeding minesafetydisclosure executiveofficersoftheregistrant partii marketforregistrantscommonequityrelatedstockholdermattersandissuerpurchasesof equitysecuritie reserve managementsdiscussionandanalysisofresultsofoperationsandfinancialcondition quantitativeandqualitativedisclosuresaboutmarketrisk financialstatementsandsupplementarydata changesinanddisagreementswithaccountantsonaccountingandfinancialdisclosure controlsandprocedures otherinformation partiii directorsexecutiveofficersandcorporategovernance executivecompensation securityownershipofcertainbeneficialownersandmanagementandrelatedstockholder matter certainrelationshipsandrelatedtransactionsanddirectorindependence principalaccountantfeesandservice partiv exhibitsandfinancialstatementschedule formksummary signature exhibitindex cautionary note forwardlooke statement thisannualreportonformkandjohnsonjohnsonsotherpubliclyavailabledocumentscontainforwardlooke statementswithinthemeaningofthesafeharborprovisionsoftheusprivatesecuritieslitigationreformactof managementandrepresentativesofjohnsonjohnsonanditssubsidiariesthecompanyalsomayfromtimeto timemakeforwardlookingstatementsforwardlookingstatementsdonotrelatestrictlytohistoricalorcurrentfactsand reflectmanagementsassumptionsviewsplansobjectivesandprojectionsaboutthefutureforwardlookingstatement maybeidentifiedbytheuseofwordssuchasplansexpectswillanticipatesestimatesandotherwordsof similarmeaninginconjunctionwithamongotherthingsdiscussionsoffutureoperationsexpectedoperatingresultsand financialperformanceimpactofplannedacquisitionsanddispositionsthecompanysstrategyforgrowthproduct developmentregulatoryapprovalsmarketpositionandexpenditure becauseforwardlookingstatementsarebasedoncurrentbeliefsexpectationsandassumptionsregardingfutureevent theyaresubjecttouncertaintiesrisksandchangesthataredifficulttopredictandmanyofwhichareoutsideofthe companyscontrolinvestorsshouldrealizethatifunderlyingassumptionsproveinaccurateorknownorunknownrisksor uncertaintiesmaterializethecompanysactualresultsandfinancialconditioncouldvarymateriallyfromexpectationsand projectionsexpressedorimpliedinitsforwardlookingstatementsinvestorsarethereforecautionednottorelyonthese forwardlookingstatementsrisksanduncertaintiesincludebutarenotlimitedto risksrelatedtoproductdevelopmentmarketsuccessandcompetition challengesanduncertaintiesinherentininnovationanddevelopmentofnewandimprovedproductsandtechnologie onwhichthecompanyscontinuedgrowthandsuccessdependincludinguncertaintyofclinicaloutcomesadditional analysisofexistingclinicaldataobtainingregulatoryapprovalshealthplancoverageandcustomeraccessandinitial andcontinuedcommercialsuccess challengestothecompanysabilitytoobtainandprotectadequatepatentandotherintellectualpropertyrightsfornew andexistingproductsandtechnologiesintheunitedstatesandotherimportantmarket theimpactofpatentexpirationstypicallyfollowedbytheintroductionofcompetingbiosimilarsandgenericsand resultingrevenueandmarketsharelosse increasinglyaggressiveandfrequentchallengestothecompanyspatentsbycompetitorsandothersseekingtolaunch competinggenericbiosimilarorotherproductsandincreasedreceptivityofcourtstheunitedstatespatentand trademarkofficeandotherdecisionmakerstosuchchallengespotentiallyresultinginlossofmarketexclusivityand rapiddeclineinsalesfortherelevantproductsoonerthanexpecte competitioninresearchanddevelopmentofnewandimprovedproductsprocessesandtechnologieswhichcanresult inproductandprocessobsolescence competitiontoreachagreementwiththirdpartiesforcollaborationlicensingdevelopmentandmarketingagreement forproductsandtechnologie competitionbasedoncosteffectivenessproductperformancetechnologicaladvancesandpatentsattainedby competitorsand allegationsthatthecompanysproductsinfringethepatentsandotherintellectualpropertyrightsofthirdpartieswhich couldadverselyaffectthecompanysabilitytoselltheproductsinquestionandrequirethepaymentofmoneydamage andfutureroyaltie risksrelatedtoproductliabilitylitigationandregulatoryactivity productefficacyorsafetyconcernswhetherornotbasedonscientificevidencepotentiallyresultinginproduct withdrawalsrecallsregulatoryactiononthepartoftheunitedstatesfoodanddrugadministrationorinternational counterpartsdecliningsalesreputationaldamageincreasedlitigationexpenseandsharepriceimpact impactincludingdecliningsalesandreputationaldamageofsignificantlitigationorgovernmentactionadversetothe companyincludingproductliabilityclaimsandallegationsrelatedtopharmaceuticalmarketingpracticesand contractingstrategie impactofanadversejudgmentorsettlementandtheadequacyofreservesrelatedtolegalproceedingsinclude patentlitigationproductliabilitypersonalinjuryclaimssecuritiesclassactionsgovernmentinvestigationsemployment andotherlegalproceeding increasedscrutinyofthehealthcareindustrybygovernmentagenciesandstateattorneysgeneralresultingin investigationsandprosecutionswhichcarrytheriskofsignificantcivilandcriminalpenaltiesincludingbutnotlimite todebarmentfromgovernmentbusiness johnsonjohnsonannualreport failuretomeetcomplianceobligationsinthemcneilppcincconsentdecreeoranyothercomplianceagreement withgovernmentsorgovernmentagencieswhichcouldresultinsignificantsanction potentialchangestoapplicablelawsandregulationsaffectingunitedstatesandinternationaloperationsinclude relatingtoapprovalofnewproductslicensingandpatentrightssalesandpromotionofhealthcareproductsaccess toandreimbursementandpricingforhealthcareproductsandservicesenvironmentalprotectionandsourcingofraw material compliancewithlocalregulationsandlawsthatmayrestrictthecompanysabilitytomanufactureorsellitsproductsin relevantmarketsincludingrequirementstocomplywithmedicaldevicereportingregulationsandotherrequirement suchastheeuropeanunionsmedicaldevicesregulation changesindomesticandinternationaltaxlawsandregulationsincludingchangesrelatedtothetaxcutsandjobsact intheunitedstatesincreasingauditscrutinybytaxauthoritiesaroundtheworldandexposurestoadditionaltax liabilitiespotentiallyinexcessofexistingreservesand issuanceofneworrevisedaccountingstandardsbythefinancialaccountingstandardsboardandregulationsbythe securitiesandexchangecommission risksrelatedtothecompanysstrategicinitiativesandhealthcaremarkettrend pricingpressuresresultingfromtrendstowardhealthcarecostcontainmentincludingthecontinuedconsolidation amonghealthcareprovidersandothermarketparticipantstrendstowardmanagedcaretheshifttowardgovernment increasinglybecomingtheprimarypayersofhealthcareexpensessignificantnewentrantstothehealthcaremarket seekingtoreducecostsandgovernmentpressureoncompaniestovoluntarilyreducecostsandpriceincrease restrictedspendingpatternsofindividualinstitutionalandgovernmentalpurchasersofhealthcareproductsand servicesduetoeconomichardshipandbudgetaryconstraint challengestothecompanysabilitytorealizeitsstrategyforgrowthincludingthroughexternallysourcedinnovation suchasdevelopmentcollaborationsstrategicacquisitionslicensingandmarketingagreementsandthepotential heightenedcostsofanysuchexternalarrangementsduetocompetitivepressure thepotentialthattheexpectedstrategicbenefitsandopportunitiesfromanyplannedorcompletedacquisitionor divestiturebythecompanymaynotberealizedormaytakelongertorealizethanexpectedand thepotentialthattheexpectedbenefitsandopportunitiesrelatedtopastandongoingrestructuringactionsmaynotbe realizedormaytakelongertorealizethanexpecte risksrelatedtoeconomicconditionsfinancialmarketsandoperatinginternationally therisksassociatedwithglobaloperationsonthecompanyanditscustomersandsuppliersincludingforeign governmentsincountriesinwhichthecompanyoperate impactofinflationandfluctuationsininterestratesandcurrencyexchangeratesandthepotentialeffectofsuch fluctuationsonrevenuesexpensesandresultingmargin potentialchangesinexportimportandtradelawsregulationsandpoliciesoftheunitedstatesandothercountrie includinganyincreasedtraderestrictionsortariffsandpotentialdrugreimportationlegislation theimpactoninternationaloperationsfromfinancialinstabilityininternationaleconomiessovereignriskpossible impositionofgovernmentalcontrolsandrestrictiveeconomicpoliciesandunstableinternationalgovernmentsandlegal system theimpactofglobalpublichealthcrisesandpandemicsincludingtheoutbreakofthenovelcoronaviruscovid pandemic changestoglobalclimateextremeweatherandnaturaldisastersthatcouldaffectdemandforthecompanysproduct andservicescausedisruptionsinmanufacturinganddistributionnetworksaltertheavailabilityofgoodsandservice withinthesupplychainandaffecttheoveralldesignandintegrityofthecompanysproductsandoperationsand theimpactofarmedconflictsandterroristattacksintheunitedstatesandotherpartsoftheworldincludingsocialand economicdisruptionsandinstabilityoffinancialandothermarket risksrelatedtosupplychainandoperation difficultiesanddelaysinmanufacturinginternallythroughthirdpartyprovidersorotherwisewithinthesupplychainthat mayleadtovoluntaryorinvoluntarybusinessinterruptionsorshutdownsproductshortageswithdrawalsor suspensionsofproductsfromthemarketandpotentialregulatoryaction interruptionsandbreachesofthecompanysinformationtechnologysystemsorthoseofthecompanysvendor whichcouldresultinreputationalcompetitiveoperationalorotherbusinessharmaswellasfinancialcostsand regulatoryaction johnsonjohnsonannualreport relianceonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexandsubjecttoincreasing regulatoryrequirementsthatmayadverselyaffectsupplysourcingandpricingofmaterialsusedinthecompany productsand thepotentialthattheexpectedbenefitsandopportunitiesrelatedtorestructuringactionscontemplatedfortheglobal supplychainincludingthecompanystransactionwithjabilmaynotberealizedormaytakelongertorealizethan expectedincludingduetoanyrequiredapprovalsfromapplicableregulatoryauthoritiesdisruptionsassociatedwiththe announcedglobalsupplychainactionsmayadverselyaffectsupplyandsourcingofmaterialsusedinthecompanys products investorsalsoshouldcarefullyreadtheriskfactorsdescribedinitemaofthisannualreportonformkfora descriptionofcertainrisksthatcouldamongotherthingscausethecompanysactualresultstodiffermateriallyfrom thoseexpressedinitsforwardlookingstatementsinvestorsshouldunderstandthatitisnotpossibletopredictoridentify allsuchfactorsandshouldnotconsidertherisksdescribedaboveandinitematobeacompletestatementofall potentialrisksanduncertaintiesthecompanydoesnotundertaketopubliclyupdateanyforwardlookingstatementthat maybemadefromtimetotimewhetherasaresultofnewinformationorfutureeventsordevelopment johnsonjohnsonannualreport item business general johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldjohnsonjohnson isaholdingcompanywithoperatingcompaniesconductingbusinessinvirtuallyallcountriesoftheworldthecompanys primaryfocusisproductsrelatedtohumanhealthandwellbeingjohnsonjohnsonwasincorporatedinthestateof newjerseyin theexecutivecommitteeofjohnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategic operationsandallocationoftheresourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesofthe companysthreebusinesssegmentsconsumerhealthpreviouslyreferredtoasconsumerpharmaceuticaland medicaldeviceswithinthestrategicparametersprovidedbythecommitteeseniormanagementgroupsatusand internationaloperatingcompaniesareeachresponsiblefortheirownstrategicplansandthedaytodayoperationsof thosecompanieseachsubsidiarywithinthebusinesssegmentsiswithlimitedexceptionsmanagedbyresidentsofthe countrywherelocate segment business thecompanyisorganizedintothreebusinesssegmentsconsumerhealthpharmaceuticalandmedicaldevice additionalinformationrequiredbythisitemisincorporatedhereinbyreferencetothenarrativeandtabulardescriptionsof segmentsandoperatingresultsunderitemmanagementsdiscussionandanalysisofresultsofoperationsand financialconditionofthisreportandnotesegmentsofbusinessandgeographicareasofthenotesto consolidatedfinancialstatementsincludedinitemofthisreport consumerhealth theconsumerhealthsegmentincludesabroadrangeofproductsfocusedonpersonalhealthcareusedintheskin healthbeautyoverthecountermedicinesbabycareoralcarewomenshealthandwoundcaremarketsmajorbrandsin skinhealthbeautyincludetheaveenocleancleardrcilaboneutrogenaandogxproduct linesoverthecounterotcmedicinesincludethebroadfamilyoftylenolacetaminophenproductssudafed coldfluandallergyproductsbenadrylandzyrtecallergyproductsmotrinibibuprofenproduct nicorettesmokingcessationproductsoutsidetheuszarbeesnaturalsandthepepcidlineofacidreflux productsbabycareincludesthejohnsonsandaveenobabylineofproductsoralcareincludesthe listerineproductlinemajorbrandsinwomenshealthoutsideofnorthamericaarestayfreeandcarefree sanitarypadsandobtamponbrandswoundcarebrandsincludethebandaidbrandadhesivebandagesand neosporinfirstaidproductlinestheseproductsaremarketedtothegeneralpublicandsoldonlineecommerce andtoretailoutletsanddistributorsthroughouttheworld pharmaceutical thepharmaceuticalsegmentisfocusedonsixtherapeuticareasimmunologyegrheumatoidarthritisinflammatory boweldiseaseandpsoriasisinfectiousdiseaseseghivaidsneuroscienceegmooddisorder neurodegenerativedisordersandschizophreniaoncologyegprostatecancerandhematologicmalignancie cardiovascularandmetabolismegthrombosisanddiabetesandpulmonaryhypertensionegpulmonaryarterial hypertensionmedicinesinthissegmentaredistributeddirectlytoretailerswholesalershospitalsandhealthcare professionalsforprescriptionusekeyproductsinthepharmaceuticalsegmentincluderemicadeinfliximaba treatmentforanumberofimmunemediatedinflammatorydiseasessimponigolimumabasubcutaneoustreatment foradultswithmoderatetosevererheumatoidarthritisactivepsoriaticarthritisactiveankylosingspondylitisand moderatelyactivetoseverelyactiveulcerativecolitissimponiariagolimumabanintravenoustreatmentforadult withmoderatetosevererheumatoidarthritisactivepsoriaticarthritisandactiveankylosingspondylitisstelara ustekinumabatreatmentforadultsandchildrenwithmoderatetosevereplaquepsoriasisforadultswithactivepsoriatic arthritisforadultswithmoderatelytoseverelyactivecrohnsdiseaseandtreatmentofmoderatelytoseverelyactive johnsonjohnsonannualreport ulcerativecolitistremfyaguselkumabatreatmentforadultswithmoderatetosevereplaquepsoriasisedurant rilpivirineprezistadarunavirandprezcobixrezolstadarunavircobicistatantiretroviralmedicinesforthe treatmentofhumanimmunodeficiencyvirushivincombinationwithotherantiretroviralproductsandsymtuza darunavircobicistatemtricitabinetenofoviralafenamideaoncedailysingletabletregimenforthetreatmentofhiv concertamethylphenidatehclextendedreleasetabletsciiatreatmentforattentiondeficithyperactivitydisorder invegasustennaxeplionpaliperidonepalmitateforthetreatmentofschizophreniaandschizoaffectivedisorder inadultsinvegatrinzatrevictapaliperidonepalmitateforthetreatmentofschizophreniainpatientsafterthey havebeenadequatelytreatedwithinvegasustennaforatleastfourmonthsrisperdalconstarisperidone longactinginjectionforthetreatmentofschizophreniaandthemaintenancetreatmentofbipolardisorderinadults zytigaabirateroneacetateatreatmentformetastaticcastrationresistantprostatecancercrpcandmetastatic highriskcastrationsensitiveprostatecancerimbruvicaibrutinibatreatmentforcertainbcellmalignanciesor bloodcancerschronicgraftversushostdiseaseandwaldenstrmsmacroglobulinemiadarzalexdaratumumaba treatmentforrelapsedrefractorymultiplemyelomaerleadaapalutamideanextgenerationandrogenreceptor inhibitorforthetreatmentofpatientswithprostatecancervelcadebortezomibatreatmentformultiplemyeloma mantlecelllymphomaprocriteprexepoetinalfaatreatmentforchemotherapyinducedanemiaandpatient withchronickidneydiseasexareltorivaroxabananoralanticoagulantforthepreventionofdeepveinthrombosis dvtwhichmayleadtopulmonaryembolismpeinpatientsundergoinghiporkneereplacementsurgerytoreducethe riskofstrokeandsystemicembolisminpatientswithnonvalvularatrialfibrillationandforthetreatmentandreductionof riskofrecurrenceofdvtandpeinvokanacanagliflozinforthetreatmentofadultswithtypediabetes invokametvokanametcanagliflozinmetforminhclacombinationtherapyoffixeddosesofcanagliflozinand metforminhydrochlorideforthetreatmentofadultswithtypediabetesandinvokametxrcanagliflozinmetformin hydrochlorideextendedreleaseaoncedailyfixeddosecombinationtherapyofcanagliflozinandmetformin hydrochlorideextendedreleaseforthetreatmentofadultswithtypediabetesopsumitmacitentanasmonotherapy orincombinationindicatedforthelongtermtreatmentofpulmonaryarterialhypertensionpahuptraviselexipag theonlyapprovedoralselectiveipreceptoragonisttargetingaprostacyclinpathwayinpahmanyofthesemedicines weredevelopedincollaborationwithstrategicpartnersorarelicensedfromothercompaniesandmaintainactivelifecycle developmentprogram medicaldevice themedicaldevicessegmentincludesabroadrangeofproductsusedintheinterventionalsolutionsorthopaedic surgeryandvisionfieldsmedicaldevicesininterventionalsolutionsincludeelectrophysiologyproductsbiosense webstertotreatcardiovasculardiseasesneurovascularcarecerenovusthattreatshemorrhagicandischemicstroke theorthopaedicsportfoliodepuysynthesiscomprisedofproductsinsupportofhipskneestraumaandspine sportsotherthesurgeryportfoliosethiconincludeadvancedandgeneralsurgeryofferingssolutionsthatfocuson breastaestheticsmentorandearnoseandthroatacclarentproceduresandjohnsonjohnsonvisionproduct suchasacuvuebranddisposablecontactlensesandophthalmicproductsrelatedtocataractandlaserrefractive surgerytheseproductsaredistributedtowholesalershospitalsandretailersandusedpredominantlyintheprofessional fieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinic geographic area johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldthecompany conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand wellbeing theproductsmadeandsoldintheinternationalbusinessincludemanyofthosedescribedaboveundersegmentsof businessconsumerhealthpharmaceuticalandmedicaldeviceshowevertheprincipalmarketsproduct andmethodsofdistributionintheinternationalbusinessvarywiththecountryandtheculturetheproductssoldin internationalbusinessincludethosedevelopedintheusandbysubsidiariesabroad investmentsandactivitiesinsomecountriesoutsidetheusaresubjecttohigherrisksthancomparableusactivitie becausetheinvestmentandcommercialclimatemaybeinfluencedbyfinancialinstabilityininternationaleconomie restrictiveeconomicpoliciesandpoliticalandlegalsystemuncertaintie johnsonjohnsonannualreportraw material rawmaterialsessentialtothecompanysbusinessaregenerallyreadilyavailablefrommultiplesourceswherethereare exceptionsthetemporaryunavailabilityofthoserawmaterialswouldnotlikelyhaveamaterialadverseeffectonthe financialresultsofthecompany patent thecompanyssubsidiarieshavemadeapracticeofobtainingpatentprotectionontheirproductsandprocesseswhere possibletheyownorarelicensedunderasignificantnumberofpatentsintheusandothercountriesrelatingtotheir productsproductusesformulationsandmanufacturingprocesseswhichintheaggregatearebelievedtobeofmaterial importancetothecompanyintheoperationofitsbusinessesthecompanyssubsidiariesfacepatentchallengesfrom thirdpartiesincludingchallengesseekingtomanufactureandmarketgenericandbiosimilarversionsofthecompanys keypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductssignificantlegal proceedingsandclaimsinvolvingthecompanyspatentandotherintellectualpropertyaredescribedinnotelegal proceedingsintellectualpropertyofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport salesofthecompanyslargestproductstelaraustekinumabaccountedforapproximatelyofthecompany totalrevenuesforfiscalaccordinglythepatentsrelatedtothisproductarebelievedtobematerialtothecompany janssenbiotechincawhollyownedsubsidiaryofjohnsonjohnsonownspatentsspecificallyrelatedtostelara thelatestexpiringunitedstatespatentexpiresinthelatestexpiringeuropeanpatentexpiresin salesofthecompanyssecondlargestproductdarzalexdaratumumabanddarzalexfasprodaratumumab andhyaluronidasefihjaccountedforapproximatelyofthecompanystotalrevenuesforfiscal accordinglythepatentsrelatedtothisproductarebelievedtobematerialtothecompanygenmabasownspatent relatedtodarzalexandjanssenbiotechinchasanexclusivelicensetothosepatentsthelatestexpiringlicense unitedstatespatentexpiresinthelatestexpiringlicensedeuropeanpatentexpiresinjanssenbiotechinc ownsaseparatepatentportfoliorelatedtodarzalexfaspro salesofthecompanysthirdlargestproductimbruvicaibrutinibaccountedforapproximatelyofthe companystotalrevenuesforfiscalaccordinglypatentsrelatedtothisproductarebelievedtobematerialtothe companypharmacyclicsllcanabbviecompanyownsthepatentsrelatedtoimbruvicaandjanssenbiotechinc hasanexclusivelicensetothosepatentsthepharmacyclicspatentsandtheirexpirationdatesarelistedintheapproved drugproductswiththerapeuticequivalenceevaluationsorangebookpharmacyclicsllcandjanssenbiotechinc haveenteredintoconfidentialsettlementagreementswithcertaingenericcompaniesgrantinglicensestomarkettheir genericibrutinibproductsintheunitedstatesbeforetheexpirationofcertainpatent trademark thecompanyssubsidiarieshavemadeapracticeofsellingtheirproductsundertrademarksandofobtainingprotection forthesetrademarksbyallavailablemeansthesetrademarksareprotectedbyregistrationintheusandothercountrie wheresuchproductsaremarketedthecompanyconsidersthesetrademarksintheaggregatetobeofmaterial importanceintheoperationofitsbusinesse seasonality worldwidesalesdonotreflectanysignificantdegreeofseasonalityhoweverspendinghasbeenheavierinthefourth quarterofeachyearthaninotherquartersthisreflectsincreasedspendingdecisionsprincipallyforadvertisingand researchanddevelopmentactivity competition inalloftheirproductlinesthecompanyssubsidiariescompetewithcompaniesbothlocallyandgloballycompetition existsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolvedcompetitionin researchbothinternallyandexternallysourcedinvolvingthedevelopmentandtheimprovementofnewandexiste productsandprocessesisparticularlysignificantthedevelopmentofnewandinnovativeproductsaswellasprotecting theunderlyingintellectualpropertyofthecompanysproductportfolioisimportanttothecompanyssuccessinallarea ofitsbusinessthecompetitiveenvironmentrequiressubstantialinvestmentsincontinuingresearchinadditionthe developmentandmaintenanceofcustomerdemandforthecompanysconsumerproductsinvolvesignificant expendituresforadvertisingandpromotion johnsonjohnsonannualreport environment thecompanyissubjecttoavarietyofusandinternationalenvironmentalprotectionmeasuresthecompanybelieve thatitsoperationscomplyinallmaterialrespectswithapplicableenvironmentallawsandregulationsthecompanys compliancewiththeserequirementsdidnotchangeduringthepastyearandisnotexpectedtohaveamaterialeffect uponitscapitalexpenditurescashflowsearningsorcompetitiveposition regulation thecompanysbusinessesaresubjecttovaryingdegreesofgovernmentalregulationinthecountriesinwhichoperation areconductedandthegeneraltrendistowardincreasinglystringentregulationandenforcementthecompanyissubject tocostlyandcomplexusandforeignlawsandgovernmentalregulationsandanyadverseregulatoryactionmay materiallyadverselyaffectthecompanysfinancialconditionandbusinessoperationsintheusthedrugdeviceand cosmeticindustrieshavelongbeensubjecttoregulationbyvariousfederalandstateagenciesprimarilyastoproduct safetyefficacymanufacturingadvertisinglabelingandsafetyreportingtheexerciseofbroadregulatorypowersbythe usfoodanddrugadministrationtheusfdacontinuestoresultinincreasesintheamountsoftestingand documentationrequiredforusfdaapprovalofnewdrugsanddevicesandacorrespondingincreaseintheexpenseof productintroductionsimilartrendsarealsoevidentinmajormarketsoutsideoftheusthenewmedicaldevice regulatoryframeworkandthenewprivacyregulationsineuropeandinothercountriesareexamplesofsuchincrease regulation theregulatoryagenciesunderwhosepurviewthecompanyoperateshaveadministrativepowersthatmaysubjectitto actionssuchasproductwithdrawalsrecallsseizureofproductsandothercivilandcriminalsanctionsinsomecasesthe companyssubsidiariesmaydeemitadvisabletoinitiateproductrecall theusfdaandregulatoryagenciesaroundtheglobearealsoincreasingtheirenforcementactivitiesiftheusfda weretoconcludethatwearenotincompliancewithapplicablelawsorregulationsorthatanyofourdrugsormedical devicesareineffectiveorposeanunreasonablehealthrisktheusfdacouldbansuchproductsdetainorseize adulteratedormisbrandedproductsorderarecallrepairreplacementorrefundofsuchproductsrefusetogrant pendingapplicationsformarketingauthorizationorrequirecertificatesofforeigngovernmentsforexportsandorrequire ustonotifyhealthprofessionalsandothersthattheproductspresentunreasonablerisksofsubstantialharmtothepublic healththeusfdamayalsoassesscivilorcriminalpenaltiesagainstusourofficersoremployeesandimpose operatingrestrictionsonacompanywidebasisorenjoinandorrestraincertainconductresultinginviolationsof applicablelawtheusfdamayalsorecommendprosecutiontotheusdepartmentofjusticeanyadverseregulatory actiondependingonitsmagnitudemayrestrictusfromeffectivelymarketingandsellingourproductsandlimitourability toobtainfutureclearancesorapprovalsandcouldresultinasubstantialmodificationtoourbusinesspracticesand operationsequivalentenforcementmechanismsexistindifferentcountriesinwhichweconductbusiness thecostsofhumanhealthcarehavebeenandcontinuetobeasubjectofstudyinvestigationandregulationby governmentalagenciesandlegislativebodiesaroundtheworldintheusattentionhasbeenfocusedbystate regulatoryagenciesandcongressondrugpricesandprofitsandprogramsthatencouragedoctorstowriteprescription forparticulardrugsortorecommenduseorpurchaseparticularmedicaldeviceslawsandregulationshavebeen enactedtorequireadherencetostrictcompliancestandardsandpreventfraudandabuseinthehealthcareindustrythere isincreasedfocusoninteractionsandfinancialrelationshipsbetweenhealthcarecompaniesandhealthcareprovider varioustransparencylawsandregulationsrequiredisclosuresofpaymentsandothertransfersofvaluemadetophysician andteachinghospitalsandbeginningwithdisclosuresintocertainnonphysicianpractitionersfederalandforeign lawsgoverninginternationalbusinesspracticesrequirestrictcompliancewithantibriberystandardsandcertain prohibitionswithrespecttopaymentstoanyforeigngovernmentofficialpayershavebecomeamorepotentforceinthe marketplaceandincreasedattentionisbeingpaidtodrugandmedicaldevicepricingappropriatedrugandmedical deviceutilizationandthequalityandcostsofhealthcaregenerally usgovernmentagenciescontinueeffortstorepealmodifyorinvalidateprovisionsofthepatientprotectionand affordablecareacttheacawhichpassedinforexamplefederallegislationrepealedtheacasindividual mandatetaxpenaltyaswellasthetaxongenerousemployersponsoredhealthcareplansthecenterformedicare medicaidservicescmsbeganpermittingstatestoimposeworkrequirementsonpersonscoveredbymedicaid expansionplanscertainfederalsubsidiestoinsurershaveendedandcertainshortterminsuranceplansnotofferingthe fullarrayofacabenefitshavebeenallowedtoextendindurationsomeofthesechangesarebeingchallengedinus courtsandsotheirlongtermimpactremainsuncertaintheacahasalsobeensubjecttojudicialchallengeinnovember theussupremecourtheardargumentintexasvazarwhichchallengestheconstitutionalityoftheaca pendingresolutionofthelitigationalloftheacabuttheindividualmandatetobuyhealthinsuranceremainsineffectthe johnsonjohnsonannualreportusgovernmentalsocontinuestoproposeandimplementchangestothemedicarepartdbenefitincludingthesizeof manufacturerdiscountsinthecoveragegapandcatastrophicphasesofthebenefitthereareanumberofadditionalbill pendingincongressandhealthcarereformproposalsatthestatelevelthatwouldaffectdrugpricinginthemedicareand medicaidprogramsthischangingfederallandscapehasbothpositiveandnegativeimpactsontheushealthcare industrywithmuchremaininguncertainastohowvariousprovisionsoffederallawandpotentialmodificationorrepealof theselawswillultimatelyaffecttheindustry inadditionbusinesspracticesinthehealthcareindustryhavecomeunderincreasedscrutinyparticularlyintheusby governmentagenciesandstateattorneysgeneralandresultinginvestigationsandprosecutionscarrytheriskofsignificant civilandcriminalpenaltie furtherthecompanyreliesonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexare subjecttoincreasingregulatoryrequirementsandmaybefacedwithunexpectedchangessuchasthoseresultingfrom thecovidpandemicandbrexitthatmayaffectsourcingsupplyandpricingofmaterialsusedinthecompany productstheseprocessesalsoaresubjecttocomplexandlengthyregulatoryapproval theglobalregulatorylandscapeisalsosubjecttochangeasthecovidpandemiccontinuestoaffecttheusand globaleconomiestheusfdaandotherhealthauthoritieshaveshiftedresourcesandprioritiestomeetthemany challengespresentedbythepandemicpandemicrelateddisruptionscouldnegativelyimpacttheprocessingofregulatory submissionsandslowagencyreviewtimesnecessaryfortheapprovalorclearanceofnewdrugsanddevicesthe durationandseverityofthecovidpandemicisunpredictableanddifficulttoassess employee human capital management asofjanuaryanddecemberthenumberofemployeeswereapproximately employee fulltimeequivalentfteposition employeeisdefinedasanindividualworkingfulltimeorparttimeexcludingfixedtermemployeesinternsandcoopemployee employeedatamaynotincludefullpopulationfrommorerecentlyacquiredcompaniesandindividualsonlongtermdisabilityare excludedcontingentworkerscontractorsandsubcontractorsarealsoexclude fterepresentsthetotalnumberoffulltimeequivalentpositionsanddoesnotreflectthetotalnumberofindividualemployeesa someworkparttime employee region percentage asiapacific emea latin america north america strategy thecompanybelievesthatitsemployeesarecriticaltoitscontinuedsuccessandareanessentialelementofitslong termstrategymanagementisresponsibleforensuringthatitspoliciesandprocessesreflectandreinforcethecompanys desiredcorporatecultureincludingpoliciesandprocessesrelatedtostrategyriskmanagementandethicsand compliancethecompanyshumancapitalmanagementstrategyisbuiltonthreefundamentalfocusarea attractingandrecruitingthebesttalent johnsonjohnsonannualreport developingandretainingtalent empoweringandinspiringtalent underpinningthesefocusareasareongoingeffortstocultivateandfosteraculturebuiltondiversityequityandinclusion deiinnovationhealthwellbeingandsafetywherethecompanysemployeesareencouragedtosucceedboth professionallyandpersonallywhilehelpingthecompanyachieveitsbusinessgoal cultureandemployeeengagement atjohnsonjohnsonemployeesareguidedbyourcredowhichsetsforththecompanysresponsibilitiestopatient consumerscustomershealthcareprofessionalsemployeescommunitiesandshareholdersemployeesworldwideare furtherguidedbythecompanyscodeofbusinessconductwhichsetsbasicrequirementsforbusinessconductand servesasafoundationforthecompanypoliciesproceduresandguidelinesallofwhichprovideadditionalguidanceon expectedemployeebehaviorsineverymarketwhereitoperatesthecompanyconductsglobalsurveysthatofferit employeestheabilitytoprovidefeedbackandvaluableinsighttohelpaddresspotentialhumanresourcesrisksandidentify opportunitiestoimproveinofglobalemployeesacrosscountriesparticipatedinourcredosurveywhich isofferedinlanguage growthanddevelopment tocontinuetoleadinthechanginghealthcarelandscapeitiscrucialthatthecompanycontinuetoattractandretaintop talentthecompanybelievesthatitsemployeesmustbeequippedwiththerightknowledgeandskillsandbeprovided withopportunitiestogrowanddevelopintheircareersaccordinglyprofessionaldevelopmentprogramsandeducational resourcesareavailabletoallemployeesthecompanysobjectiveistofosteralearningculturethathelpsshapeeach personsuniquecareerpathwhilecreatingarobustpipelineoftalenttodeliveronthecompanyslongtermstrategiesin furtheranceofthisobjectivethecompanydeploysaglobalapproachtoensuredevelopmentisforeveryoneregardlessof wheretheyareontheircareerjourneyinofemployeesinmanagerandabovejobcategoriestookadvantage ofcareeropportunitiesbymovingacrossfunctionscountryorbusinesssegmentlinesincludingupwardpromotionor lateraltransferandexcludingemployeesintheresearchanddevelopmentorganizationsthecompanysvoluntary turnoverratewa diversityequityandinclusiondei thecompanyiscommittedtoworkplacediversityandtocultivatingfosteringandadvancingacultureofequityand inclusionenablingemployeestoperformattheirbestwhilebeingthemselvesisfundamentaltothecompanyscontinue successthecompanysdeivisionisbeyourselfchangetheworldthecompanysdeistrategyfocusesonthreepillar thatreflectthestrategicprioritiesidentifiedtoenablethecompanytoaddressthechallengesandopportunitiespresente bythisevolvingunderstandingofdiversity acceleratethecompanyseffortstoadvanceacultureofinclusionandinnovation buildadiverseworkforceforthefuture enhancebusinessresultsandreputation thecompanysdeistrategyisguidedbyinternalandexternalinsightsglobalbestpracticesandcontinualemployee feedbackwhichremindthecompanythatwhilediversitychangesbylocationinclusionisthesameeverywhere compensationandbenefit aspartofthecompanystotalrewardsphilosophythecompanyofferscompetitivecompensationandbenefitstoattract andretaintoptalentthecompanyiscommittedtofairnessandequitabletreatmentinitscompensationandbenefitsfor employeesatalllevelsthecompanyobserveslegalminimumwageprovisionsandexceedsthemwherepossiblethe companystotalrewardsofferingsincludeanarrayofprogramstosupportitsemployeesfinancialphysicalandmental wellbeingincludingannualperformanceincentiveopportunitiespensionandretirementsavingsprogramshealthand welfarebenefitspaidtimeoffleaveprogramsflexibleworkschedulesandemployeeassistanceprogram healthwellnessandsafety thecompanysinvestmentinemployeehealthwellbeingandsafetyisbuiltonitsconvictionthatadvancinghealthfor humanitystartswithadvancingthehealthofitsemployeeswiththerightawarenessfocuspracticesandtoolsthe johnsonjohnsonannualreportcompanyensuresthatallitsemployeesaroundtheworldaswellastemporarycontractorsandvisitorstothecompanys sitescanworksafelythecompanyhascontinuouslyexpandedhealthandwellbeingprogramsthroughoutthecompany andacrosstheglobeincorporatingnewthinkingandtechnologiestokeepitsofferingsbestinclassandtohelp employeesachievetheirpersonalmindandbodyhealthgoalstheprogramsandpracticesthecompanyadvancescover threecoredimensionshealthyeatinghealthymovementandhealthymind available information thecompanysmaincorporatewebsiteaddressiswwwjnjcomallofthecompanyssecfilingsarealsoavailableonthe companyswebsiteatwwwinvestorjnjcomseccfmassoonasreasonablypracticableafterhavingbeenelectronically filedorfurnishedtothesecallsecfilingsarealsoavailableatthesecswebsiteatwwwsecgov investorsandthepublicshouldnotethatthecompanyalsoannouncesinformationat wwwfactsaboutourprescriptionopioidscomandwwwfactsabouttalccomweusethesewebsitestocommunicatewith investorsandthepublicaboutourproductslitigationandothermattersitispossiblethattheinformationweposttothese websitescouldbedeemedtobematerialinformationthereforeweencourageinvestorsandothersinterestedinthe companytoreviewtheinformationpostedtothesewebsitesinconjunctionwithwwwjnjcomthecompanyssecfiling pressreleasespublicconferencecallsandwebcast inadditiontheamendedandrestatedcertificateofincorporationbylawsthewrittenchartersoftheauditcommittee thecompensationbenefitscommitteethenominatingcorporategovernancecommitteetheregulatory compliancecommitteeandthesciencetechnologysustainabilitycommitteeoftheboardofdirectorsandthe companysprinciplesofcorporategovernancecodeofbusinessconductforemployeescodeofbusiness conductethicsformembersoftheboardofdirectorsandexecutiveofficersandothercorporategovernance materialsareavailableatwwwinvestorjnjcomgovcfmonthecompanyswebsiteandwillbeprovidedwithoutchargeto anyshareholdersubmittingawrittenrequestasprovidedabovetheinformationonwwwjnjcom wwwfactsaboutourprescriptionopioidscomandwwwfactsabouttalccomisnotandwillnotbedeemedapartofthisreport orincorporatedintoanyotherfilingsthecompanymakeswiththesec item risk factor aninvestmentinthecompanyscommonstockordebtsecuritiesinvolvesrisksanduncertaintiesthecompanyseeksto identifymanageandmitigateriskstoourbusinessbutuncertaintiesandrisksaredifficulttopredictandmanyareoutside ofthecompanyscontrolandcannotthereforebeeliminatedinadditiontotheotherinformationinthisreportandthe companysotherfilingswiththesecinvestorsshouldconsidercarefullythefactorssetforthbelowinvestorsshouldbe awarethatitisnotpossibletopredictoridentifyallsuchfactorsandthatthefollowingisnotmeanttobeacomplete discussionofallpotentialrisksoruncertaintiesifknownorunknownrisksoruncertaintiesmaterializethecompany businessresultsofoperationsorfinancialconditioncouldbeadverselyaffectedpotentiallyinamaterialway risk relate business industry operation thecompanysbusinessesoperateinhighlycompetitiveproductmarketsandcompetitivepressurescould adverselyaffectthecompanysearning thecompanyfacessubstantialcompetitioninallthreeoperatingsegmentsandinallgeographicmarketsthecompanys businessescompetewithcompaniesofallsizesonthebasisofcosteffectivenesstechnologicalinnovationsintellectual propertyrightsproductperformancerealorperceivedproductadvantagespricingandavailabilityandrateof reimbursementthecompanyalsocompeteswithothermarketparticipantsinsecuringrightstoacquisition collaborationsandlicensingagreementswiththirdpartiescompetitionforrightstoproductcandidatesandtechnologie mayresultinsignificantinvestmentandacquisitioncostsandonerousagreementtermsforthecompanycompetitor developmentofmoreeffectiveorlesscostlyproductsandortheirabilitytosecurepatentandotherintellectualproperty rightsandsuccessfullymarketproductsaheadofthecompanycouldnegativelyimpactsalesofthecompanysexisting productsaswellasitsabilitytobringnewproductstomarketdespitesignificantpriorinvestmentintherelatedproduct development forthecompanyspharmaceuticalbusinesseslossofpatentexclusivityforaproductoftenisfollowedbyasubstantial reductioninsalesascompetitorsgainregulatoryapprovalforgenericandothercompetingproductsandenterthemarket similarcompetitioncanbetriggeredbythelossofexclusivityforabiologicalproductforthecompanysmedicaldevice businessestechnologicalinnovationproductqualityreputationandcustomerserviceareespeciallyimportantto johnsonjohnsonannualreport competitivenessdevelopmentbyothercompaniesofneworimprovedproductsprocessesandtechnologiescould threatentomakethecompanysproductsortechnologieslessdesirablelesseconomicalorobsoletethecompany consumerhealthbusinessesfaceintensecompetitionfromotherbrandedproductsandretailersprivatelabelbrandsifthe companyfailstosufficientlydifferentiateandmarketitsbrandnameconsumerproductsthiscouldadverselyaffect revenuesandprofitabilityofthoseproduct interruptionsanddelaysinmanufacturingoperationscouldadverselyaffectthecompanysbusinesssale andreputation thecompanysmanufactureofproductsrequiresthetimelydeliveryofsufficientamountsofcomplexhighquality componentsandmaterialsthecompanyssubsidiariesoperatemanufacturingfacilitiesaswellassourcingfrom hundredsofsuppliersaroundtheworldthecompanyhasinthepastandmayinthefuturefaceunanticipated interruptionsanddelaysinmanufacturingthroughitsinternalorexternalsupplychainmanufacturingdisruptionscanoccur formanyreasonsincludingregulatoryactionproductionqualitydeviationsorsafetyissueslabordisputessitespecific incidentssuchasfiresnaturaldisasterssuchashurricanesandothersevereweathereventsrawmaterialshortage politicalunrestterroristattacksandepidemicsorpandemicssuchdelaysanddifficultiesinmanufacturingcanresultin productshortagesdeclinesinsalesandreputationalimpactaswellassignificantremediationandrelatedcostsassociate withaddressingtheshortage thecompanyreliesonthirdpartiestomanufacturecertainofourproductsanyfailurebyorlossofathird partymanufacturercouldresultindelaysandincreasedcostswhichmayadverselyaffectourbusiness thecompanyreliesonthirdpartiestomanufacturecertainofourproductswedependonthesethirdparty manufacturerstoallocatetousaportionoftheirmanufacturingcapacitysufficienttomeetourneedstoproduceproduct ofacceptablequalityandatacceptablemanufacturingyieldsandtodeliverthoseproductstousonatimelybasisandat acceptablepriceshoweverwecannotguaranteethatthesethirdpartymanufacturerswillbeabletomeetournearterm orlongtermmanufacturingrequirementswhichcouldresultinlostsalesandhaveanadverseeffectonourbusiness otherrisksassociatedwithourrelianceonthirdpartiesincludingthecompanysstrategicpartnershipwithjabilinthe medicaldevicessegmenttomanufacturetheseproductsincluderelianceonthethirdpartyforregulatorycomplianceand qualityassurancemisappropriationofthecompanysintellectualpropertylimitedabilitytomanageourinventorypossible breachofthemanufacturingagreementbythethirdpartyandthepossibleterminationornonrenewalofthemanufacturing agreementbythethirdpartyatatimethatiscostlyorinconvenientforusmoreoverifanyofourthirdpartymanufacturer sufferanydamagetofacilitieslosebenefitsundermaterialagreementsexperiencepoweroutagesencounterfinancial difficultiesareunabletosecurenecessaryrawmaterialsfromtheirsuppliersorsufferanyotherreductioninefficiencythe companymayexperiencesignificantbusinessdisruptionintheeventofanysuchdisruptionthecompanywouldneedto seekandsourceotherqualifiedthirdpartymanufacturerslikelyresultinginfurtherdelaysandincreasedcostswhichcould affectourbusinessadversely counterfeitversionsofourproductscouldharmourpatientsandhaveanegativeimpactonourrevenue earningsreputationandbusiness ourindustrycontinuestobechallengedbythevulnerabilityofdistributionchannelstoillegalcounterfeitingandthe presenceofcounterfeitproductsinagrowingnumberofmarketsandovertheinternetthirdpartiesmayillegallydistribute andsellcounterfeitversionsofourproductswhichdonotmeetourrigorousmanufacturingandtestingstandardsto distributorsandpatientscounterfeitproductsmaybevisuallyindistinguishablefromtheauthenticversioncounterfeit medicinesposearisktopatienthealthandsafetybecauseoftheconditionsunderwhichtheyaremanufacturedoftenin unregulatedunlicenseduninspectedandunsanitarysitesaswellasthelackofregulationoftheircontent theindustrysfailuretomitigatethethreatofcounterfeitmedicinescouldadverselyimpactourbusinessandreputationby impactingpatientconfidenceinourauthenticproductspotentiallyresultinginlostsalesproductrecallsandanincrease threatoflitigationinadditiondiversionofourproductsfromtheirauthorizedmarketintootherchannelsmayresultin reducedrevenuesandnegativelyaffectourprofitability thecovidpandemichasadverselyimpactedcertainaspectsofthecompanysbusinessandcould causedisruptionsorfutureimpacttothecompanysbusinessresultsofoperationsandfinancial condition wearesubjecttorisksassociatedwithglobalhealthcrisesandpandemicsincludingtheglobaloutbreakofthenovel coronavirusanditsmutationscovidthecovidpandemichasadverselyimpactedandisexpectedtocontinue toadverselyimpactcertainaspectsofthecompanysbusinessresultsofoperationsandfinancialconditioninclude johnsonjohnsonannualreportlowersalesandreducedcustomerdemandandusageofcertainofourproductsthespreadofcovidhascause thecompanytomodifyitsbusinesspracticesincludinginstitutingremoteworkformanyofthecompanysemployee andthecompanymaytakefurtheractionsasmayberequiredbygovernmentauthoritiesorasthecompanydetermine areinthebestinterestsofourpatientscustomersemployeesandbusinesspartnersthecompanycontinuestomonitor thesituationandwhilewehaverobustbusinesscontinuityplansinplaceacrossourglobalsupplychainnetworktohelp mitigatetheimpactofcovidtheseeffortsmaynotcompletelypreventourbusinessfrombeingadverselyaffected andfutureimpactsremainuncertain whiletheusandothercountrieshavebegunorwillbegintoreopentheireconomiestheextenttowhichcovidwill impactthecompanysfutureoperationswilldependonmanyfactorswhichcannotbepredictedwithconfidence includingthedurationoftheoutbreakanyresurgenceincovidinfectionscouldresultintheimpositionofnew mandatesandprolongedrestrictivemeasuresimplementedinordertocontrolthespreadofthediseasethecontinue globalspreadofcovidcouldadverselyimpactthecompanysoperationsincludingamongotherthingsour manufacturingoperationssupplychainincludingthirdpartysupplierssalesandmarketingandclinicaltrialoperation anyofthesefactorscouldadverselyaffectthecompanysbusinessfinancialresultsandglobaleconomiccondition generally wealsofaceuncertaintiesrelatedtooureffortstodevelopacovidvaccinecandidateincludinguncertaintiesrelate totheriskthatourdevelopmentprogramsmaynotbesuccessfulcommerciallyviableorreceiveapprovaloremergency useauthorizationfromregulatoryauthoritiesrisksassociatedwithclinicaltrialdataincludingfurtheranalysesofexiste preclinicalorclinicaltrialdatathatmaybeinconsistentwiththedatausedforselectionofthejnjvaccine candidateanddoselevelforthephaseensembletrialtheriskthatclinicaltrialdataaresubjecttodiffering interpretationsandassessmentsincludingduringthepeerreviewpublicationprocessinthescientificcommunity generallyandbyregulatoryauthoritiesdisruptionsintherelationshipsbetweenusourthirdpartysuppliersandexternal manufacturerstheriskthatothercompaniesmayproducesuperiororcompetitiveproductstheriskthatdemandforany productswemaydevelopmaynolongerexistrisksrelatedtotheavailabilityofrawmaterialstomanufactureanysuch productstheriskthatwemaynotbeabletorecoupcostsassociatedwithourrdandmanufacturingeffortsandrisk associatedwithanychangesinthewayweapproachorprovideadditionalresearchfundingforpotentialdrug developmentrelatedtocovidtheriskthatwemaynotbeabletocreateorscaleupmanufacturingcapacityona timelybasisthatwemayexperiencemanufacturingdelaysonceamanufacturingsiteisactivatedorhaveaccessto logisticsorsupplychannelscommensuratewithglobaldemandforanypotentialapprovedvaccineorproductcandidate whichwouldnegativelyimpactourabilitytosupplytheestimatednumbersofdosesofourvaccinecandidatewithinthe projectedtimeperiodsindicatedandotherchallengesandrisksassociatedwiththepaceofourvaccinedevelopment programandpricingandaccesschallengesforsuchproductsincludingintheus inadditiontotheextentthecovidpandemicadverselyaffectsourbusinessandfinancialresultsitmayalsohavethe effectofheighteningmanyoftheotherrisksdescribedinthisriskfactorssectionandthoseincorporatedbyreference hereinincludingrisksrelatingtothecompanyseffectivetaxrateasaresultofchangesinconsumptionaswella changesinlawsrelatingtosupplyofthecompanysproductsgiventhatdevelopmentsconcerningthecovid pandemichavebeenconstantlyevolvingadditionalimpactsandrisksmayariseincludinglitigationthatarenotpresently knowntothecompany risk relate government regulation legal proceeding globalsalesinthecompanyspharmaceuticalandmedicaldevicessegmentsmaybenegatively impactedbyhealthcare reformsandincreasingpricingpressure salesofthecompanyspharmaceuticalandmedicaldeviceproductsaresignificantlyaffectedbyreimbursementsby thirdpartypayerssuchasgovernmenthealthcareprogramsprivateinsuranceplansandmanagedcareorganizationsas partofvariouseffortstocontainhealthcarecoststhesepayersareputtingdownwardpressureonpricesatwhich productswillbereimbursedintheusincreasedpurchasingpowerofentitiesthatnegotiateonbehalfofmedicare medicaidandprivatesectorbeneficiariesinpartduetocontinuedconsolidationamonghealthcareproviderscould resultinfurtherpricingpressuresinadditionincreasedpoliticalscrutinycouldresultinadditionalpricingpressure outsidetheusnumerousmajormarketsincludingtheeuunitedkingdomandjapanhavepervasivegovernment involvementinfundinghealthcareandinthatregarddirectlyorindirectlyimposepricecontrolslimitaccesstoor reimbursementforthecompanysproductsorreducethevalueofitsintellectualpropertyprotection johnsonjohnsonannualreport thecompanyissubjecttosignificantlegalproceedingsthatcanresultinsignificantexpense finesandreputationaldamage intheordinarycourseofbusinessjohnsonjohnsonanditssubsidiariesaresubjecttonumerousclaimsandlawsuit involvingvariousissuessuchaspatentdisputesproductliabilityandclaimsthattheirproductsalesmarketingandprice practicesviolatevariousantitrustunfairtradepracticesandorconsumerprotectionlawsthecompanysmoresignificant legalproceedingsaredescribedinnotelegalproceedingsundernotestotheconsolidatedfinancialstatement includedinitemofthisreportlitigationingeneralandsecuritiesderivativeactionclassactionandmultidistrict litigationinparticularcanbeexpensiveanddisruptivesomeofthesemattersmayincludethousandsofplaintiffsmay involvepartiesseekinglargeandorindeterminateamountsincludingpunitiveorexemplarydamagesandmayremain unresolvedforseveralyearsforexamplethecompanyisadefendantinnumerouslawsuitsarisingoutoftheuseofbody powderscontainingtalcprimarilyjohnsonsbabypowderandthecompanyssalemanufacturingandmarketingof opioidswhilethecompanybelievesithassubstantialdefensesinthesemattersitisnotfeasibletopredicttheultimate outcomeoflitigationthecompanycouldinthefutureberequiredtopaysignificantamountsasaresultofsettlementsor judgmentsinthesematterspotentiallyinexcessofaccrualsincludingmatterswherethecompanycouldbeheldjointly andseverallyliableamongotherdefendantstheresolutionoforincreaseinaccrualsforoneormoreofthesemattersin anyreportingperiodcouldhaveamaterialadverseeffectonthecompanysresultsofoperationsandcashflowsforthat periodthecompanydoesnotpurchasethirdpartyproductliabilityinsurancehoweverthecompanyutilizesawholly ownedcaptiveinsurancecompanysubjecttocertainlimit productreliabilitysafetyandeffectivenessconcernscanhavesignificantnegativeimpactson salesandresultsofoperationsleadtolitigationandcausereputationaldamage concernsaboutproductsafetywhetherraisedinternallyorbylitigantsregulatorsorconsumeradvocatesandwhetheror notbasedonscientificevidencecanresultinsafetyalertsproductrecallsgovernmentalinvestigationsregulatoryaction onthepartoftheusfoodanddrugadministrationoritscounterpartinothercountriesprivateclaimsandlawsuit paymentoffinesandsettlementsdecliningsalesandreputationaldamagethesecircumstancescanalsoresultin damagetobrandimagebrandequityandconsumertrustinthecompanysproductsproductrecallshaveinthepast andcouldinthefuturepromptgovernmentinvestigationsandinspectionstheshutdownofmanufacturingfacilities continuedproductshortagesandrelatedsalesdeclinessignificantremediationcostsreputationaldamagepossiblecivil penaltiesandcriminalprosecution thecompanyfacessignificantregulatoryscrutinywhichimposessignificantcompliancecost andexposesthecompanytogovernmentinvestigationslegalactionsandpenaltie likeothercompaniesinthehealthcareindustrythecompanyissubjecttoextensiveregulationinvestigationsandlegal actionbynationalstateandlocalgovernmentagenciesintheusandothercountriesinwhichtheyoperateregulatory issuesregardingcompliancewithcurrentgoodmanufacturingpracticescgmpandcomparablequalityregulationsin foreigncountriesbymanufacturersofdrugsdevicesandconsumerproductscanleadtofinesandpenaltiesproduct recallsproductshortagesinterruptionsinproductiondelaysinnewproductapprovalsandlitigationinadditionthe marketingpricingandsaleofthecompanysproductsaresubjecttoregulationinvestigationsandlegalactionsinclude underthefederalfooddrugandcosmeticactthemedicaidrebateprogramfederalandstatefalseclaimsactsstate unfairtradepracticesactsandconsumerprotectionlawsscrutinyofhealthcareindustrybusinesspracticesby governmentagenciesandstateattorneysgeneralintheusandanyresultinginvestigationsandprosecutionscarryrisk ofsignificantcivilandcriminalpenaltiesincludingbutnotlimitedtodebarmentfromparticipationingovernment healthcareprogramsanysuchdebarmentcouldhaveamaterialadverseeffectonthecompanysbusinessandresultsof operationsthemostsignificantcurrentinvestigationsandlitigationbroughtbygovernmentagenciesaredescribedin notelegalproceedingsgovernmentproceedingsundernotestotheconsolidatedfinancialstatementsinclude initemofthisreport changesintaxlawsorexposurestoadditionaltaxliabilitiescouldnegativelyimpactthecompany operatingresult changesintaxlawsorregulationsaroundtheworldcouldnegativelyimpactthecompanyseffectivetaxrateandresult ofoperationsachangeinstatutorytaxrateinanycountrywouldresultintherevaluationofthecompanysdeferredtax assetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhichthenewtaxlawisenactedthischange wouldresultinanexpenseorbenefitrecordedtothecompanysconsolidatedstatementofearningsthecompany closelymonitorstheseproposalsastheyariseinthecountrieswhereitoperateschangestothestatutorytaxratemay occuratanytimeandanyrelatedexpenseorbenefitrecordedmaybematerialtothefiscalquarterandyearinwhichthe lawchangeisenacte johnsonjohnsonannualreportseenoteonincometaxesforadditionalinformation thecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandisaddressingtaxauditsanddispute withmanytaxauthoritiesinconnectionwiththeorganizationforeconomiccooperationanddevelopmentbase erosionandprofitshiftingbepsprojectcompaniesarerequiredtodisclosemoreinformationtotaxauthoritieson operationsaroundtheworldwhichmayleadtogreaterauditscrutinyofprofitsearnedinothercountriesthecompany regularlyassessesthelikelyoutcomesofitstaxauditsanddisputestodeterminetheappropriatenessofitstaxreserve howeveranytaxauthoritycouldtakeapositionontaxtreatmentthatiscontrarytothecompanysexpectationswhich couldresultintaxliabilitiesinexcessofreserve risk relate intellectual property thecompanymaynotbeabletosuccessfullysecureanddefendintellectualpropertyrightsessentialto thecompanysbusinesse thecompanyownsorlicensesasignificantnumberofpatentsandotherproprietaryrightsrelatingtoitsproductsand manufacturingprocessestheserightsareessentialtothecompanysbusinessesandmateriallyimportanttothe companysresultsofoperationspublicpolicybothwithinandoutsidetheushasbecomeincreasinglyunfavorable towardintellectualpropertyrightsthecompanycannotbecertainthatitwillobtainadequatepatentprotectionfornew productsandtechnologiesintheunitedstatesandotherimportantmarketsorthatsuchprotectionsoncegrantedwill lastaslongasoriginallyanticipate competitorsroutinelychallengethevalidityorextentofthecompanysownedorlicensedpatentsandproprietaryright throughlitigationinterferencesoppositionsandotherproceedingssuchasinterpartesreviewiprproceedingsbefore theunitedstatespatenttrademarkofficeusptotheseproceedingsabsorbresourcesandcanbeprotractedas wellasunpredictableinadditionchallengesthatthecompanysproductsinfringethepatentsofthirdpartiescouldresult intheneedtopaypastdamagesandfutureroyaltiesandadverselyaffectthecompetitivepositionandsalesofthe productsinquestion thecompanyhasfacedincreasingpatentchallengesfromthirdpartiesseekingtomanufactureandmarketgenericand biosimilarversionsofthecompanyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscovering thoseproductsintheusmanufacturersofgenericversionsofinnovativehumanpharmaceuticalproductsmay challengethevalidityorclaimnoninfringementofinnovatorproductsthroughtheabbreviatednewdrugapplicationor andaprocesswiththefdaandrelatedandalitigationthebiologicspricecompetitionandinnovationactbpcia enactedinwhichcreatedanewregulatorypathwayfortheapprovalbythefdaofbiosimilaralternativesto innovatordevelopedbiologicalproductsalsocreatedmechanismsforbiosimilarapplicantstochallengethepatentson theinnovatorbiologicstheiprprocesswiththeusptoisalsobeingusedbycompetitorstochallengepatentsasserted inlitigation intheeventthecompanyisnotsuccessfulindefendingitspatentsagainstsuchchallengesorupontheatrisklaunch despitependingpatentinfringementlitigationbythegenericorbiosimilarfirmofitsproductthecompanycanlosea majorportionofrevenuesforthereferencedproductinaveryshortperiodoftimecurrentlegalproceedingsinvolvingthe companyspatentsandotherintellectualpropertyrightsaredescribedinnotelegalproceedingsintellectual propertyofthenotestotheconsolidatedfinancialstatementsincludedinitemofthisreport risksrelatedtoproductdevelopmentregulatoryapprovalandcommercialization significantchallengesordelaysinthecompanysinnovationanddevelopmentofnewproduct technologiesandindicationscouldhaveanadverseimpactonthecompanyslongtermsuccess thecompanyscontinuedgrowthandsuccessdependsonitsabilitytoinnovateanddevelopnewanddifferentiate productsandservicesthataddresstheevolvinghealthcareneedsofpatientsprovidersandconsumersdevelopmentof successfulproductsandtechnologiesisalsonecessarytooffsetrevenuelosseswhenthecompanysexistingproduct losemarketshareduetovariousfactorssuchascompetitionandlossofpatentexclusivitynewproductsintroduce withinthepastfiveyearsaccountedforapproximatelyofsalesthecompanycannotbecertainwhenor whetheritwillbeabletodeveloplicenseorotherwiseacquirecompaniesproductsandtechnologieswhetherparticular productcandidateswillbegrantedregulatoryapprovalandifapprovedwhethertheproductswillbecommercially successful johnsonjohnsonannualreport thecompanypursuesproductdevelopmentthroughinternalresearchanddevelopmentaswellasthroughcollaboration acquisitionsjointventuresandlicensingorotherarrangementswiththirdpartiesinallofthesecontextsdevelopingnew productsparticularlypharmaceuticalandbiotechnologyproductsandmedicaldevicesrequiressignificantinvestmentof resourcesovermanyyearsonlyaveryfewbiopharmaceuticalresearchanddevelopmentprogramsresultincommercially viableproductstheprocessdependsonmanyfactorsincludingtheabilitytodiscernpatientsandhealthcareproviders futureneedsdeveloppromisingnewcompoundsstrategiesandtechnologiesachievesuccessfulclinicaltrialresults secureeffectiveintellectualpropertyprotectionobtainregulatoryapprovalsonatimelybasisandifandwhentheyreach themarketsuccessfullydifferentiatethecompanysproductsfromcompetingproductsandapproachestotreatment newproductsorenhancementstoexistingproductsmaynotbeacceptedquicklyorsignificantlyinthemarketplacedue toproductandpricecompetitionchangesincustomerpreferencesorhealthcarepurchasingpatternsresistanceby healthcareprovidersoruncertaintyoverthirdpartyreimbursementevenfollowinginitialregulatoryapprovalthesuccess ofaproductcanbeadverselyimpactedbysafetyandefficacyfindingsinlargerrealworldpatientpopulationsaswellas marketentryofcompetitiveproduct risk relate financial economic market condition thecompanyfacesavarietyofrisksassociatedwithconductingbusinessinternationally thecompanysextensiveoperationsandbusinessactivityoutsidetheusareaccompaniedbycertainfinancial economicandpoliticalrisksincludingthoselistedbelow foreigncurrencyexchangeinfiscalapproximatelyofthecompanyssalesoccurredoutsideoftheuswith approximatelyineuropeinthewesternhemisphereexcludingtheusandintheasiapacificandafrica regionchangesinnonuscurrenciesrelativetotheusdollarimpactthecompanysrevenuesandexpenseswhile thecompanyusesfinancialinstrumentstomitigatetheimpactoffluctuationsincurrencyexchangeratesonitscashflow unhedgedexposurescontinuetobesubjecttocurrencyfluctuationsinadditiontheweakeningorstrengtheningofthe usdollarmayresultinsignificantfavorableorunfavorabletranslationeffectswhentheoperatingresultsofthe companysnonusbusinessactivityaretranslatedintousdollar inflationandcurrencydevaluationrisksthecompanyfaceschallengesinmaintainingprofitabilityofoperationsin economiesexperiencinghighinflationratesthecompanyhasaccountedforoperationsinargentinabeginninginthe fiscalthirdquarterofandvenezuelaashighlyinflationaryasthepriorthreeyearcumulativeinflationratesurpassed whilethecompanystrivestomaintainprofitmarginsintheseareasthroughcostreductionprogramsproductivity improvementsandperiodicpriceincreasesitmightexperienceoperatinglossesasaresultofcontinuedinflationin additiontheimpactofcurrencydevaluationsincountriesexperiencinghighinflationratesorsignificantcurrencyexchange fluctuationscouldnegativelyimpactthecompanysoperatingresult illegalimportationofpharmaceuticalproductstheillegalimportationofpharmaceuticalproductsfromcountrieswhere governmentpricecontrolsorothermarketdynamicsresultinlowerpricesmayadverselyaffectthecompanyssalesand profitabilityintheusandothercountriesinwhichthecompanyoperateswiththeexceptionoflimitedquantitiesof prescriptiondrugsforpersonaluseforeignimportsofpharmaceuticalproductsareillegalundercurrentuslaw howeverthevolumeofillegalimportscontinuestoriseastheabilityofpatientsandothercustomerstoobtainthelower pricedimportshasgrownsignificantly antibriberyandotherregulationsthecompanyissubjecttovariousfederalandforeignlawsthatgovernitsinternational businesspracticeswithrespecttopaymentstogovernmentofficialsthoselawsincludetheusforeigncorrupt practicesactfcpawhichprohibitsuspubliclytradedcompaniesfrompromisingofferingorgivinganythingofvalue toforeignofficialswiththecorruptintentofinfluencingtheforeignofficialforthepurposeofhelpingthecompanyobtain orretainbusinessorgainanyimproperadvantagethecompanysbusinessisheavilyregulatedandthereforeinvolve significantinteractionwithforeignofficialsalsoinmanycountriesoutsidetheusthehealthcareproviderswho prescribehumanpharmaceuticalsareemployedbythegovernmentandthepurchasersofhumanpharmaceuticalsare governmententitiesthereforethecompanysinteractionswiththeseprescribersandpurchasersaresubjecttoregulation underthefcpainadditiontotheusapplicationandenforcementofthefcpavariousjurisdictionsinwhichthe companyoperateshavelawsandregulationsincludingtheukbriberyactaimedatpreventingandpenalize corruptandanticompetitivebehaviorenforcementactivitiesundertheselawscouldsubjectthecompanytoadditional administrativeandlegalproceedingsandactionswhichcouldincludeclaimsforcivilpenaltiescriminalsanctionsand administrativeremediesincludingexclusionfromhealthcareprogram johnsonjohnsonannualreportotherlegalsocialandpoliticalrisksotherrisksinherentinconductingbusinessgloballyinclude protectiveeconomicpoliciestakenbygovernmentssuchastradeprotectionmeasuresandimportexportlicensing requirement compliancewithlocalregulationsandlawsincludinginsomecountriesregulatoryrequirementsrestrictingthe companysabilitytomanufactureorsellitsproductsintherelevantmarket diminishedprotectionofintellectualpropertyandcontractualrightsincertainjurisdiction potentialnationalizationorexpropriationofthecompanysforeignasset politicalorsocialupheavalseconomicinstabilityrepressionorhumanrightsissuesand geopoliticaleventsincludingnaturaldisastersdisruptionstomarketsduetowararmedconflictterrorismepidemicsor pandemic failuretomaintainasatisfactorycreditratingcouldadverselyaffectourliquiditycapitalposition borrowingcostsandaccesstocapitalmarket wecurrentlymaintaininvestmentgradecreditratingswithmoodysinvestorsserviceandstandardpoorsrating servicesratingagenciesroutinelyevaluateusandtheirratingsofourlongtermandshorttermdebtarebasedona numberoffactorsanydowngradeofourcreditratingsbyacreditratingagencywhetherasaresultofouractionsor factorswhicharebeyondourcontrolcanincreasethecostofborrowingunderanyindebtednesswemayincurreduce marketcapacityforourcommercialpaperorrequirethepostingofadditionalcollateralunderourderivativecontract therecanbenoassurancethatwewillbeabletomaintainourcreditratingsandanyadditionalactualoranticipate changesordowngradesinourcreditratingsincludinganyannouncementthatourratingsareunderreviewfora downgrademayhaveanegativeimpactonourliquiditycapitalpositionandaccesstocapitalmarket risk ourbusinessdependsonourabilitytorecruitandretaintalentedhighlyskilledemployeesandadiverse workforce ourcontinuedgrowthrequiresustorecruitandretaintalentedemployeesrepresentingdiversebackgroundsexperience andskillsetsthemarketforhighlyskilledworkersandleadersinourindustryisextremelycompetitiveandourabilityto competedependsonourabilitytohiredevelopandmotivatehighlyskilledpersonnelinallareasofourorganization maintainingourbrandandreputationaswellasadiverseequitableandinclusiveworkenvironmentenablesustoattract toptalentifwearelesssuccessfulinourrecruitingeffortsorifwecannotretainhighlyskilledworkersandkeyleader ourabilitytodevelopanddeliversuccessfulproductsandservicesmaybeadverselyaffectedinadditioneffective successionplanningisimportanttoourlongtermsuccessanyunsuccessfulimplementationofoursuccessionplansor failuretoensureeffectivetransferofknowledgeandsmoothtransitionsinvolvingkeyemployeescouldadverselyaffectour businessfinancialconditionorresultsofoperation aninformationsecurityincidentincludingacybersecuritybreachcouldhaveanegativeimpacttothe companysbusinessorreputation tomeetbusinessobjectivesthecompanyreliesonbothinternaltechnologyitsystemsandnetworksandthoseof thirdpartiesandtheirvendorstoprocessandstoresensitivedataincludingconfidentialresearchbusinessplans financialinformationintellectualpropertyandpersonaldatathatmaybesubjecttolegalprotectionandensurethe continuityofthecompanyssupplychaintheextensiveinformationsecurityandcybersecuritythreatswhichaffect companiesgloballyposearisktothesecurityandavailabilityofthesesystemsandnetworksandtheconfidentiality integrityandavailabilityofthecompanyssensitivedatathecompanycontinuallyassessesthesethreatsandmake investmentstoincreaseinternalprotectiondetectionandresponsecapabilitiesaswellasensurethecompanysthird partyprovidershaverequiredcapabilitiesandcontrolstoaddressthisrisktodatethecompanyhasnotexperiencedany materialimpacttothebusinessoroperationsresultingfrominformationorcybersecurityattackshoweverbecauseofthe frequentlychangingattacktechniquesalongwiththeincreasedvolumeandsophisticationoftheattacksthereisthe potentialforthecompanytobeadverselyimpactedthisimpactcouldresultinreputationalcompetitiveoperationalor otherbusinessharmaswellasfinancialcostsandregulatoryactionthecompanymaintainscybersecurityinsurancein theeventofaninformationsecurityorcyberincidenthoweverthecoveragemaynotbesufficienttocoverallfinancial legalbusinessorreputationallosse johnsonjohnsonannualreport climatechangeorlegalregulatoryormarketmeasurestoaddressclimatechangemaynegativelyaffect ourbusinessandresultsofoperation climatechangeresultingfromincreasedconcentrationsofcarbondioxideandothergreenhousegasesintheatmosphere couldpresentriskstoouroperationsincludinganadverseimpactonglobaltemperaturesweatherpatternsandthe frequencyandseverityofextremeweatherandnaturaldisastersnaturaldisastersandextremeweatherconditionssuch asahurricanetornadoearthquakewildfireorfloodingmayposephysicalriskstoourfacilitiesanddisrupttheoperation ofoursupplychaintheimpactsofthechangingclimateonwaterresourcesmayresultinwaterscarcitylimitingourability toaccesssufficienthighqualitywaterincertainlocationswhichmayincreaseoperationalcost concernoverclimatechangemayalsoresultinneworadditionallegalorregulatoryrequirementsdesignedtoreduce greenhousegasemissionsandormitigatetheeffectsofclimatechangeontheenvironmentifsuchlawsorregulation aremorestringentthancurrentlegalorregulatoryobligationswemayexperiencedisruptioninoranincreaseinthecost associatedwithsourcingmanufacturinganddistributionofourproductswhichmayadverselyaffectourbusinessresults ofoperationsorfinancialcondition item unresolved staff comment notapplicable item property thecompanyssubsidiariesoperatemanufacturingfacilitiesoccupyingapproximatelymillionsquarefeetoffloor spacethemanufacturingfacilitiesareusedbytheindustrysegmentsofthecompanysbusinessapproximatelyas follow squarefeet segment inthousand consumerhealth pharmaceutical medicaldevice worldwidetotal withintheusfivefacilitiesareusedbytheconsumerhealthsegmentfivebythepharmaceuticalsegmentandby themedicaldevicessegmentoutsideoftheusfacilitiesareusedbytheconsumerhealthsegmentbythe pharmaceuticalsegmentandbythemedicaldevicessegment thelocationsofthemanufacturingfacilitiesbymajorgeographicareasoftheworldareasfollow squarefeet geographicarea numberoffacilitie inthousand unitedstate europe westernhemisphereexcludingus africaasiaandpacific worldwidetotal inadditiontothemanufacturingfacilitiesdiscussedabovethecompanymaintainsnumerousofficeandwarehouse facilitiesthroughouttheworldresearchfacilitiesarealsodiscussedinitemmanagementsdiscussionandanalysisof resultsofoperationsandfinancialconditionofthisreport thecompanyssubsidiariesgenerallyseektoownratherthanleasetheirmanufacturingfacilitiesalthoughsome principallyinnonuslocationsareleasedofficeandwarehousefacilitiesareoftenleasedthecompanyalsoengage contractmanufacturer thecompanyiscommittedtomaintainingallofitspropertiesingoodoperatingcondition mcneilppcincnowjohnsonjohnsonconsumerincmcneilppccontinuestooperateunderaconsentdecree signedinwiththefdawhichgovernscertainmcneilconsumerhealthcaremanufacturingoperationsandrequire mcneilppctoremediatethefacilitiesitoperatesinlancasterpennsylvaniafortwashingtonpennsylvaniaandlas johnsonjohnsonannualreportpiedraspuertoricotheconsentdecreefollowingfdainspectionsmcneilppcreceivednotificationsfromthe fdathatallthreemanufacturingfacilitiesareinconformitywithapplicablelawsandregulationsandcommercial productionrestartedin undertheconsentdecreeafterreceivingnoticefromthefdaofbeingincompliancewithapplicablelawsand regulationseachofthethreefacilitiesissubjecttoafiveyearauditperiodbyathirdpartycgmpexpertathirdparty expertcontinuedtoreassessthesitesatvarioustimesthroughmcneilppcisawaitingfdainspectionsofthe facilitieswhichhavebeendelayedduetocovid segmentinformationonadditionstopropertyplantandequipmentiscontainedinnotesegmentsofbusinessand geographicareasofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport item legal proceeding theinformationcalledforbythisitemisincorporatedhereinbyreferencetotheinformationsetforthinnotelegal proceedingsofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport inadditionjohnsonjohnsonanditssubsidiariesarealsopartiestoanumberofproceedingsbroughtunderthe comprehensiveenvironmentalresponsecompensationandliabilityactcommonlyknownassuperfundand comparablestatelocalorforeignlawsinwhichtheprimaryreliefsoughtisthecostofpastandorfutureremediation item safety disclosure notapplicable johnsonjohnsonannualreport executive officer registrant listedbelowaretheexecutiveofficersofthecompanytherearenofamilyrelationshipsbetweenanyoftheexecutive officersandthereisnoarrangementorunderstandingbetweenanyexecutiveofficerandanyotherpersonpursuantto whichtheexecutiveofficerwasselectedattheannualmeetingoftheboardofdirectorstheexecutiveofficersare electedbytheboardtoholdofficeforoneyearanduntiltheirrespectivesuccessorsareelectedandqualifiedoruntil earlierresignationorremoval informationwithregardtothedirectorsofthecompanyincludinginformationforalexgorskywhoisalsoanexecutive officerisincorporatedhereinbyreferencetothematerialcaptioneditemelectionofdirectorsintheproxystatement age position joaquinduato vicechairmanexecutivecommitteea memberexecutivecommitteeexecutivevicepresidentchiefhuman petermfasolophd resourcesofficerb chairmanboardofdirectorschairmanexecutivecommitteechiefexecutive alexgorsky officer memberexecutivecommitteeexecutivevicepresidentworldwidechairman ashleymcevoy medicaldevicesc memberexecutivecommitteeexecutivevicepresidentworldwidechairman thibautmongon consumerhealthd memberexecutivecommitteeexecutivevicepresidentglobalcorporate michaelesnee affairsandchiefcommunicationofficere paulusstoffelsmd vicechairmanexecutivecommitteechiefscientificofficerf memberexecutivecommitteeexecutivevicepresidentworldwidechairman jenniferltaubert pharmaceuticalsg michaelhullmann memberexecutivecommitteeexecutivevicepresidentgeneralcounselh memberexecutivecommitteeexecutivevicepresidentchiefglobalsupply kathrynewengel chainofficeri memberexecutivecommitteeexecutivevicepresidentchieffinancial josephjwolk officerj mrjduatojoinedthecompanyinwithjanssenfarmaceuticasaspainasubsidiaryofthecompanyandheldexecutive positionsofincreasingresponsibilityinthepharmaceuticalsectorinhewasnamedcompanygroupchairman pharmaceuticalsandinhewasnamedworldwidechairmanpharmaceuticalsinmrduatobecameamemberofthe executivecommitteeandwasnamedexecutivevicepresidentworldwidechairmanpharmaceuticalsinjulymrduatowa promotedtovicechairmanoftheexecutivecommitteewithresponsibilityforthecompanyspharmaceuticalandconsumerhealth sectorssupplychaininformationtechnologyglobalservicesandthehealthwellnessgroup drpmfasolojoinedthecompanyinasvicepresidentworldwidehumanresourcesforcordiscorporationasubsidiary ofthecompanyandwassubsequentlynamedvicepresidentglobaltalentmanagementforthecompanyheleftjohnson johnsonintojoinkohlbergkravisrobertscoaschieftalentofficerdrfasoloreturnedtothecompanyinasthe vicepresidentglobalhumanresourcesandinhebecameamemberoftheexecutivecommitteeinaprilhewas namedexecutivevicepresidentchiefhumanresourcesofficerdrfasolohasresponsibilityforglobaltalentrecruitingdiversity compensationbenefitsemployeerelationsandallaspectsofthehumanresourcesagendaforthecompany msamcevoyjoinedthecompanyinasassistantbrandmanagerofmcneilconsumerhealthasubsidiaryofthecompany advancingthroughpositionsofincreasingresponsibilitiesuntilshewasappointedcompanygroupchairmanvisioncarein followedbycompanygroupchairmanconsumermedicaldevicesininjulymsmcevoywaspromotedtoexecutive vicepresidentworldwidechairmanmedicaldevicesandbecameamemberoftheexecutivecommitteemsmcevoyha responsibilityforthesurgeryorthopaedicsinterventionalsolutionsandeyehealthbusinessesacrossethicondepuysynthes biosensewebsterandjohnsonjohnsonvision mrtmongonjoinedthecompanyinasdirectorofmarketingforthevisioncaregroupinfranceandsubsequentlyheld generalmanagementpositionsascountrymanagerfrancebelgiumandnorthafricamanagingdirectorlatinamericaand presidentasiapacificmrmongontransitionedtothepharmaceuticalsectorinastheglobalcommercialstrategyleaderfor theneurosciencetherapeuticareabeforejoiningtheconsumerhealthsectorascompanygroupchairmanasiapacificin hewaspromotedtoexecutivevicepresidentandworldwidechairmanconsumerhealthandbecameamemberoftheexecutive committeemrmongonhasresponsibilityfortheglobaldevelopmentofjohnsonjohnsonshealthandwellnessproductsand solutionsinbeautyotcoralcarebabycarewomenshealthandwoundcare johnsonjohnsonannualreporte mrmesneedjoinedthecompanyinasmarketingassistantforpersonalproductscompanyasubsidiaryofthecompany andgainedincreasedresponsibilitiesinexecutivepositionsacrosstheglobalenterpriseinmrsneedwasappointe companygroupchairmanconsumernorthamericafollowedbycompanygroupchairmanvisioncarefranchiseinin hebecamethevicepresidentglobalcorporateaffairsandchiefcommunicationsofficermrsneedwasappointe executivevicepresidentglobalcorporateaffairsandchiefcommunicationsofficerinjanuaryandbecameamemberofthe executivecommitteeinjulyleadingthecompanysglobalmarketingcommunicationdesignandphilanthropyfunction drpstoffelsrejoinedthecompanyinwiththeacquisitionoftibotecvirconvwherehewaschiefexecutiveofficerofvirco nvandchairmanoftibotecnvinhewasappointedcompanygroupchairmanglobalvirologyinheassumedthe roleofcompanygroupchairmanpharmaceuticalsdrstoffelswasappointedglobalheadresearchdevelopment pharmaceuticalsinandinbecameworldwidechairmanpharmaceuticalsindrstoffelswasappointedchief scientificofficerandbecameamemberoftheexecutivecommitteeindrstoffelswasnamedexecutivevicepresident chiefscientificofficerindrstoffelswaspromotedtovicechairmanoftheexecutivecommitteechiefscientificofficerhe isresponsibleforthecompanysinnovationagendaacrossthepharmaceuticalmedicaldevicesandconsumerhealthsector productsafetystrategyandthecompanysglobalpublichealthstrategy msjltaubertjoinedthecompanyinasworldwidevicepresidentatjohnsonjohnsonpharmaceuticalservicesa subsidiaryofthecompanysheheldseveralexecutivepositionsofincreasingresponsibilityinthepharmaceuticalsectoruntil whenshewasappointedcompanygroupchairmannorthamericapharmaceuticalsandinbecamecompanygroup chairmantheamericaspharmaceuticalsinjulymstaubertwaspromotedtoexecutivevicepresidentworldwide chairmanpharmaceuticalsandbecameamemberoftheexecutivecommitteemstauberthasresponsibilityfortheimmunology infectiousdiseasesneuroscienceoncologycardiovascularandmetabolismandpulmonaryhypertensionbusinessesthroughout janssen mrmhullmannjoinedthecompanyinasacorporateattorneyinthelawdepartmenthewasappointedcorporate secretaryinandservedinthatroleuntilduringthattimehealsoheldvariousmanagementpositionsinthelaw departmentinhewasnamedgeneralcounselmedicaldevicesanddiagnosticsandwasappointedvicepresidentgeneral counselandbecameamemberoftheexecutivecommitteeininaprilmrullmannwasnamedexecutivevice presidentgeneralcounselmrullmannhasworldwideresponsibilityforlegalgovernmentaffairspolicyglobalsecurityaviation healthcarecomplianceglobalbrandprotectionandprivacy mskewengeljoinedthecompanyinasprojectengineerandengineeringsupervisoratjanssenasubsidiaryofthe companyduringhertenurewiththecompanyshehasheldavarietyofstrategicleadershipandexecutivepositionsacrossthe globalenterpriseinroleswithinoperationsqualityengineeringnewproductsinformationtechnologyandothertechnicaland businessfunctionsinmswengelbecamethefirstchiefqualityofficerofthecompanyinshewaspromotedtovice presidentjohnsonjohnsonsupplychaininjulyshewaspromotedtoexecutivevicepresidentchiefglobalsupplychain officerandbecameamemberoftheexecutivecommittee mrjjwolkjoinedthecompanyinasfinancemanagerbusinessdevelopmentfororthomcneilasubsidiaryofthe companyandthroughtheyearsheldavarietyofseniorleadershiprolesinseveralsegmentsandfunctionsacrossthecompanys subsidiariesinpharmaceuticalsmedicaldevicesandsupplychainfromtoheservedasvicepresidentfinanceand chieffinancialofficerofthejanssenpharmaceuticalcompaniesofjohnsonjohnsoninmrwolkbecamethevice presidentinvestorrelationsinjulyhewasappointedexecutivevicepresidentchieffinancialofficerandbecameamember oftheexecutivecommitteemrwolkplaysastrategicroleintheoverallmanagementofthecompanyandleadsthedevelopment andexecutionofthecompanysgloballongtermfinancialstrategy johnsonjohnsonannualreport item market registrant common equity relate stockholder matter issuer purchase equity security asoffebruarytherewererecordholdersofcommonstockofthecompanyadditionalinformation calledforbythisitemisincorporatedhereinbyreferencetothefollowingsectionsofthisreportnotecommon stockstockoptionplansandstockcompensationagreementsofthenotestoconsolidatedfinancialstatement includedinitemanditemsecurityownershipofcertainbeneficialownersandmanagementandrelate stockholdermattersequitycompensationplaninformation issuer purchase equity security thefollowingtableprovidesinformationwithrespecttocommonstockpurchasesbythecompanyduringthefiscalfourth quarterofcommonstockpurchasesontheopenmarketaremadeaspartofasystematicplantomeettheneed ofthecompanyscompensationprogramstherepurchasesbelowalsoincludethestockforstockoptionexercisesthat settledinthefiscalfourthquarter totalnumberof maximumnumberor sharesorunit approximatedollar purchasedaspart valueofsharesorunit totalnumber ofpublicly thatmayyetbe ofshare avgprice announcedplans purchasedunderthe fiscalperiod purchase paidpershare orprogram plansorprogram septemberthrough october octoberthrough november novemberthroughjanuary total duringthefiscalfourthquarterofthecompanyrepurchasedanaggregateofsharesofjohnsonjohnson commonstockinopenmarkettransactionsallofwhichwerepurchasedinopenmarkettransactionsaspartofasystematicplanto meettheneedsofthecompanyscompensationprograms item reserve johnsonjohnsonannualreportitem management discussion analysis result operation financial condition organization business segment description company business segment johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldthecompany conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand wellbee thecompanyisorganizedintothreebusinesssegmentsconsumerhealthpreviouslyreferredtoasconsumer pharmaceuticalandmedicaldevicestheconsumerhealthsegmentincludesabroadrangeofproductsusedinthebaby careoralcareskinhealthbeautyoverthecounterpharmaceuticalwomenshealthandwoundcaremarketsthese productsaremarketedtothegeneralpublicandsoldonlineecommerceandtoretailoutletsanddistributorsthroughout theworldthepharmaceuticalsegmentisfocusedonsixtherapeuticareasincludingimmunologyinfectiousdisease neuroscienceoncologypulmonaryhypertensionandcardiovascularandmetabolicdiseasesproductsinthissegment aredistributeddirectlytoretailerswholesalershospitalsandhealthcareprofessionalsforprescriptionusethemedical devicessegmentincludesabroadrangeofproductsusedintheorthopaedicsurgeryinterventionalsolution cardiovascularandneurovascularandeyehealthfieldstheseproductsaredistributedtowholesalershospitalsand retailersandusedprincipallyintheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinic theexecutivecommitteeofjohnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategic operationsandallocationoftheresourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesofthe consumerhealthpharmaceuticalandmedicaldevicesbusinesssegment inallofitsproductlinesthecompanycompeteswithothercompaniesbothlocallyandgloballythroughouttheworld competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolve competitioninresearchinvolvingthedevelopmentandtheimprovementofnewandexistingproductsandprocessesis particularlysignificantthedevelopmentofnewandinnovativeproductsaswellasprotectingtheunderlyingintellectual propertyofthecompanysproductportfolioisimportanttothecompanyssuccessinallareasofitsbusinessthe competitiveenvironmentrequiressubstantialinvestmentsincontinuingresearchinadditionthedevelopmentand maintenanceofcustomerdemandforthecompanysconsumerproductsinvolvessignificantexpendituresforadvertising andpromotion managementsobjective withourcredoasthefoundationthecompanyspurposeistoblendheartscienceandingenuitytoprofoundly changethetrajectoryofhealthforhumanitythecompanyiscommittedtobringingitsfullbreadthanddepthtoensure healthforpeopletodayandforfuturegenerationsunitedaroundthiscommonambitionthecompanyispoisedtofulfillits purposeandsuccessfullymeetthedemandsoftherapidlyevolvingmarketsinwhichitcompete thecompanyisbroadlybasedinhumanhealthcareandiscommittedtocreatingvaluebydevelopingaccessiblehigh qualityinnovativeproductsandservicesnewproductsintroducedwithinthepastfiveyearsaccountedforapproximately ofsalesinbillionwasinvestedinresearchanddevelopmentandbillionspenton acquisitionsreflectingmanagementscommitmenttocreatelifeenhancinginnovationsandtocreatevaluethrough partnershipsthatwillprofoundlychangethetrajectoryofhealthforhumanity acriticaldriverofthecompanyssuccessisthediverseemployeesworldwideemployeesareempoweredand inspiredtoleadwiththecompanysourcredoandpurposeasguidesthisallowseveryemployeetousethecompany reachandsizetoadvancethecompanyspurposeandtoalsoleadwithagilityandurgencyleveragingtheextensive resourcesacrosstheenterpriseenablesthecompanytoinnovateandexecutewithexcellencethisensuresthe companycanremainfocusedonaddressingtheunmetneedsofsocietyeverydayandinvestforanenduringimpact ultimatelydeliveringvaluetoitspatientsconsumersandhealthcareprofessionalsemployeescommunitiesand shareholders johnsonjohnsonannualreport snoillib snoillib srallod research acquisicidon net dividend pay development cash acquire share result operation analysisofconsolidatedsale fordiscussiononresultsofoperationsandfinancialconditionpertainingtothefiscalyearsandseethe companysannualreportonformkforthefiscalyearendeddecemberitemmanagementsdiscussion andanalysisofresultsofoperationsandfinancialcondition inworldwidesalesincreasedtobillionascomparedtoanincreaseofinthesesale changesconsistedofthefollowing salesincreasedecreasedueto volume price currency total thenetimpactofacquisitionsanddivestituresontheworldwidesalesgrowthwasanegativeimpactofinand anegativeimpactofin salesbyuscompanieswerebillioninandbillioninthisrepresentsincreasesofin andinsalesbyinternationalcompanieswerebillioninandbillioninthisrepresent adecreaseofinandanincreaseofin thefiveyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectivelythetenyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectively insalesbycompaniesineuropeachievedgrowthofascomparedtotheprioryearwhichinclude operationalgrowthofandapositivecurrencyimpactofsalesbycompaniesinthewesternhemisphere excludingtheusexperiencedasalesdeclineofascomparedtotheprioryearwhichincludedoperational growthofoffsetbyanegativecurrencyimpactofsalesbycompaniesintheasiapacificafricaregion experiencedasalesdeclineofascomparedtotheprioryearincludinganoperationaldeclineofpartiallyoffset byapositivecurrencyimpactof theresultsbenefitedfromtheinclusionofardweekseenotetotheconsolidatedfinancialstatementsfor annualclosingdatedetailsthecompanyestimatedthatthefiscalyearsalesgrowthratewasenhancedby approximatelywhiletheadditionalweekaddedafewdaystosalesitalsoaddedafullweeksworthofoperate coststhereforethenetearningsimpactwasnegligible inthecompanyutilizedthreewholesalersdistributingproductsforallthreesegmentsthatrepresente approximatelyandofthetotalconsolidatedrevenuesinthecompanyhadthreewholesaler distributingproductsforallthreesegmentsthatrepresentedapproximatelyandofthetotal consolidatedrevenue johnsonjohnsonannualreport sale geographic region billion sale segment billions europe western hemisphere consumer health pharmaceutical asiapacific africa medical device notevaluesmayhavebeenrounde analysis sale business segment consumerhealthsegment consumerhealthsegmentsalesinwerebillionanincreaseoffromwhichinclude operationalgrowthandanegativecurrencyimpactofusconsumerhealthsegmentsaleswerebillionan increaseofinternationalsaleswerebillionadecreaseofwhichincludedanoperationaldeclineof andanegativecurrencyimpactofinacquisitionsanddivestitureshadanetnegativeimpactofonthe operationalsalesgrowthoftheworldwideconsumerhealthsegment majorconsumerhealthfranchisesale change dollarsinmillion otc skinhealthbeauty oralcare babycare womenshealth woundcareother totalconsumerhealthsales previouslyreferredtoasconsumer previouslyreferredtoasbeauty johnsonjohnsonannualreport theotcfranchisesalesofbillionincreasedascomparedtotheprioryeargrowthwasprimarilyattributable tosalesfromtylenoldrivenbycovidstockingdemandzyrtecduetocompetitorproductoutofstockand pepcidduetocompetitiveproductwithdrawalbothintheusandincreasedconsumptioninantismokingaid internationalsaleswerenegativelyimpactedbycovidandlowincidenceofcoughandflu theskinhealthbeautyfranchisesaleswerebillioninadecreaseofascomparedtotheprioryearthe declinewasprimarilyduetonegativecovidrelatedimpactsandskurationalizationpartiallyoffsetbygrowthin ecommerceandnewproductinnovation theoralcarefranchisesalesofbillionincreasedascomparedtotheprioryearprimarilyattributabletosalesof listerinemouthwashduetousecommerceandclubchannelgrowthincreasedstockingdemandrelatedto covidandnewproductlaunchesinasiapacific thebabycarefranchisesaleswerebillioninadecreaseofcomparedtotheprioryearthedeclinewa primarilyduetocovidrelatedimpactsskurationalizationandthebabycenterdivestitureintheuspartiallyoffset bystrengthinaveenobaby thewomenshealthfranchisesaleswerebillioninadecreaseofascomparedtotheprioryearthe declinewasprimarilydrivenbycovidimpact thewoundcareotherfranchisesaleswerebillioninanincreaseofascomparedtotheprioryear growthwasduetostrongperformanceofneosporinandbandaidbrandadhesivebandagesandcovid relateddemandintheasiapacificregion johnsonjohnsonannualreportpharmaceutical segment pharmaceuticalsegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthofandanegativecurrencyimpactofussaleswerebillionanincreaseofinternational saleswerebillionanincreaseofwhichincludedoperationalgrowthandanegativecurrencyimpactof inacquisitionsanddivestitureshadanetnegativeimpactofontheoperationalsalesgrowthofthe worldwidepharmaceuticalsegmentadjustmentstopreviousreserveestimatespositivelyimpactedthepharmaceutical segmentoperationalgrowthbyapproximatelyinbothfiscalyearsand majorpharmaceutical therapeuticareasale change dollarsinmillion totalimmunology remicade simponisimponiaria stelara tremfya otherimmunology totalinfectiousdisease edurantrilpivirine prezistaprezcobixrezolstasymtuza otherinfectiousdisease totalneuroscience concertamethylphenidate invegasustennaxeplioninvegatrinzatrevicta risperdalconsta otherneuroscience totaloncology darzalex erleada imbruvica velcade zytigaabirateroneacetate otheroncology totalpulmonaryhypertension opsumit uptravi otherpulmonaryhypertension totalcardiovascularmetabolismother xarelto invokanainvokamet procriteprex totalpharmaceuticalsale certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation percentagegreaterthanornotmeaningful johnsonjohnsonannualreport previouslyincludedinotheroncology inclusiveoftracleerwhichwaspreviouslydisclosedseparately immunologyproductssaleswerebillioninrepresentinganincreaseofascomparedtotheprioryear drivenbystronguptakeofstelaraustekinumabincrohnsdiseaseandulcerativecolitisandstrengthintremfya guselkumabinpsoriasisthiswaspartiallyoffsetbycovidrelateddemandandlowersalesofremicade infliximabduetoincreaseddiscountsrebatesandbiosimilarcompetition thepatentsforremicadeinfliximabincertaincountriesineuropeexpiredinfebruarybiosimilarversionsof remicadehavebeenintroducedincertainmarketsoutsidetheunitedstatesresultinginareductioninsalesof remicadeinthosemarketsadditionalbiosimilarcompetitionwilllikelyresultinafurtherreductioninsalesof remicadeinmarketsoutsidetheunitedstatesintheunitedstatesabiosimilarversionofremicadewas introducedinandadditionalcompetitorscontinuetoenterthemarketcontinuedinfliximabbiosimilarcompetitionin theusmarketwillresultinafurtherreductioninussalesofremicade infectiousdiseaseproductssaleswerebillioninrepresentinganincreaseofascomparedtotheprior yearprimarilyduetostrongsalesofsymtuzaandjulucathiswaspartiallyoffsetbylowersalesofprezista andprezcobixrezolstaduetoincreasedcompetitionandlossofexclusivityofprezistaincertaincountrie outsidetheus neuroscienceproductssaleswerebillionrepresentinganincreaseofascomparedtotheprioryear paliperidonelongactinginjectablesgrowthdrivenbysalesofinvegasustennaxeplionpaliperidonepalmitate andinvegatrinzatrevictafromnewpatientstartsandpersistencethegrowthwaspartiallyoffsetbymigration fromrisperdalconstarisperidoneanddeclinesinconcertamethylphenidateduetocompetitiveentrant oncologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yearcontributorstothegrowthwerestrongsalesofdarzalexdaratumumabdrivenbypatientuptakeinalllinesof therapyandthelaunchofasubcutaneousformulationintheusandeuimbruvicaibrutinibduetomarketgrowth globallyandmaintainingstrongshareandthecontinuedgloballaunchuptakeandsharegainsoferleada apalutamideadditionallythegrowthwasnegativelyimpactedbydecliningsalesofzytigaabirateroneacetateand velcadebortezomibduetogenericcompetition pulmonaryhypertensionproductsachievedsalesofbillionrepresentinganincreaseofascomparedtothe prioryearsalesgrowthofopsumitmacitentananduptraviselexipagwereduetocontinuedsharegainsand marketgrowthadditionallysalesoftracleerbosentanwerenegativelyimpactedbygenericsandmigrationto opsumit cardiovascularmetabolismotherproductssaleswerebillionadeclineofascomparedtotheprioryearsale growthofinvokanainvokametcanagliflozinwereduetomarketgrowthandfavorablechannelmixdynamicsin theusandstrengthintheeuropeanregionpartiallyoffsetbyussharedeclinesduetocompetitivepressuresthe growthofxareltorivaroxabanwasduetodemandgrowthpartiallyoffsetbyhigherrebateslowersalesof procriteprexepoetinalfawereduetobiosimilarcompetition johnsonjohnsonannualreportduringthecompanyadvanceditspipelinewithseveralregulatorysubmissionsandapprovalsfornewdrugsand additionalindicationsforexistingdrugsasfollow productnamechemical indication approval approval filing filing amivantamab treatmentofpatientswithmetastaticnonsmallcelllung cancerwithegfrexoninsertionmutation darzalexdaratumumab combinationregimenfornewlydiagnosedtransplant eligiblepatientswithmultiplemyeloma darzalexdaratumumab combinationwithcarfilzomibanddexamethasoneforpatient withrelapsedrefractorymultiplemyeloma darzalexfaspro subcutaneousformulationofdaratumumabinthetreatment daratumumaband ofpatientswithmultiplemyeloma hyaluronidase erleadaapalutamide treatmentofmetastaticcastrationsensitiveprostatecancer imbruvicaibrutinib incombinationwithrituximabfortreatmentofchronic lymphocyticleukemia invokanacanagliflozin treatmentofdiabetickidneydisease rilpivirineandcabotegravir formonthlyinjectabletwodrugregimenfortreatmentof hiv paliperidonepamitatemonth treatmentofschizophrenia ponesimod treatmentofadultswithrelapsedmultiplesclerosis simponiariagolimumab treatmentofpolyarticularjuvenileidiopathicarthritisand juvenilepsoriaticarthritis sirturobedaquiline combinationtherapytotreatchildrenwithpulmonary multidrugresistanttuberculosis spravatoesketamine rapidreductionofdepressivesymptomsinadultswith majordepressivedisorderwhohaveactivesuicidalideation withintent stelaraustekinumab treatmentofpediatricpatientswithmoderatetosevere plaquepsoriasis tremfyaguselkumab treatmentofadultswithactivepsoriaticarthritis uptraviiv pulmonaryarterialhypertension xareltorivaroxaban newindicationtoexpanduseinpatientswithperipheral arterydisease zabdenoadzebovand preventiveebolavaccine mvabeamvabnfilo johnsonjohnsonannualreport medicaldevicessegment themedicaldevicessegmentsalesinwerebillionadecreaseoffromwhichincludedan operationaldecreaseofandanegativecurrencyimpactofussaleswerebillionadecreaseof ascomparedtotheprioryearinternationalsaleswerebillionadecreaseofascomparedtotheprior yearwithanoperationaldecreaseofandanegativecurrencyimpactofinthenetimpactof acquisitionsanddivestituresonthemedicaldevicessegmentworldwideoperationalsalesgrowthwasanegativeof whichthedivestitureofadvancedsterilizationproductsasphadanimpactofapproximatelygrowthwa negativelyimpactedbycovidandassociateddeferralofmedicalprocedure majormedicaldevicesfranchisesale change dollarsinmillion surgery advanced general orthopaedic hip knee trauma spinesportsother vision contactlensesother surgical interventionalsolution totalmedicaldevicessale certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation includesspecialtysurgerywhichwaspreviouslydisclosedseparately previouslyreferredtoasspineother thesurgeryfranchisesaleswerebillioninadecreaseoffromthedeclineinadvancedsurgery wasprimarilydrivenbythenegativeimpactofcovidandcompetitivepressuresintheusthiswaspartiallyoffsetby thesuccessofnewproductsoutsidetheusandtherecoveryofanisolatedsupplydisruptionintheprioryearrelatedto surgiflothedeclineingeneralsurgerywasprimarilydrivenbythenegativeimpactofcovidandtheasp divestiture theorthopaedicsfranchisesaleswerebillioninadecreaseoffromthedeclineinhipswa drivenbythenegativeimpactofcovidpartiallyoffsetbyaleadershippositionintheanteriorapproachstrongmarket demandfortheactisstemandenablingtechnologieskinciseandvelyshipnavigationthedeclineinknee wasdrivenbythenegativeimpactofcovidthedeclineintraumawasdrivenbythenegativeimpactofcovid partiallyoffsetbystrengthfromnewproductsthedeclineinspinesportsotherwasdrivenbythenegativeimpactof covidpartiallyoffsetbytheuptakeofnewproduct thevisionfranchisesaleswereofbillioninadecreaseoffromthecontactlensesother operationaldeclinewasduetothenegativeimpactofcovidthesurgicaloperationaldeclinewasprimarilydrivenby thenegativeimpactofcovidandcompetitivepressuresintheus theinterventionalsolutionsfranchiseachievedsalesofbillioninanincreaseoffromgrowthin theelectrophysiologybusinesswasdrivenbyatrialfibrillationproceduregrowthcoupledwithstrengthfromnewproduct andmarketrecoveryoffsettingnegativeimpactsfromcovid johnsonjohnsonannualreportanalysisofconsolidatedearningsbeforeprovisionfortaxesonincome consolidatedearningsbeforeprovisionfortaxesonincomewasbillionandbillionfortheyearsand respectivelyasapercenttosalesconsolidatedearningsbeforeprovisionfortaxesonincomewasand inandrespectively earning provision taxis dollar billion percentage chart percent total sale costofproductssoldandsellingmarketingandadministrativeexpense cost product sell sell markecidng administracidve dollar billion percentage chart percent total sale costofproductssoldincreasedasapercenttosalesdrivenby medicaldeviceidlecapacitycostsassociatedwithcovidrelatedproductionslowdown establishmentofobsolescencereservesandfixedcostdeleveragingassociatedwiththeimpactofcovidinthe medicaldevicesbusiness supplychaincostsassociatedwiththedevelopmentofthecovidvaccineinthepharmaceuticalbusiness partiallyoffsetby favorablemixwithinthepharmaceuticalbusiness favorableproductmixwithahigherpercentageofsalescomingfromthepharmaceuticalbusiness johnsonjohnsonannualreport theintangibleassetamortizationexpenseincludedincostofproductssoldwasbillionandbillionfortheyear andrespectively sellingmarketingandadministrativeexpensesdecreasedasapercenttosalesdrivenby leveraginginthepharmaceuticalandconsumerhealthbusinesse portfolioandinvestmentoptimizationincludingexecutionoftheongoingskurationalizationprogramintheconsumer healthbusiness favorablesegmentmixwithahigherpercentageofsalescomingfromthepharmaceuticalbusiness partiallyoffsetby thenegativeimpactonsalesresultingfromcovidinthemedicaldevicesbusiness researchanddevelopmentexpense researchanddevelopmentexpensebysegmentofbusinesswasasfollow dollarsinmillion ofsale ofsale consumerhealth pharmaceutical medicaldevice totalresearchanddevelopmentexpense percentincreasedecreaseovertheprioryear asapercenttosegmentsale researchanddevelopmentactivitiesrepresentasignificantpartofthecompanysbusinesstheseexpendituresrelateto theprocessesofdiscoveringtestinganddevelopingnewproductsupfrontpaymentsanddevelopmentalmilestone improvingexistingproductsaswellasensuringproductefficacyandregulatorycompliancepriortolaunchthecompany remainscommittedtoinvestinginresearchanddevelopmentwiththeaimofdeliveringhighqualityandinnovative product researchanddevelopmentincreasedasapercenttosalesprimarilydrivenby segmentmixdrivenbyahigherpercentageofsalesgeneratedbythepharmaceuticalbusinessversustheprioryear thenegativecovidimpactonmedicaldevicessale increasedinvestmentinthemedicaldevicesbusinessrelatedtoroboticsanddigitalprogram portfolioprogressionincludingthecovidvaccineinthepharmaceuticalbusinessnetofgovernmental reimbursement researchfacilitiesarelocatedintheusbelgiumbrazilchinafrancegermanyindiaisraelthenetherlandspoland singaporeswedenswitzerlandandtheunitedkingdomwithadditionalrdsupportinoverothercountrie inprocessresearchanddevelopmentiprdinfiscalyearthecompanyrecordedaniprdchargeof billionprimarilyrelatedtoapartialimpairmentduetotimingandprogressionofoneofthedigitalsurgeryplatform acquiredwiththeaurishealthacquisitioninthefiscalyearthecompanyrecordedaniprdchargeofbillion fortheremainingintangibleassetvaluerelatedtothedevelopmentprogramofalaninvestigationaldrugforthe treatmentofrespiratorysyncytialvirusrsvandhumanmetapneumovirushmpvacquiredwiththeacquisitionof aliosbiopharmainctheimpairmentchargewasbasedonadditionalinformationincludingclinicaldatawhichbecame availableandledtothecompanysdecisiontoabandonthedevelopmentofal otherincomeexpensenetotherincomeexpensenetistheaccountwherethecompanyrecordsgainsand lossesrelatedtothesaleandwritedownofcertaininvestmentsinequitysecuritiesheldbyjohnsonjohnsoninnovation jjdcincjjdcunrealizedgainsandlossesoninvestmentsgainsandlossesondivestiturescertaintransactional currencygainsandlossesacquisitionrelatedcostslitigationaccrualsandsettlementsaswellasroyaltyincome johnsonjohnsonannualreportotherincomeexpensenetforthefiscalyearwasunfavorablebybillionascomparedtotheprioryear primarilyduetothefollowe dollarsinbillionsincomeexpense change litigationexpense acquisitionandintegrationrelate unrealizedgainslossesonsecuritie equitystepupgainrelatedtodrcilabo divestituregain restructuringrelated totalotherincomeexpensenet litigationexpenseprimarilyassociatedwithtalcrelatedreservesandcertainsettlementsbillionlitigationexpense primarilyrelatedtotheagreementinprincipletosettleopioidlitigationbillion isprimarilydrivenbyacontingentconsiderationreversalofapproximatelybillionrelatedtothetimingofcertain developmentalmilestonesassociatedwiththeaurishealthacquisition includedthedivestitureofasp interestincomeexpensethefiscalyearincludednetinterestexpenseofmillionascomparedtoincomeof millioninthefiscalyearthiswasprimarilyduetoreducedinterestincomeresultingfromlowerratesofinterest earnedoncashbalancesandahigheraveragedebtbalancethiswaspartiallyoffsetbyaloweraveragedebtinterestrate andahigheraveragecashbalancecashcashequivalentsandmarketablesecuritiestotaledbillionattheendof andaveragedbillionascomparedtothecashcashequivalentsandmarketablesecuritiestotalof billionandbillionaveragecashbalanceinthetotaldebtbalanceattheendofwasbillion withanaveragedebtbalanceofbillionascomparedtobillionattheendofandanaveragedebt balanceofbillioninthefiscalthirdquarterofthecompanyissuedapproximatelybillionofcommercial paperwithapproximatelybillionoutstandingatyearendinthefiscalthirdquarterofthecompanyissue seniorunsecurednotesforatotalofbillion incomebeforetaxbysegment incomelossbeforetaxbysegmentofbusinesswereasfollow percentof incomebeforetax segmentsale segmentsale dollarsinmillions consumerhealth pharmaceutical medicaldevice total lessnetexpensenotallocatedtosegment earningsbeforeprovisionfortaxesonincome seenotetotheconsolidatedfinancialstatementsformoredetail amountsnotallocatedtosegmentsincludeinterestincomeexpenseandgeneralcorporateincomeexpense consumerhealthsegmentintheconsumerhealthsegmentlossbeforetaxasapercentofsaleswas versusincomebeforetaxofinthedecreaseintheincomebeforetaxasapercentofsaleswasprimarily drivenbythefollowe higherlitigationexpenseofbillioninvsbillioninprimarilyassociatedwithtalcrelatedreserve andcertainsettlement johnsonjohnsonannualreport thefiscalyearincludedagainofbillionrelatedtothecompanyspreviouslyheldequityinvestmentindr cilabo partiallyoffsetby portfolioandinvestmentoptimizationincludingexecutionoftheongoingskurationalizationprogram pharmaceuticalsegmentinthepharmaceuticalsegmentincomebeforetaxasapercenttosaleswas versusintheincreaseintheincomebeforetaxasapercentofsaleswasprimarilydrivenbythefollowe lowerlitigationexpenseofbillioninvsbillioninprimarilyrelatedtotheagreementinprincipleto settleopioidlitigationofwhichbillionisinandbillionisin aninprocessresearchanddevelopmentchargeofbillioninfiscalrelatedtoalio loweracquisitionandintegrationrelatedcostsinfiscal leveraginginsellingmarketingandadministrativeexpense medicaldevicessegmentinthemedicaldevicessegmentincomebeforetaxasapercenttosaleswas versusinthedecreaseintheincomebeforetaxasapercenttosaleswasprimarilydrivenbythefollowe againofbillionrelatedtotheaspdivestiturerecordedinthefiscal idlecapacitycostsassociatedwithcovidrelatedproductionslowdownsinfiscal establishmentofobsolescencereservesandfixedcostdeleveragingassociatedwiththeimpactofcovidinfiscal thenegativeimpactofcovidonsalesinfiscal aninprocessresearchanddevelopmentchargeofbillioninfiscalprimarilyrelatedtotheaurishealth acquisition partiallyoffsetby acontingentconsiderationreversalofapproximatelybillioninfiscalrelatedtothetimingofcertain developmentalmilestonesassociatedwiththeaurishealthacquisition litigationexpensewasbillioninvsbillionin restructuringinthefiscalsecondquarterofthecompanyannouncedplanstoimplementactionsacrossit globalsupplychainthatareintendedtoenablethecompanytofocusresourcesandincreaseinvestmentsincritical capabilitiestechnologiesandsolutionsnecessarytomanufactureandsupplyitsproductportfolioofthefutureenhance agilityanddrivegrowththecompanyexpectsthesesupplychainactionswillincludeexpandingitsuseofstrategic collaborationsandbolsteringitsinitiativestoreducecomplexityimprovingcostcompetitivenessenhancingcapabilitie andoptimizingitsnetworkdiscussionsregardingspecificfutureactionsareongoingandaresubjecttoallrelevant consultationrequirementsbeforetheyarefinalizedintotalthecompanyexpectstheseactionstogenerateapproximately tobillioninannualpretaxcostsavingsthatwillbesubstantiallydeliveredbythecompanyexpectsto recordpretaxrestructuringchargesofapproximatelytobillionthecompanyestimatesthatapproximately ofthecumulativepretaxcostswillresultincashoutlaysinthecompanyrecordedapretaxchargeof billionwhichisincludedonthefollowinglinesoftheconsolidatedstatementofearningsbillionin restructuringbillioninotherincomeexpenseandbillionincostofproductssoldtotalprojectcostsof approximatelybillionhavebeenrecordedsincetherestructuringwasannounce seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtotherestructuringprogram provisionfortaxesonincometheworldwideeffectiveincometaxratewasinandin duringthefiscalfirstquarteroftheinternalrevenueservicepublishedfinalregulationsaddressingthe requirementsfortaxdeductibilityofsettlementpaymentsthecompanyrecordedapretaxreserveforbillioninthe fiscalyearbasedontheagreementinprincipletosettleopioidlitigationandrecordedanadditionalpretax billioninthefiscalthirdquarterofuponwhichaneffectiverateofhasbeenapplie fordiscussionrelatedtothefiscalprovisionfortaxesrefertonotetotheconsolidatedfinancialstatement johnsonjohnsonannualreportliquidity capital resource liquiditycashflow cashandcashequivalentswerebillionattheendofascomparedtobillionattheendof theprimarysourcesandusesofcashthatcontributedtothebilliondecreasewere dollarsinbillion qcashandcashequivalentsbalance cashgeneratedfromoperatingactivitie netcashusedbyinvestingactivitie netcashusedbyfinancingactivitie effectofexchangerateandrounde qcashandcashequivalentsbalance inadditionthecompanyhadbillioninmarketablesecuritiesattheendoffiscalyearandbillionatthe endoffiscalyearseenotetotheconsolidatedfinancialstatementsforadditionaldetailsoncashcash equivalentsandmarketablesecuritie cashflowfromoperationsofbillionwastheresultof dollarsinbillion netearning noncashexpensesandotheradjustmentsprimarilyfordepreciationandamortizationstockbase compensationassetwritedownsandcreditlossesandaccountsreceivableallowancespartiallyoffsetbythe deferredtaxprovisionandnetgainonsaleofassetsbusinesse decreaseinaccountsreceivable anincreaseinaccountspayableandaccruedliabilitiesandothercurrentandnoncurrentliabilitie anincreaseininventoriesandothercurrentandnoncurrentasset contingentconsiderationreversalrelatedtothetimingofcertaindevelopmentalmilestonesassociatedwiththe aurishealthacquisitionandrounde cashflowfromoperation investingactivitiesuseofbillionofcashwasprimarilyusedfor dollarsinbillion primarilyrelatedtotheacquisitionsofmomentabermekimabandrelatedassetsfromxbiotechincaswellasthe acquisitionofalloutstandingsharesinverbsurgicalinc additionstopropertyplantandequipment netpurchasesofinvestment creditsupportagreementsactivitynet proceedsfromthedisposalofassetsbusinessesnet otherprimarilylicensesandmilestone netcashusedforinvestingactivitie financingactivitiesuseofbillionofcashwasprimarilyusedfor dollarsinbillion dividendstoshareholder repurchaseofcommonstock netproceedsfromshortandlongtermdebt proceedsfromstockoptionsexercisedemployeewithholdingtaxonstockawardsnet creditsupportagreementsactivitynet netcashusedforfinancingactivitie asofjanuarythecompanysnotespayableandlongtermdebtwasinexcessofcashcashequivalentsand marketablesecuritiesasofjanuarythenetdebtpositionwasbillionascomparedtotheprioryearof billiontherewasanincreaseinthenetdebtpositionduetoincreasedborrowingsinthefiscalthirdquarterof johnsonjohnsonannualreport thedebtbalanceattheendofwasbillionascomparedtobillioninconsideringrecentmarket conditionsandtheongoingcovidcrisisthecompanyhasevaluateditsoperatingcashflowsandliquidityprofile anddoesnotforeseeanysignificantincrementalriskthecompanyanticipatesthatoperatingcashflowstheabilityto raisefundsfromexternalsourcesborrowingcapacityfromexistingcommittedcreditfacilitiesandaccesstothe commercialpapermarketswillcontinuetoprovidesufficientresourcestofundoperatingneedsincludingthetalclitigation andagreementinprincipletosettleopioidlitigationofwhichthemajoritymaybepaidoverthenexttwotothreeyearsin additionthecompanymonitorstheglobalcapitalmarketsonanongoingbasisandfromtimetotimemayraisecapital whenmarketconditionsarefavorableinthefiscalthirdquarterofthecompanyissuedapproximatelybillionof commercialpaperwithapproximatelybillionoutstandingatyearendinthefiscalthirdquarterofthecompany issuedseniorunsecurednotesforatotalofbillionforadditionaldetailsonborrowingsseenotetothe consolidatedfinancialstatementsthenetproceedsfromthisofferingwereusedtofundthemomentapharmaceutical incacquisitionwhichclosedonoctoberandforgeneralcorporatepurposesadditionallyasaresultofthetax cutsandjobsacttcjathecompanyhasaccesstoitscashoutsidetheusatasignificantlyreducedcost thefollowingtablesummarizesthecompanysmaterialcontractualobligationsandtheiraggregatematuritiesasof januarytosatisfytheseobligationsthecompanyintendstousecashfromoperation tax intereston legislation debt debt dollarsinmillion tcja obligation obligation total total fortaxmattersseenotetotheconsolidatedfinancialstatementsthetabledoesnotincludeactivityrelatedto businesscombinationsorthecompanysapproximatebillionincontractualsupplycommitmentsassociatedwithit developmentofacovidvaccine financingandmarketrisk thecompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflow accordinglythecompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcostsgainsorlosse onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactionsaappreciationoftheusdollar fromthejanuarymarketrateswouldincreasetheunrealizedvalueofthecompanysforwardcontractsby millionconverselyadepreciationoftheusdollarfromthejanuarymarketrateswoulddecrease theunrealizedvalueofthecompanysforwardcontractsbymillionineitherscenariothegainorlossontheforward contractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhavenoimpactonfuture anticipatedearningsandcashflow thecompanyhedgestheexposuretofluctuationsincurrencyexchangeratesandtheeffectoncertainassetsand liabilitiesinforeigncurrencybyenteringintocurrencyswapcontractsachangeinthespreadbetweenusand foreigninterestratesonthecompanysinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe unrealizedvalueofthecompanysswapcontractsbyapproximatelymillionineitherscenarioatmaturitythegain orlossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhave noimpactonfutureanticipatedcashflow thecompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposesfurtherthecompanyhasa policyofonlyenteringintocontractswithpartiesthathaveatleastaninvestmentgradecreditratingthecounterpartiesto thesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone counterpartymanagementbelievestheriskoflossisremotethecompanyenteredintocreditsupportagreement csawithcertainderivativecounterpartiesestablishingcollateralthresholdsbasedonrespectivecreditratingsand nettingagreementsseenotetotheconsolidatedfinancialstatementsforadditionaldetailsoncreditsupport agreement thecompanyinvestsinbothfixedrateandfloatingrateinterestearningsecuritieswhichcarryadegreeofinterestrate riskthefairmarketvalueoffixedratesecuritiesmaybeadverselyimpactedduetoariseininterestrateswhilefloate johnsonjohnsonannualreportratesecuritiesmayproducelessincomethanpredictedifinterestratesfallabasispointschangeinspreadon thecompanysinterestratesensitiveinvestmentswouldeitherincreaseordecreasetheunrealizedvalueofcash equivalentsandcurrentmarketablesecuritiesbyapproximatelymillion thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids providedbybankslondoninterbankofferedratesliborsecuredovernightfinancingratesofrswapcurveor otherapplicablemarketrateasallowedplusapplicablemarginscommitmentfeesundertheagreementarenotmaterial totalborrowingsattheendofandwerebillionandbillionrespectivelytheincreasein borrowingswastheissuanceofnotesinwhenmarketconditionswerefavorableinnetdebtcashand currentmarketablesecuritiesnetofdebtwasbillioncomparedtonetdebtofbillionintotaldebt representedoftotalcapitalshareholdersequityandtotaldebtinandoftotalcapitalin shareholdersequitypershareattheendofwascomparedtoatyearend asummaryofborrowingscanbefoundinnotetotheconsolidatedfinancialstatement dividend thecompanyincreaseditsdividendinforthethconsecutiveyearcashdividendspaidwerepersharein andpersharein onjanuarytheboardofdirectorsdeclaredaregularcashdividendofpersharepayableonmarch toshareholdersofrecordasoffebruary information criticalaccountingpoliciesandestimate managementsdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedonthecompany consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin theusgaapthepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand assumptionsthataffecttheamountsreportedforrevenuesexpensesassetsliabilitiesandotherrelateddisclosure actualresultsmayormaynotdifferfromtheseestimatesthecompanybelievesthattheunderstandingofcertainkey accountingpoliciesandestimatesareessentialinachievingmoreinsightintothecompanysoperatingresultsand financialconditionthesekeyaccountingpoliciesincluderevenuerecognitionincometaxeslegalandselfinsurance contingenciesvaluationoflonglivedassetsassumptionsusedtodeterminetheamountsrecordedforpensionsandother employeebenefitplansandaccountingforstockbasedawards theextenttowhichcovidimpactsthecompanysbusinessandfinancialresultswilldependonnumerousevolve factorsincludingbutnotlimitedtothemagnitudeanddurationofcovidtheextenttowhichitwillimpactworldwide macroeconomicconditionsincludinginterestratesemploymentratesandhealthinsurancecoveragethespeedofthe anticipatedrecoveryandgovernmentalandbusinessreactionstothepandemicthecompanyassessedcertain accountingmattersthatgenerallyrequireconsiderationofforecastedfinancialinformationincontextwiththeinformation reasonablyavailabletothecompanyandtheunknownfutureimpactsofcovidasofjanuaryandthroughthe dateofthisreporttheaccountingmattersassessedincludedbutwerenotlimitedtothecompanysallowancefor doubtfulaccountsandcreditlossesinventoryandrelatedreservesaccruedrebatesandassociatedreservesandthe carryingvalueofthegoodwillandotherlonglivedassetswhiletherewasnotamaterialimpacttothecompanys consolidatedfinancialstatementsasofandfortheyearendedjanuarythecompanysfutureassessmentofthe magnitudeanddurationofcovidaswellasotherfactorscouldresultinmaterialimpactstothecompanys consolidatedfinancialstatementsinfuturereportingperiod revenuerecognitionthecompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofa contractwiththecustomeraresatisfiedgenerallythisoccurswiththetransferofcontrolofthegoodstocustomersthe companysglobalpaymenttermsaretypicallybetweentodaysprovisionsforcertainrebatessalesincentives tradepromotionscouponsproductreturnsanddiscountstocustomersareaccountedforasvariableconsiderationand recordedasareductioninsale johnsonjohnsonannualreport productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingconsiderationofcompetitorpricingrebatesareestimatedbasedoncontractual termshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsinthevariousmarket servedthecompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughtheanalysisof wholesalerandotherthirdpartysellthroughandmarketresearchdataaswellasinternallygeneratedinformation salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibitunusual salesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas partoftheaccountingforsalesreturnaccrual salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket asapercenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescredit tocustomersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerhealthandpharmaceuticalsegmentsarealmostexclusivelynotresalablesale returnsforcertainfranchisesinthemedicaldevicessegmentaretypicallyresalablebutarenotmaterialthecompany infrequentlyexchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyha beenapproximatelyofannualnettradesalesduringthefiscalyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe sameperiodasrelatedsalescontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentive programstheredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue volumebasedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas productsaresoldthesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas areductionofrevenuethecompanyalsoearnsprofitsharepaymentsthroughcollaborativearrangementsofcertain productswhichareincludedinsalestocustomersforallyearspresentedprofitsharepaymentswerelessthanof thetotalrevenuesandareincludedinsalestocustomer inadditionthecompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivitie amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivere basedontherelativesellingpriceupfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedover theperformanceperiodseenotetotheconsolidatedfinancialstatementsforadditionaldisclosuresoncollaboration reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebatesreturnsandpromotionsarenot anticipatedtohaveamaterialeffectonthefinancialstatementsthecompanycurrentlydisclosestheimpactofchange toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact belowaretablesthatshowtheprogressionofaccruedrebatesreturnspromotionsreservefordoubtfulaccountsand reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendedjanuaryanddecember johnsonjohnsonannualreportconsumerhealthsegment balanceat balanceat beginning payment endof dollarsinmillion ofperiod accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatdecemberrecordedasacontra asset pharmaceutical segment balanceat balanceat beginning payment endof dollarsinmillion ofperiod accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatdecemberrecordedasa contraasset includesadjustment johnsonjohnsonannualreport medicaldevicessegment balanceat balanceat beginning payment endof dollarsinmillion ofperiod accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatdecemberrecordedasa contraasset incometaxesincometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe resultsofanydifferencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitie thecompanyestimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesin taxlawsandratesmayaffectrecordeddeferredtaxassetsandliabilitie thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition thecompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortodecemberfromit internationalsubsidiariesthecompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto januaryfromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvestedthe companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperationsifthecompanydecidesata laterdatetorepatriatetheseearningstotheusthecompanywouldberequiredtoprovideforthenettaxeffectson theseamountsthecompanyestimatesthatthetotaltaxeffectofthisrepatriationwouldbeapproximatelybillion undercurrentenactedtaxlawsandregulationsandatcurrentcurrencyexchangerate duringthefiscalfirstquarteroftheinternalrevenueservicepublishedfinalregulationsaddressingthe requirementsfortaxdeductibilityofsettlementpaymentsthecompanyrecordedapretaxreserveforbillioninfiscal basedontheagreementinprincipletosettleopioidlitigationandrecordedanadditionalpretaxbillioninthe fiscalthirdquarterofuponwhichaneffectiverateofhasbeenapplie seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxe legalandselfinsurancecontingenciesthecompanyrecordsaccrualsforvariouscontingenciesincludinglegal proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusinesstheaccrualsarebasedon managementsjudgmentastotheprobabilityoflossesandwhereapplicableactuariallydeterminedestimatesthe companyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyinadditiontoaccrualsintheself insuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe reasonablyestimate johnsonjohnsonannualreportthecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorde whenalossisprobableandcanbereasonablyestimate seenotesandtotheconsolidatedfinancialstatementsforfurtherinformationregardingproductliabilityandlegal proceeding longlivedandintangibleassetsthecompanyassesseschangesbothqualitativelyandquantitativelyineconomic conditionsandmakesassumptionsregardingestimatedfuturecashflowsinevaluatingthevalueofthecompany propertyplantandequipmentgoodwillandintangibleassetsastheseassumptionsandestimatesmaychangeovertime itmayormaynotbenecessaryforthecompanytorecordimpairmentcharge employeebenefitplansthecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefit definedcontributionandterminationindemnityplanswhichcovermostemployeesworldwidetheseplansarebasedon assumptionsforthediscountrateexpectedreturnonplanassetsmortalityratesexpectedsalaryincreaseshealthcare costtrendratesandattritionratesseenotetotheconsolidatedfinancialstatementsforfurtherdetailsonthese rate stockbasedcompensationthecompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity instrumentstoemployeesfortheirservicesbasedonthetypeofequityinstrumentthefairvalueisestimatedonthedate ofgrantusingeithertheblackscholesoptionvaluationmodeloracombinationofboththeblackscholesoption valuationmodelandmontecarlovaluationmodelandisexpensedinthefinancialstatementsovertheserviceperiodthe inputassumptionsusedindeterminingfairvaluearetheexpectedlifeexpectedvolatilityriskfreerateandexpecte dividendyieldpriortofiscalforperformanceshareunitsthefairmarketvaluewascalculatedforeachofthethree componentgoalsatthedateofgrantoperationalsalesadjustedoperationalearningspershareandrelativetotal shareholderreturnbeginninginfiscalforperformanceshareunitsthefairmarketvalueiscalculatedforthetwo componentgoalsatthedateofgrantadjustedoperationalearningspershareandrelativetotalshareholderreturnthefair valuesfortheearningspersharegoalofeachperformanceshareunitwasestimatedonthedateofgrantusingthefair marketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenotpaidontheperformanceshare unitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalofeachperformanceshareunit wasestimatedonthedateofgrantusingthemontecarlovaluationmodelseenotetotheconsolidatedfinancial statementsforadditionalinformation newaccountingpronouncement refertonotetotheconsolidatedfinancialstatementsforrecentlyadoptedaccountingpronouncementsandrecently issuedaccountingpronouncementsnotyetadoptedasofjanuary economicandmarketfactor covidconsiderationsandbusinesscontinuity thecompanyhasconsideredvariousinternalandexternalfactorsinassessingthepotentialimpactofcovidonit businessandfinancialresultsbaseduponinformationavailableatthistimeasfollow operatingmodelthecompanyhasadiversifiedbusinessmodelacrossthehealthcareindustrywithflexibilitydesigned intoitsmanufacturingresearchanddevelopmentclinicaloperationsandcommercialcapabilitie supplychainthecompanycontinuestoleverageitsglobalmanufacturingfootprintanddualsourcecapabilitieswhile closelymonitoringandmaintainingcriticalinventoryatmajordistributioncentersawayfromhighriskareastoensure adequateandeffectivedistribution businesscontinuitytherobustactivebusinesscontinuityplansacrossthecompanysnetworkhavebeeninstrumental inpreparingthecompanyforeventslikecovidandtheabilitytomeetthemajorityofpatientandconsumerneed remainsuninterrupte workforcethecompanyhasputproceduresinplacetoprotectitsessentialworkforceinmanufacturingdistribution commercialandresearchoperationswhileensuringappropriateremoteworkingprotocolshavebeenestablishedfor otheremployee liquiditythecompanyshighqualitycreditratingallowsthecompanysuperioraccesstothefinancialcapitalmarket fortheforeseeablefutureinthefiscalthirdquarterofthecompanyissuedapproximatelybillionof commercialpaperwithapproximatelybillionoutstandingatyearendforadditionalliquidityadditionallyinthe fiscalthirdquarterofthecompanyissuedseniorunsecurednotesforatotalofbillionthenetproceed fromthisofferingwereusedtofundthemomentapharmaceuticalsincacquisitiononoctoberandforgeneral corporatepurpose johnsonjohnsonannualreport domesticandforeignlegislationthecompanywillcontinuetoassessandevaluatetheongoinggloballegislative effortstocombatthecovidimpactoneconomiesandthesectorsinwhichitparticipatescurrentlytherecent legislativeactsputinplacearenotexpectedtohaveamaterialimpactonthecompanysoperation infiscalthecompanyenteredintoaseriesofcontractmanufacturingarrangementsforvaccineproductionwith thirdpartycontractmanufacturingorganizationsthesearrangementsprovidethecompanywithfuturesupplemental commercialcapacityforvaccineproductionandpotentiallytransferablerightstosuchproductionifcapacityisnot requiredamountspaidandcontractuallyobligatedtobepaidtothesecontractmanufacturingorganizationsof approximatelybillionarereflectedintheprepaidexpensesandotherotherassetsaccruedliabilitiesandother liabilitiesaccountsinthecompanysconsolidatedbalancesheetuponexecutionofeachagreementadditionallythe companyhasenteredintocertainvaccinedevelopmentcostsharingarrangementswithgovernmentrelatedorganization thecompanyisawarethatitsproductsareusedinanenvironmentwhereformorethanadecadepolicymaker consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcareinresponsetotheseconcern thecompanyhasalongstandingpolicyofpricingproductsresponsiblyfortheperiodintheusthe weightedaveragecompoundannualgrowthrateofthecompanysnetpriceincreasesforhealthcareproduct prescriptionandoverthecounterdrugshospitalandprofessionalproductswasbelowtheusconsumerpriceindex cpi thecompanyoperatesincertaincountrieswheretheeconomicconditionscontinuetopresentsignificantchallengesthe companycontinuestomonitorthesesituationsandtakeappropriateactionsinflationratescontinuetohaveaneffecton worldwideeconomiesandconsequentlyonthewaycompaniesoperatethecompanyhasaccountedforoperationsin argentinabeginninginthefiscalthirdquarterofandvenezuelaashighlyinflationaryasthepriorthreeyear cumulativeinflationratesurpassedthisdidnothaveamaterialimpacttothecompanysresultsintheperiodin thefaceofincreasingcoststhecompanystrivestomaintainitsprofitmarginsthroughcostreductionprogram productivityimprovementsandperiodicpriceincrease injunetheunitedkingdomukheldareferenduminwhichvotersapprovedanexitfromtheeuropeanunion eucommonlyreferredtoasbrexittheukofficiallyexitedtheeuonjanuaryhowevertherewasa transitionperiodtoallowtimetoagreethetermsofanewtradedealondecembertheukeuandthe europeanatomicenergycommunityeuratomsignedtheeuuktradeandcooperationagreementtcaoverthe lastfewyearsbrexithascreatedglobalpoliticalandeconomicuncertaintyandhasledtovolatilityinexchangeratesand interestratesadditionalcostcontainmentbythirdpartypayorsandchangesinregulationswhiletheukandeuhave nowagreedonafuturetradeandcooperationagreementitisstillunclearwhattheultimatefinancialtraderegulatoryand legalimplicationsthewithdrawaloftheukfromtheeuwillhavehoweverthecompanycurrentlydoesnotbelievethat theseandotherrelatedeffectswillhaveamaterialimpactonthecompanysconsolidatedfinancialpositionoroperate resultsasofjanuarythebusinessofthecompanysuksubsidiariesrepresentedlessthanofthe companysconsolidatedassetsandlessthanofthecompanysfiscaltwelvemonthsrevenue thecompanyisexposedtofluctuationsincurrencyexchangeratesachangeinthevalueoftheusdollaras comparedtoallforeigncurrenciesinwhichthecompanyhadsalesincomeorexpenseinwouldhaveincreasedor decreasedthetranslationofforeignsalesbyapproximatelymillionandnetincomebyapproximatelymillion governmentsaroundtheworldconsidervariousproposalstomakechangestotaxlawswhichmayincludeincreasingor decreasingexistingstatutorytaxratesachangeinstatutorytaxrateinanycountrywouldresultintherevaluationofthe companysdeferredtaxassetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhichthenewtaxlawis enactedthischangewouldresultinanexpenseorbenefitrecordedtothecompanysconsolidatedstatementof earningsthecompanycloselymonitorstheseproposalsastheyariseinthecountrieswhereitoperateschangestothe statutorytaxratemayoccuratanytimeandanyrelatedexpenseorbenefitrecordedmaybematerialtothefiscalquarter andyearinwhichthelawchangeisenacte thecompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude healthcarecostcontainmentandgovernmentlegislationrelatingtosalespromotionsandreimbursementofhealthcare product changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservicesincludingdelaye medicalproceduresrationingprescriptionmedicationsreducingthefrequencyofphysicianvisitsandforegoinghealth careinsurancecoverageasaresultofthecurrentglobaleconomicdownturnmaycontinuetoimpactthecompany business johnsonjohnsonannualreportthecompanyalsooperatesinanenvironmentincreasinglyhostiletointellectualpropertyrightsfirmshavefile abbreviatednewdrugapplicationsorbiosimilarbiologicalproductapplicationswiththefdaorotherwisechallenge thecoverageandorvalidityofthecompanyspatentsseekingtomarketgenericorbiosimilarformsofmanyofthe companyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductsintheevent thecompanyisnotsuccessfulindefendingthepatentclaimschallengedintheresultinglawsuitsgenericorbiosimilar versionsoftheproductsatissuewillbeintroducedtothemarketresultinginthepotentialforsubstantialmarketshareand revenuelossesforthoseproductsandwhichmayresultinanoncashimpairmentchargeinanyassociatedintangible assetthereisalsoariskthatoneormorecompetitorscouldlaunchagenericorbiosimilarversionoftheproductatissue followingregulatoryapprovaleventhoughoneormorevalidpatentsareinplace legalproceeding johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialandothermattersgovernmentalinvestigationsandotherlegalproceedingsthatarise fromtimetotimeintheordinarycourseofbusiness thecompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimatedasofjanuarythecompanyhas determinedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimatedthe companyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmight bewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithascfortheseand otherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossiblethecompany isunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsaccruedamountsaccruedforlegal contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon estimatesandassumptionsincludingtimingofrelatedpaymentstheabilitytomakesuchestimatesandjudgmentscanbe affectedbyvariousfactorsincludingamongotherthingswhetherdamagessoughtintheproceedingsare unsubstantiatedorindeterminatescientificandlegaldiscoveryhasnotcommencedorisnotcompleteproceedingsarein earlystagesmatterspresentlegaluncertaintiestherearesignificantfactsindisputeproceduralorjurisdictionalissue theuncertaintyandunpredictabilityofthenumberofpotentialclaimsabilitytoachievecomprehensivemultiparty settlementscomplexityofrelatedcrossclaimsandcounterclaimsandortherearenumerouspartiesinvolvedtothe extentadverseverdictshavebeenrenderedagainstthecompanythecompanydoesnotrecordanaccrualuntilalossis determinedtobeprobableandcanbereasonablyestimate inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutionoforincreaseinaccrualsfor oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardinglegalproceeding commonstock thecompanyscommonstockislistedonthenewyorkstockexchangeunderthesymboljnjasoffebruary therewererecordholdersofcommonstockofthecompany johnsonjohnsonannualreport item quantitative qualitative disclosure market risk theinformationcalledforbythisitemisincorporatedhereinbyreferencetoitemmanagementsdiscussionand analysisofresultsofoperationsandfinancialconditionliquidityandcapitalresourcesfinancingandmarketrisk ofthisreportandnotesummaryofsignificantaccountingpoliciesfinancialinstrumentsofthenotesto consolidatedfinancialstatementsincludedinitemofthisreport item financial statement supplementary data indextoauditedconsolidatedfinancialstatement consolidatedbalancesheet consolidatedstatementsofearning consolidatedstatementsofcomprehensiveincome consolidatedstatementsofequity consolidatedstatementsofcashflow notestoconsolidatedfinancialstatement reportofindependentregisteredpublicaccountingfirm managementsreportoninternalcontroloverfinancialreporte johnsonjohnsonannualreportjohnson johnson subsidiaries consolidate balance sheet atjanuaryanddecember dollarsinmillionsexceptshareandpershareamountsnote asset currentasset cashandcashequivalentsnotesand marketablesecuritiesnotesand accountsreceivabletradelessallowancesfordoubtfulaccount inventoriesnotesand prepaidexpensesandotherreceivable assetsheldforsalenote totalcurrentassets propertyplantandequipmentnetnotesand intangibleassetsnetnotesand goodwillnotesand deferredtaxesonincomenote otherasset totalasset liabilitiesandshareholdersequity currentliabilitie loansandnotespayablenote accountspayable accruedliabilitie accruedrebatesreturnsandpromotion accruedcompensationandemployeerelatedobligation accruedtaxesonincomenote totalcurrentliabilities longtermdebtnote deferredtaxesonincomenote employeerelatedobligationsnotesand longtermtaxespayablenote otherliabilitie totalliabilitie commitmentsandcontingenciesnote shareholdersequity preferredstockwithoutparvalueauthorizedandunissuedshare commonstockparvaluepersharenoteauthorizedsharesissue share accumulatedothercomprehensiveincomelossnote retainedearning lesscommonstockheldintreasuryatcostnotesharesandshare totalshareholdersequity totalliabilitiesandshareholdersequity seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreport johnson johnson subsidiaries consolidate statement earning dollarsandsharesinmillionsexceptpershareamountsnote salestocustomer costofproductssold grossprofit sellingmarketingandadministrativeexpense researchanddevelopmentexpense inprocessresearchanddevelopmentnote interestincome interestexpensenetofportioncapitalizednote otherincomeexpensenet restructuringnote earningsbeforeprovisionfortaxesonincome provisionfortaxesonincomenote netearning netearningspersharenotesand basic diluted averagesharesoutstandingnotesand basic diluted seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportjohnson johnson subsidiaries consolidate statement comprehensive income dollarsinmillionsnote netearning othercomprehensiveincomelossnetoftax foreigncurrencytranslation security unrealizedholdinggainlossarisingduringperiod reclassificationstoearning netchange employeebenefitplans priorservicecreditcostnetofamortization gainlossnetofamortization effectofexchangerate netchange derivativeshedge unrealizedgainlossarisingduringperiod reclassificationstoearning netchange othercomprehensiveincomeloss comprehensiveincome thetaxeffectsinothercomprehensiveincomeforthefiscalyearsandrespectivelyforeigncurrency translationmillionmillionandmillionemployeebenefitplansmillionmillionandmillion derivativeshedgesmillionmillionandmillion seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreport johnson johnson subsidiaries consolidate statement equity dollarsinmillionsnote accumulate common stock treasury retain comprehensive issue stock total earning incomeloss balancedecember cumulativeadjustment netearning cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancedecember netearning cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancedecember netearning cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancejanuary seenotetoconsolidatedfinancialstatementsforadditionaldetailsontheeffectofcumulativeadjustmentstoretainedearning seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportjohnson johnson subsidiaries consolidate statement cash flow dollarsinmillionsnote cashflowsfromoperatingactivitie netearning adjustmentstoreconcilenetearningstocashflowsfromoperatingactivitie depreciationandamortizationofpropertyandintangible stockbasedcompensation assetwritedown contingentconsiderationreversal netgainonsaleofassetsbusinesse deferredtaxprovision creditlossesandaccountsreceivableallowance changesinassetsandliabilitiesnetofeffectsfromacquisitionsanddivestiture decreaseincreaseinaccountsreceivable increaseininventorie increaseinaccountspayableandaccruedliabilitie increaseinothercurrentandnoncurrentasset increasedecreaseinothercurrentandnoncurrentliabilitie netcashflowsfromoperatingactivitie cashflowsfrominvestingactivitie additionstopropertyplantandequipment proceedsfromthedisposalofassetsbusinessesnet acquisitionsnetofcashacquirednote purchasesofinvestment salesofinvestment creditsupportagreementsactivitynet otherprimarilylicensesandmilestone netcashusedbyinvestingactivitie cashflowsfromfinancingactivitie dividendstoshareholder repurchaseofcommonstock proceedsfromshorttermdebt repaymentofshorttermdebt proceedsfromlongtermdebtnetofissuancecosts repaymentoflongtermdebt proceedsfromtheexerciseofstockoptionsemployeewithholdingtaxonstockawardsnet creditsupportagreementsactivitynet netcashusedbyfinancingactivitie effectofexchangeratechangesoncashandcashequivalent decreaseincreaseincashandcashequivalent cashandcashequivalentsbeginningofyearnote cashandcashequivalentsendofyearnote supplementalcashflowdata cashpaidduringtheyearfor interest interestnetofamountcapitalize incometaxe supplementalscheduleofnoncashinvestingandfinancingactivitie treasurystockissuedforemployeecompensationandstockoptionplansnetofcashproceedsemployee withholdingtaxonstockaward conversionofdebt acquisition fairvalueofassetsacquire fairvalueofliabilitiesassumedandnoncontrollinginterest netcashpaidforacquisitionsnote seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreport note consolidated financial statement summary significant accounting policy principlesofconsolidation theconsolidatedfinancialstatementsincludetheaccountsofjohnsonjohnsonanditssubsidiariesthecompany intercompanyaccountsandtransactionsareeliminatedcolumnsandrowswithintablesmaynotaddduetorounde percentageshavebeencalculatedusingactualnonroundedfigure descriptionofthecompanyandbusinesssegment thecompanyhasapproximatelyemployeesworldwideengagedintheresearchanddevelopmentmanufacture andsaleofabroadrangeofproductsinthehealthcarefieldthecompanyconductsbusinessinvirtuallyallcountriesof theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwellbeing thecompanyisorganizedintothreebusinesssegmentsconsumerhealthpreviouslyreferredtoasconsumer pharmaceuticalandmedicaldevicestheconsumerhealthsegmentincludesabroadrangeofproductsusedinthebaby careoralcareskinhealthbeautyoverthecounterpharmaceuticalwomenshealthandwoundcaremarketsthese productsaremarketedtothegeneralpublicandsoldonlineecommerceandtoretailoutletsanddistributorsthroughout theworldthepharmaceuticalsegmentisfocusedonsixtherapeuticareasincludingimmunologyinfectiousdisease neuroscienceoncologypulmonaryhypertensionandcardiovascularandmetabolicdiseasesproductsinthissegment aredistributeddirectlytoretailerswholesalershospitalsandhealthcareprofessionalsforprescriptionusethemedical devicessegmentincludesabroadrangeofproductsusedintheorthopaedicsurgeryinterventionalsolution cardiovascularandneurovascularandeyehealthfieldswhicharedistributedtowholesalershospitalsandretailersand usedprincipallyintheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinic newaccountingstandard recentlyadoptedaccountingstandard asucollaborativearrangement thecompanyadoptedthisstandardasofthebeginningofthefiscalyearthisupdateclarifiestheinteraction betweenasccollaborativearrangementsandascrevenuefromcontractswithcustomerstheupdate clarifiesthatcertaintransactionsbetweenparticipantsinacollaborativearrangementshouldbeaccountedforunderasc whenthecounterpartyisacustomerinadditiontheupdateprecludesanentityfrompresentingconsiderationfroma transactioninacollaborativearrangementasrevenueifthecounterpartyisnotacustomerforthattransactionthe adoptionofthisstandarddidnothaveamaterialimpactonthecompanysconsolidatedfinancialstatement asufinancialinstrumentscreditlosse thecompanyadoptedthisstandardasofthebeginningofthefiscalyearthisupdateintroducesthecurrent expectedcreditlossceclmodelwhichrequiresanentitytomeasurecreditlossesforcertainfinancialinstrumentsand financialassetsincludingtradereceivablesunderthisupdateoninitialrecognitionandateachreportingperiodanentity isrequiredtorecognizeanallowancethatreflectstheentityscurrentestimateofcreditlossesexpectedtobeincurre overthelifeofthefinancialinstrumenttheadoptionofthisstandarddidnothaveamaterialimpactonthecompany consolidatedfinancialstatement asucompensationdefinedbenefitplans thecompanyadoptedthisstandardinthefiscalyearendedthisstandardrevisedthefinancialstatementnote disclosurerequirementsofascfordefinedbenefitplansponsorstheadoptionofthisstandardhadnoimpact onthecompanysconsolidatedfinancialstatementsseenotetotheconsolidatedfinancialstatementsfordefine benefitplandisclosure johnsonjohnsonannualreportaccountingstandardsadoptedinthefiscalwithacumulativeeffecttotheopene balanceofretainedearning thefollowingtablesummarizesthecumulativeeffectadjustmentsmadetotheopeningbalanceofretainedearning uponadoptionoftheseaccountingstandardsin cumulativeeffect adjustmentincrease decreaseto dollarsinmillion retainedearning asurevenuefromcontractswithcustomer asufinancialinstrument asuincometaxesintraentitytransfer total recentlyissuedaccountingstandard notadoptedasofjanuary thecompanyassessestheadoptionimpactsofrecentlyissuedaccountingstandardsbythefinancialaccounte standardsboardonthecompanysfinancialstatementsaswellasmaterialupdatestopreviousassessmentsifanyfrom thecompanysannualreportonformkforthefiscalyearendeddecembertherewerenonewmaterial accountingstandardsissuedinfiscalthatimpactedthecompany cashequivalent thecompanyclassifiesallhighlyliquidinvestmentswithstatedmaturitiesofthreemonthsorlessfromdateofpurchase ascashequivalentsandallhighlyliquidinvestmentswithstatedmaturitiesofgreaterthanthreemonthsfromthedateof purchaseascurrentmarketablesecuritiesthecompanyhasapolicyofmakinginvestmentsonlywithcommercial institutionsthathaveatleastaninvestmentgradecreditratingthecompanyinvestsitscashprimarilyingovernment securitiesandobligationscorporatedebtsecuritiesmoneymarketfundsandreverserepurchaseagreementsrra rrasarecollateralizedbydepositsintheformofgovernmentsecuritiesandobligationsforanamountnotlessthan oftheirvaluethecompanydoesnotrecordanassetorliabilityasthecompanyisnotpermittedtosellor repledgetheassociatedcollateralthecompanyhasapolicythatthecollateralhasatleastanaorequivalentcredit ratingthecompanyutilizesathirdpartycustodiantomanagetheexchangeoffundsandensurethatcollateralreceivedis maintainedatofthevalueoftherrasonadailybasisrraswithstatedmaturitiesofgreaterthanthreemonth fromthedateofpurchaseareclassifiedasmarketablesecuritie investment investmentsclassifiedasheldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesare reportedinearningsinvestmentsclassifiedasavailableforsaledebtsecuritiesarecarriedatestimatedfairvaluewith unrealizedgainsandlossesrecordedasacomponentofaccumulatedothercomprehensiveincomeavailableforsale securitiesavailableforcurrentoperationsareclassifiedascurrentassetsotherwisetheyareclassifiedaslongterm managementdeterminestheappropriateclassificationofitsinvestmentindebtandequitysecuritiesatthetimeof purchaseandreevaluatessuchdeterminationateachbalancesheetdatethecompanyreviewsitsinvestmentsfor impairmentandadjuststheseinvestmentstofairvaluethroughearningsasrequire propertyplantandequipmentanddepreciation propertyplantandequipmentarestatedatcostthecompanyutilizesthestraightlinemethodofdepreciationoverthe estimatedusefullivesoftheasset buildingandbuildingequipment year landandleaseholdimprovement year machineryandequipment year johnsonjohnsonannualreport thecompanycapitalizescertaincomputersoftwareanddevelopmentcostsincludedinmachineryandequipmentwhen incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternalusecapitalizedsoftwarecostsare amortizedovertheestimatedusefullivesofthesoftwarewhichgenerallyrangefromtoyears thecompanyreviewslonglivedassetstoassessrecoverabilityusingundiscountedcashflowswhencertaineventsor changesinoperatingoreconomicconditionsoccuranimpairmentassessmentmaybeperformedontherecoverabilityof thecarryingvalueoftheseassetsiftheassetisdeterminedtobeimpairedthelossismeasuredbasedonthedifference betweentheassetsfairvalueanditscarryingvalueifquotedmarketpricesarenotavailablethecompanywillestimate fairvalueusingadiscountedvalueofestimatedfuturecashflow revenue recognition thecompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofacontractwiththecustomer aresatisfiedgenerallythisoccurswiththetransferofcontrolofthegoodstocustomersthecompanysglobalpayment termsaretypicallybetweentodaysprovisionsforcertainrebatessalesincentivestradepromotionscoupon productreturnsanddiscountstocustomersareaccountedforasvariableconsiderationandrecordedasareductionin salestheliabilityisrecognizedwithinaccruedrebatesreturnsandpromotionsontheconsolidatedbalancesheet productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingconsiderationofcompetitorpricingrebatesareestimatedbasedoncontractual termshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsinthevariousmarket servedasignificantportionoftheliabilityrelatedtorebatesisfromthesaleofthecompanyspharmaceuticalproduct withintheusprimarilythemanagedcaremedicareandmedicaidprogramswhichamountedtobillionand billionasofjanuaryanddecemberrespectivelythecompanyevaluatesmarketconditionsfor productsorgroupsofproductsprimarilythroughtheanalysisofwholesalerandotherthirdpartysellthroughandmarket researchdataaswellasinternallygeneratedinformation salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibitunusual salesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas partoftheaccountingforsalesreturnaccrual salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket asapercenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescredit tocustomersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerhealthandpharmaceuticalsegmentsarealmostexclusivelynotresalablesale returnsforcertainfranchisesinthemedicaldevicessegmentaretypicallyresalablebutarenotmaterialthecompany infrequentlyexchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyha beenapproximatelyofannualnettradesalesduringeachofthefiscalyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe sameperiodasrelatedsalescontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentive programstheredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue volumebasedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas productsaresoldthesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas areductionofrevenuethecompanyalsoearnsprofitsharepaymentsthroughcollaborativearrangementsforcertain productswhichareincludedinsalestocustomersforallyearspresentedprofitsharepaymentswerelessthanof thetotalrevenuesandareincludedinsalestocustomer seenotetotheconsolidatedfinancialstatementsforfurtherdisaggregationofrevenue shippingandhandle shippingandhandlingcostsincurredwerebillionbillionandbillioninfiscalyearsand respectivelyandareincludedinsellingmarketingandadministrativeexpensetheamountofrevenuereceivedfor shippingandhandlingislessthanofsalestocustomersforallperiodspresente johnsonjohnsonannualreportinventorie inventoriesarestatedatthelowerofcostornetrealizablevaluedeterminedbythefirstinfirstoutmethod intangibleassetsandgoodwill theauthoritativeliteratureonusgaaprequiresthatgoodwillandintangibleassetswithindefinitelivesbeassesse annuallyforimpairmentthecompanycompleteditsannualimpairmenttestforinthefiscalfourthquarterfuture impairmenttestswillbeperformedannuallyinthefiscalfourthquarterorsoonerifwarrantedpurchasedinprocess researchanddevelopmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscomplete atwhichpointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleassetorabandonedatwhichpoint theintangibleassetwillbewrittenofforpartiallyimpaire intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullivesandarereviewedfor impairmentwhenwarrantedbyeconomicconditionsseenoteforfurtherdetailsonintangibleassetsandgoodwill financialinstrument asrequiredbyusgaapallderivativeinstrumentsarerecordedonthebalancesheetatfairvaluefairvalueistheexit pricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbasedmeasurement determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitytheauthoritativeliterature establishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluewithlevelhavingthehighest priorityandlevelhavingthelowestchangesinthefairvalueofderivativesarerecordedeachperiodincurrentearning orothercomprehensiveincomedependingonwhetherthederivativeisdesignatedaspartofahedgetransactionandif sothetypeofhedgetransaction thecompanydocumentsallrelationshipsbetweenhedgeditemsandderivativestheoverallriskmanagementstrategy includesreasonsforundertakinghedgetransactionsandenteringintoderivativestheobjectivesofthisstrategyare minimizeforeigncurrencyexposuresimpactonthecompanysfinancialperformanceprotectthecompanyscash flowfromadversemovementsinforeignexchangeratesensuretheappropriatenessoffinancialinstrumentsand managetheenterpriseriskassociatedwithfinancialinstitutionsseenoteforadditionalinformationonfinancial instrument lease thecompanydetermineswhetheranarrangementisaleaseatcontractinceptionbyestablishingifthecontractconvey therighttocontroltheuseofidentifiedpropertyplantorequipmentforaperiodoftimeinexchangeforconsideration rightofuserouassetsandleaseliabilitiesforoperatingleasesareincludedinotherassetsaccruedliabilitiesand otherliabilitiesontheconsolidatedbalancesheettherouassetsrepresenttherighttouseanunderlyingassetforthe leasetermandleaseliabilitiesrepresentanobligationtomakeleasepaymentsarisingfromtheleasecommitmentsunder financeleasesarenotsignificantandareincludedinpropertyplantandequipmentloansandnotespayableandlong termdebtontheconsolidatedbalancesheet rouassetsandleaseliabilitiesarerecognizedattheleasecommencementdatebasedonthepresentvalueofall minimumleasepaymentsovertheleasetermthecompanyusesitsincrementalborrowingratebasedontheinformation availableatcommencementdateindeterminingthepresentvalueofleasepaymentswhentheimplicitrateisnotreadily determinableleasetermsmayincludeoptionstoextendorterminatetheleasetheseoptionsareincludedinthelease termwhenitisreasonablycertainthatthecompanywillexercisethatoptionoperatingleaseexpenseisrecognizedona straightlinebasisovertheleasetermthecompanyhaselectedthefollowingpolicyelectionsonadoptionuseof portfolioapproachonleasesofassetsundermasterserviceagreementsexclusionofshorttermleasesonthebalance sheetandnotseparatingleaseandnonleasecomponent thecompanyprimarilyhasoperatingleaseforspacevehiclesmanufacturingequipmentanddataprocessingequipment therouassetpertainingtooperatingleaseswasbillionandbillioninandrespectivelythelease liabilitywasbillionandbillioninandrespectivelytheoperatingleasecostswerebillion billionandbillioninandrespectivelycashpaidforamountsincludedinthemeasurementof leaseliabilitieswerebillionandbillioninandrespectively productliability accrualsforproductliabilityclaimsarerecordedonanundiscountedbasiswhenitisprobablethataliabilityhasbeen incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformationandactuarially johnsonjohnsonannualreport determinedestimateswhereapplicabletheaccrualsareadjustedperiodicallyasadditionalinformationbecome availablethecompanyaccruesanestimateofthelegaldefensecostsneededtodefendeachmatterwhenthosecost areprobableandcanbereasonablyestimatedtotheextentadverseverdictshavebeenrenderedagainstthecompany thecompanydoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimate thecompanyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyinadditiontoaccrualsintheself insuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe reasonablyestimate researchanddevelopment researchanddevelopmentexpensesareexpensedasincurredinaccordancewithascresearchand developmentupfrontandmilestonepaymentsmadetothirdpartiesinconnectionwithresearchanddevelopment collaborationsareexpensedasincurreduptothepointofregulatoryapprovalpaymentsmadetothirdpartiessubsequent toregulatoryapprovalarecapitalizedandamortizedovertheremainingusefullifeoftherelatedproductamount capitalizedforsuchpaymentsareincludedinotherintangiblesnetofaccumulatedamortization thecompanyentersintocollaborativearrangementstypicallywithotherpharmaceuticalorbiotechnologycompaniesto developandcommercializedrugcandidatesorintellectualpropertythesearrangementstypicallyinvolvetwoormore partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe commercialsuccessoftheactivitiesthesecollaborationsusuallyinvolvevariousactivitiesbyoneormorepartie includingresearchanddevelopmentmarketingandsellinganddistributionoftenthesecollaborationsrequireupfront milestoneandroyaltyorprofitsharepaymentscontingentupontheoccurrenceofcertainfutureeventslinkedtothe successoftheassetindevelopment amountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesaregenerallyreflectedasareductionof researchanddevelopmentexpensebecausetheperformanceofcontractdevelopmentservicesisnotcentraltothe companysoperationsingeneraltheincomestatementpresentationforthesecollaborationsisasfollow naturetypeofcollaboration statementofearningspresentation thirdpartysaleofproductprofitsharepaymentsreceive salestocustomer royaltiesmilestonespaidtocollaborativepartnerpost costofproductssold regulatoryapproval royaltiesreceivedfromcollaborativepartner otherincomeexpensenet upfrontpaymentsmilestonespaidtocollaborativepartner researchanddevelopmentexpense preregulatoryapproval researchanddevelopmentpaymentstocollaborative researchanddevelopmentexpense partner researchanddevelopmentpaymentsreceivedfrom reductionofresearchanddevelopmentexpense collaborativepartnerorgovernmententity milestonesarecapitalizedasintangibleassetsandamortizedtocostofproductssoldovertheusefullife forallyearspresentedtherewasnoindividualprojectthatrepresentedgreaterthanofthetotalannualconsolidate researchanddevelopmentexpense thecompanyhasanumberofproductsandcompoundsdevelopedincollaborationwithstrategicpartnersincluding xareltocodevelopedwithbayerhealthcareagandimbruvicadevelopedincollaborationandcomarkete withpharmacyclicsllcanabbviecompany separatelythecompanyhasanumberoflicensingarrangementsforproductsandcompoundsincludingdarzalex licensedfromgenmabas advertising costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinsellingmarketingand administrativeexpensesadvertisingexpensesworldwidewhichcomprisedtelevisionradioprintmediaandinternet advertisingwerebillionbillionandbillioninfiscalyearsandrespectively johnsonjohnsonannualreportincometaxe incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany differencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitiesthecompany estimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesintaxlawsand ratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition intheunitedstatesenactedintolawnewustaxlegislationtheustaxcutsandjobsacttcjathislaw includedprovisionsforacomprehensiveoverhaulofthecorporateincometaxcodeincludingareductionofthestatutory corporatetaxratefromtoeffectiveonjanuarythetcjaincludedaprovisionforataxonall previouslyundistributedearningsofuscompanieslocatedinforeignjurisdictionsundistributedearningsintheformof cashandcashequivalentsweretaxedatarateofandallotherearningsweretaxedatarateofthistaxis payableoveryearsandwillnotaccrueinterestthesepaymentsbeganinandwillcontinuethroughthe remainingbalanceattheendofthewasapproximatelybillionofwhichbillionisclassifiedasnoncurrent andreflectedaslongtermtaxespayableonthecompanysbalancesheetthebalanceofthisaccountisrelatedto receivablesfromtaxauthoritiesnotexpectedtobereceivedinthenextmonth thetcjaalsoincludesprovisionsforataxonglobalintangiblelowtaxedincomegiltigiltiisdescribedasthe excessofausshareholderstotalnetforeignincomeoveradeemedreturnontangibleassetsasprovidedbythetcja injanuarythefasbissuedguidancethatallowscompaniestoelectasanaccountingpolicywhethertorecordthe taxeffectsofgiltiintheperiodthetaxliabilityisgeneratedieperiodcostorprovidefordeferredtaxassetsand liabilitiesrelatedtobasisdifferencesthatexistandareexpectedtoeffecttheamountofgiltiinclusioninfutureyears uponreversaliedeferredmethodinthecompanyelectedtoaccountforgiltiunderthedeferredmethod thedeferredtaxamountsrecordedarebasedontheevaluationoftemporarydifferencesthatareexpectedtoreverseas giltiisincurredinfutureperiod thecompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortodecemberfromit internationalsubsidiariesthecompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto januaryfromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvestedthe companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperationsifthecompanydecidesata laterdatetorepatriatetheseearningstotheusthecompanywouldberequiredtoprovideforthenettaxeffectson theseamountsthecompanyestimatesthatthetotaltaxeffectofthisrepatriationwouldbeapproximatelybillion undercurrentenactedtaxlawsandregulationsandatcurrentcurrencyexchangerate seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxe netearningspershare basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage numberofcommonsharesoutstandingfortheperioddilutedearningspersharereflectsthepotentialdilutionthatcould occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod useofestimate thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe usrequiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreportedestimatesareusedwhen accountingforsalesdiscountsrebatesallowancesandincentivesproductliabilitiesincometaxeswithholdingtaxes depreciationamortizationemployeebenefitscontingenciesandintangibleassetandliabilityvaluationsactualresults mayormaynotdifferfromthoseestimate thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorde whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrue theextenttowhichcovidimpactsthecompanysbusinessandfinancialresultswilldependonnumerousevolve factorsincludingbutnotlimitedtothemagnitudeanddurationofcovidtheextenttowhichitwillimpactworldwide johnsonjohnsonannualreport macroeconomicconditionsincludinginterestratesemploymentratesandhealthinsurancecoveragethespeedofthe anticipatedrecoveryandgovernmentalandbusinessreactionstothepandemicthecompanyassessedcertain accountingmattersthatgenerallyrequireconsiderationofforecastedfinancialinformationincontextwiththeinformation reasonablyavailabletothecompanyandtheunknownfutureimpactsofcovidasofjanuaryandthroughthe dateofthisreporttheaccountingmattersassessedincludedbutwerenotlimitedtothecompanysallowancefor doubtfulaccountsandcreditlossesinventoryandrelatedreservesaccruedrebatesandassociatedreservesandthe carryingvalueofthegoodwillandotherlonglivedassetswhiletherewasnotamaterialimpacttothecompany consolidatedfinancialstatementsasofandforthefiscalyearendedjanuarythecompanysfutureassessmentof themagnitudeanddurationofcovidaswellasotherfactorscouldresultinmaterialimpactstothecompany consolidatedfinancialstatementsinfuturereportingperiod annualclosingdate thecompanyfollowstheconceptofafiscalyearwhichendsonthesundaynearesttotheendofthemonthof decembernormallyeachfiscalyearconsistsofweeksbuteveryfiveorsixyearsthefiscalyearconsistsofweek andthereforeincludesadditionalshippingdaysaswasthecaseinfiscalyearandwillbethecaseagaininfiscal year reclassification certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation cash cash equivalent current marketable security attheendofthefiscalyearandcashcashequivalentsandcurrentmarketablesecuritieswerecomprisedof estimate cash current carry unrecognized fair cash marketable dollarsinmillion gain value equivalent security cash nonussovereignsecuritie usreverserepurchaseagreement corporatedebtsecuritie moneymarketfund timedeposits subtotal usgovtsecuritie othersovereignsecuritie corporatedebtsecuritie subtotalavailableforsale totalcashcashequivalentsandcurrentmarketable security johnsonjohnsonannualreport cash current carry cash marketable dollarsinmillion equivalent security cash nonussovereignsecuritie usreverserepurchaseagreement otherreverserepurchaseagreement corporatedebtsecuritie moneymarketfund timedeposit subtotal govtsecuritie corporatedebtsecuritie subtotalavailableforsale totalcashcashequivalentsandcurrentmarketablesecuritie heldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesarereportedinearning availableforsaledebtsecuritiesarereportedatfairvaluewithunrealizedgainsandlossesreportednetoftaxesinother comprehensiveincome attheendoffiscalyearthecarryingamountwasthesameastheestimatedfairvalue fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker pricesandsignificantotherobservableinput thecontractualmaturitiesoftheavailableforsaledebtsecuritiesatjanuaryareasfollow cost fair dollarsinmillion basis value duewithinoneyear dueafteroneyearthroughfiveyear dueafterfiveyearsthroughtenyear totaldebtsecuritie thecompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhighquality moneymarketinstrumentsthecompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat leastaninvestmentgradecreditrate inventory attheendoffiscalyearsandinventorieswerecomprisedof dollarsinmillion rawmaterialsandsupplie goodsinprocess finishedgood totalinventorie seenotetotheconsolidatedfinancialstatementsfordetailsonassetsheldforsaleandtherelateddivestituresforthefiscal yearendeddecembertherewerenoassetsheldforsaleatjanuary johnsonjohnsonannualreport property plant equipment attheendoffiscalyearsandpropertyplantandequipmentatcostandaccumulateddepreciationwere dollarsinmillion landandlandimprovement buildingsandbuildingequipment machineryandequipment constructioninprogress totalpropertyplantandequipmentgross lessaccumulateddepreciation totalpropertyplantandequipmentnet seenotetotheconsolidatedfinancialstatementsfordetailsonassetsheldforsaleandtherelateddivestituresforthefiscal yearendeddecembertherewerenoassetsheldforsaleatjanuary thecompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipmentinterestexpense capitalizedinfiscalyearsandwasmillionmillionandmillionrespectively depreciationexpenseincludingtheamortizationofcapitalizedinterestinfiscalyearsandwas billionbillionandbillionrespectively uponretirementorotherdisposalofpropertyplantandequipmentthecostsandrelatedamountsofaccumulate depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccountsrespectivelythe differenceifanybetweenthenetassetvalueandtheproceedsarerecordedinearning intangible asset goodwill attheendoffiscalyearsandthegrossandnetamountsofintangibleassetswere dollarsinmillion intangibleassetswithdefinitelive patentsandtrademarksgross lessaccumulatedamortization patentsandtrademarksnet customerrelationshipsandotherintangiblesgross lessaccumulatedamortization customerrelationshipsandotherintangiblesnet intangibleassetswithindefinitelive trademark purchasedinprocessresearchanddevelopment totalintangibleassetswithindefinitelive totalintangibleassetsnet themajorityiscomprisedofcustomerrelationship infiscalyearthecompanycompletedmultipleacquisitionsandrecordedinprocessresearchanddevelopmentintangible assetsofbillionfrommomentapharmaceuticalsincbillionforbermekimabandcertainrelatedassetsfromxbiotechinc andbillionfromtheacquisitionofalloutstandingsharesinverbsurgicalinc johnsonjohnsonannualreportgoodwillasofjanuaryanddecemberasallocatedbysegmentofbusinesswasasfollow dollarsinmillion consumerhealth pharmaceutical medicaldevice total goodwillatdecember goodwillrelatedtoacquisition currencytranslationother goodwillatdecember goodwillrelatedtoacquisition currencytranslationother goodwillatjanuary theweightedaverageamortizationperiodforpatentsandtrademarksisyearstheweightedaverageamortization periodforcustomerrelationshipsandotherintangibleassetsisyearstheamortizationexpenseofamortizableasset includedincostofproductssoldwasbillionbillionandbillionbeforetaxforthefiscalyearsende januarydecemberanddecemberrespectivelyintangibleassetwritedownsareincludedin otherincomeexpensenet theestimatedamortizationexpenseforapprovedproductsbeforetaxforthefivesucceedingyearsisapproximately dollarsinmillion seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtoacquisitionsanddivestiture fair value measurement thecompanyusesforwardforeignexchangecontractstomanageitsexposuretothevariabilityofcashflowsprimarily relatedtotheforeignexchangeratechangesoffutureintercompanyproductsandthirdpartypurchasesofmaterial denominatedinaforeigncurrencythecompanyusescrosscurrencyinterestrateswapstomanagecurrencyrisk primarilyrelatedtoborrowingsbothtypesofderivativesaredesignatedascashflowhedge additionallythecompanyusesinterestrateswapsasaninstrumenttomanageinterestrateriskrelatedtofixedrate borrowingsthesederivativesaredesignatedasfairvaluehedgesthecompanyusescrosscurrencyinterestrateswap andforwardforeignexchangecontractsdesignatedasnetinvestmenthedgesadditionallythecompanyusesforward foreignexchangecontractstooffsetitsexposuretocertainforeigncurrencyassetsandliabilitiestheseforwardforeign exchangecontractsarenotdesignatedashedgesandthereforechangesinthefairvaluesofthesederivativesare recognizedinearningstherebyoffsettingthecurrentearningseffectoftherelatedforeigncurrencyassetsandliabilitie thecompanydoesnotenterintoderivativefinancialinstrumentsfortradingorspeculativepurposesorthatcontaincredit riskrelatedcontingentfeaturesthecompanymaintainscreditsupportagreementscsawithcertainderivative counterpartiesestablishingcollateralthresholdsbasedonrespectivecreditratingsandnettingagreementsasof januarythetotalamountofcashcollateralpaidbythecompanyunderthecsaamountedtobillionnet relatedtonetinvestmentandcashflowhedgesonanongoingbasisthecompanymonitorscounterpartycreditrating thecompanyconsiderscreditnonperformancerisktobelowbecausethecompanyprimarilyentersintoagreement withcommercialinstitutionsthathaveatleastaninvestmentgradecreditratingrefertothetableonsignificantfinancial assetsandliabilitiesmeasuredatfairvaluecontainedinthisfootnoteforreceivablesandpayableswiththesecommercial institutionsasofjanuarythecompanyhadnotionalamountsoutstandingforforwardforeignexchange contractsandcrosscurrencyinterestrateswapsofbillionandbillionrespectivelyasofdecember thecompanyhadnotionalamountsoutstandingforforwardforeignexchangecontractsandcrosscurrencyinter rateswapsofbillionandbillionrespectively allderivativeinstrumentsarerecordedonthebalancesheetatfairvaluechangesinthefairvalueofderivativesare recordedeachperiodincurrentearningsorothercomprehensiveincomedependingonwhetherthederivativeis designatedaspartofahedgetransactionandifsothetypeofhedgetransaction johnsonjohnsonannualreport thedesignationasacashflowhedgeismadeattheentrancedateofthederivativecontractatinceptionallderivative areexpectedtobehighlyeffectiveforeignexchangecontractsdesignatedascashflowhedgesareaccountedforunder theforwardmethodandallgainslossesassociatedwiththesecontractswillberecognizedintheincomestatementwhen thehedgeditemimpactsearningschangesinthefairvalueofthesederivativesarerecordedinaccumulatedother comprehensiveincomeuntiltheunderlyingtransactionaffectsearningsandarethenreclassifiedtoearningsinthesame accountasthehedgedtransaction gainsandlossesassociatedwithinterestrateswapsandchangesinfairvalueofhedgeddebtattributabletochangesin interestratesarerecordedtointerestexpenseintheperiodinwhichtheyoccurtheeffectofwhichareimmaterialforthe fiscalyearsendedjanuaryanddecembergainsandlossesonnetinvestmenthedgeareaccounte throughthecurrencytranslationaccountwithinaccumulatedothercomprehensiveincometheportionexcludedfrom effectivenesstestingisrecordedthroughinterestincomeexpenseusingthespotmethodonanongoingbasisthe companyassesseswhethereachderivativecontinuestobehighlyeffectiveinoffsettingchangesofhedgeditemsifand whenaderivativeisnolongerexpectedtobehighlyeffectivehedgeaccountingisdiscontinue thecompanydesignateditseurodenominatednotesissuedinmaywithduedatesrangingfromtoas anetinvestmenthedgeofthecompanysinvestmentsincertainofitsinternationalsubsidiariesthatusetheeuroastheir functionalcurrencyinordertoreducethevolatilitycausedbychangesinexchangerate asofjanuarythebalanceofdeferrednetgainonderivativesincludedinaccumulatedothercomprehensive incomewasmillionaftertaxforadditionalinformationseetheconsolidatedstatementsofcomprehensiveincome andnotethecompanyexpectsthatsubstantiallyalloftheamountsrelatedtoforwardforeignexchangecontractswill bereclassifiedintoearningsoverthenextmonthsasaresultoftransactionsthatareexpectedtooccuroverthat periodthemaximumlengthoftimeoverwhichthecompanyishedgingtransactionexposureismonthsexclude interestratecontractsnetinvestmenthedgestheamountultimatelyrealizedinearningsmaydifferasforeignexchange rateschangerealizedgainsandlossesareultimatelydeterminedbyactualexchangeratesatmaturityofthederivative thefollowingtableisasummaryoftheactivityrelatedtoderivativesandhedgesforthefiscalyearsendedjanuary anddecembernetoftax january december costof interest costof interest product income income product income income dollarsinmillion sale sell expense expense expense sale sell expense expense expense theeffectsoffairvaluenetinvestment andcashflowhedge gainlossonnetinvestment hedgingrelationship crosscurrencyinterestrateswap contract amountofgainorlossrecognizedin incomeonderivativeamount excludedfromeffectivenessteste amountofgainorlossrecognizedin aoci gainlossoncashflowhedge relationship forwardforeignexchange contract amountofgainorlossreclassifie fromaociintoincome amountofgainorlossrecognizedin aoci crosscurrencyinterestrateswap contract amountofgainorlossreclassifie fromaociintoincome amountofgainorlossrecognizedin aoci johnsonjohnsonannualreportthefollowingtableistheeffectofderivativesnotdesignatedashedginginstrumentforthefiscalyearsendedjanuary anddecember locationofgainloss gainloss recognizedinincomeon recognizedin dollarsinmillion derivative incomeonderivative derivativesnotdesignatedashedginginstrument january december foreignexchangecontract otherincomeexpense thefollowingtableistheeffectofnetinvestmenthedgesforthefiscalyearsendedjanuaryanddecember gainloss gainloss locationofgainorlossreclassifie reclassifiedfrom recognizedin fromaccumulatedothercomprehensive accumulatedoci accumulatedoci incomeintoincome intoincome january december january december dollarsinmillion debt interestincomeexpense crosscurrencyinterestrateswap interestincomeexpense thecompanyholdsequityinvestmentswithreadilydeterminablefairvaluesandequityinvestmentswithoutreadily determinablefairvaluesthecompanymeasuresequityinvestmentsthatdonothavereadilydeterminablefairvaluesat costminusimpairmentifanyplusorminuschangesresultingfromobservablepricechangesinorderlytransactionsfor theidenticalorasimilarinvestmentofthesameissuer thefollowingtableisasummaryoftheactivityrelatedtoequityinvestmentsforthefiscalyearsendedjanuary anddecember january changesinfairvalue december reflectedinnet sale noncurrentother dollarsinmillion carryingvalue income purchasesother carryingvalue asset equityinvestmentswithreadily determinablevalue equityinvestmentswithoutreadily determinablevalue december changesinfairvalue december reflectedinnet sale noncurrentother dollarsinmillion carryingvalue income purchasesother carryingvalue asset equityinvestmentswithreadily determinablevalue equityinvestmentswithoutreadily determinablevalue recordedinotherincomeexpense otherincludesimpactofcurrency forthefiscalyearsendedjanuaryanddecemberforequityinvestmentswithoutreadilydeterminable marketvaluesmillionandmillionrespectivelyofthechangesinfairvaluereflectedinnetincomeweretheresult ofimpairmentsthereweremillionandmillionrespectivelyofchangesinfairvaluereflectedinnetincomedue tochangesinobservableprice fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbase measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilityin accordancewithascathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevelswithinthe hierarchyaredescribedbelowwithlevelhavingthehighestpriorityandlevelhavingthelowest thefairvalueofaderivativefinancialinstrumentieforwardforeignexchangecontractsinterestratecontractsisthe aggregationbycurrencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesand johnsonjohnsonannualreport subsequentlyconvertedtotheusdollaratthecurrentspotforeignexchangeratethecompanydoesnotbelievethat fairvaluesofthesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementor maturityorthatthechangesinfairvaluewillhaveamaterialeffectonthecompanysresultsofoperationscashflowsor financialpositionthecompanyalsoholdsequityinvestmentswhichareclassifiedaslevelanddebtsecuritieswhich areclassifiedaslevelthecompanyholdsacquisitionrelatedcontingentliabilitiesbaseduponcertainregulatoryand commercialeventswhichareclassifiedaslevelwhosevaluesaredeterminedusingdiscountedcashflow methodologiesorsimilartechniquesforwhichthedeterminationoffairvaluerequiressignificantjudgmentorestimation thefollowingthreelevelsofinputsareusedtomeasurefairvalue levelquotedpricesinactivemarketsforidenticalassetsandliabilitie levelsignificantotherobservableinput levelsignificantunobservableinput thecompanyssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofthefiscalyearendedjanuary anddecemberwereasfollow dollarsinmillion level level level total total derivativesdesignatedashedginginstrument asset forwardforeignexchangecontract interestratecontract total liability forwardforeignexchangecontract interestratecontract total derivativesnotdesignatedashedginginstrument asset forwardforeignexchangecontract liability forwardforeignexchangecontract availableforsaleotherinvestment equityinvestment debtsecuritie otherliabilitie contingentconsideration grosstonetderivativereconciliation dollarsinmillion totalgrossasset creditsupportagreementcsa totalnetasset totalgrossliabilitie creditsupportagreementcsa totalnetliabilitie johnsonjohnsonannualreportsummarizedinformationaboutchangesinliabilitiesforcontingentconsiderationisasfollow dollarsinmillion beginningbalance changesinestimatedfairvalue addition payment endingbalance assetsandliabilitiesareallclassifiedaslevelwiththeexceptionofequityinvestmentsofmillionwhichareclassified aslevelandcontingentconsiderationofmillionclassifiedaslevel includesmillionofnoncurrentassetsasofdecember includescrosscurrencyinterestrateswapsandinterestrateswap classifiedasnoncurrentotherasset classifiedascashequivalentsandcurrentmarketablesecuritie includesmillionmillionprimarilyrelatedtoaurishealthandmillionclassifiedasnoncurrentotherliabilitiesas ofjanuarydecemberanddecemberrespectivelyincludesmillionandmillionclassifiedas currentliabilitiesasofjanuaryanddecemberrespectively ongoingfairvalueadjustmentamountsarerecordedprimarilyinresearchanddevelopmentexpensethecompanyrecordeda contingentconsiderationreversalofmillioninrelatedtothetimingofcertaindevelopmentalmilestonesassociatedwith theaurishealthacquisitionthereversalofthecontingentconsiderationwasrecordedinotherincomeandexpense seenotesandforfinancialassetsandliabilitiesheldatcarryingamountontheconsolidatedbalancesheet johnsonjohnsonannualreport borrowing thecomponentsoflongtermdebtareasfollow effective effective dollarsinmillion rate rate zerocouponconvertiblesubordinateddebenturesdue debenturesdue notesdue notesdue notesdue notesdue notesduebeurobeuro notesdue debenturesdue notesdue notesdue notesduemmeurommeuro notesdue mmgbpmmgbp notesdue notesdue notesdue notesdue notesdue notesduemmeurommeuro notesdue notesdue notesdue debenturesdue notesdue notesduebeurobeuro notesdue notesdue notesdue debenturesdue notesdue debenturesdue notesdue notesdue notesdue notesdue notesdue notesdue notesdue notesdue subtotal lesscurrentportion totallongtermdebt johnsonjohnsonannualreport weightedaverageeffectiverate translationrateatjanuary translationrateatdecember theexcessofthefairvalueoverthecarryingvalueofdebtwasbillionattheendoffiscalyearandbillionattheend offiscalyear inthefiscalthirdquarterofthecompanyissuedseniorunsecurednotesforatotalofbillion fairvalueofthelongtermdebtwasestimatedusingmarketpriceswhichwerecorroboratedbyquotedbrokerpricesand significantotherobservableinput thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids providedbybankslondoninterbankofferedratesliborsecuredovernightfinancingratesofrswapcurveor otherapplicablemarketrateasallowedplusapplicablemarginscommitmentfeesundertheagreementsarenotmaterial throughoutfiscalyearthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarket shorttermborrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionattheendof fiscalyearofwhichbillionisthecurrentportionofthelongtermdebtandtheremainderiscommercialpaper andlocalborrowingsbyinternationalsubsidiarie throughoutfiscalyearthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarket shorttermborrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionattheendof fiscalyearofwhichbillionisthecurrentportionofthelongtermdebtandtheremainderprincipallyrepresent localborrowingbyinternationalsubsidiarie aggregatematuritiesoflongtermdebtobligationscommencinginare dollarsinmillion income taxis theprovisionfortaxesonincomeconsistsof dollarsinmillion currentlypayable ustaxe internationaltaxe totalcurrentlypayable defer ustaxe internationaltaxe totaldeferre provisionfortaxesonincome includesbillionofdeferredtaxexpensefortheadoptionofthedeferredmethodtoaccountforgilti johnsonjohnsonannualreport acomparisonofincometaxexpenseattheusstatutoryrateofinfiscalyearsandtothe companyseffectivetaxrateisasfollow dollarsinmillion international earningsbeforetaxesonincome taxrate usstatutoryrate internationaloperation ustaxesoninternationalincome taxbenefitsoncapitalloss taxbenefitsonsharebasedcompensation tcjaandrelatedimpact allother effectiverate forallperiodspresentedthecompanyhassubsidiariesoperatinginpuertoricoundervarioustaxincentivesinternational operationsreflectstheimpactsofoperationsinjurisdictionswithstatutorytaxratesdifferentthantheusparticularlyireland switzerlandandpuertoricowhichisafavorableimpactontheeffectivetaxrateascomparedwiththeusstatutoryratethe andamountsincludetheimpactofthenewtaxlegislationenactmentinswitzerlandwhichisfurtherdescribedbelow includestheimpactofthegiltitaxtheforeignderivedintangibleincomedeductionandotherforeignincomethatistaxableunder theustaxcode representsimpactofadjustmentstobalancesoriginallyrecordedaspartofthetcjaprovisionaltaxchargefurther informationprovidedbelow certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation thefiscalyeartaxratedecreasedbycomparedtothefiscalyeartaxratewhichwasprimarilydrivenby thefollowingitemsinfiscalyearswitzerlandenactedthefederalactontaxreformandahvfinancingtraf whichbecameeffectiveonjanuarythefederaltransitionalprovisionsoftrafallowcompaniesundercertain conditionstoadjustthetaxbasisincertainassetstofairvalueiestepuptobedepreciatedandamortizedresulte inanincrementalswisstaxdeductionoverthetransitionalperiod trafalsoprovidesforparameterswhichenabletheswisscantonstoestablishlocalizedtaxratesandregulationsfor companiesthenewcantonaltaxparametersincludefavorabletaxbenefitsforpatentsandadditionalresearchand developmenttaxdeductionsthecantonaltransitionalprovisionsoftrafallowedcompaniestoelecteithertaxbasis stepupsimilartothefederaltransitionbenefitoralternativestatutorytaxrateforaperiodnottoexceedyearsthe companycurrentlyhasoperationslocatedinvariousswisscantonsduringthefiscalyearasdescribedinfurther detailbelowthecompanyrecordedtheimpactsofthetrafthatwereenactedinthatperiod duringthefiscalyearthefinalcantonwherethecompanymaintainssignificantoperationsenactedtraf legislationadditionallythecompanyreceivedrulingsfromtheswissfederalandcantonaltaxauthoritiesintheremaine jurisdictionswhereithassignificantoperationstheserulingsresultedinthecompanyrevisingitsestimateonthetax basisadjustmentiestepupforitsassetsandasaresultthecompanyrecordedadditionaldeferredtaxbenefitsin thecompanyrecognizedanetbenefitinthefiscalyearforswisstaxreformofapproximatelybillionor benefittothecompanysannualeffectivetaxratecomprisedofthefollowingitem approximatelybilliontaxbenefitrelatingtotheremeasurementofswissdeferredtaxassetsandliabilitiesforthe changeinthefederalandcantonaltaxrateswhereenactmentoccurredinthefiscalyearthisbenefithasbeen reflectedasinternationaloperationsonthecompanyseffectivetaxratereconciliation amilliondeferredtaxassetrelatedtotheestimatedvalueofafederaltaxbasisstepupofthecompanysswiss subsidiariesassetsasdescribedabovethisbenefithasbeenreflectedasinternationaloperationsonthecompany effectivetaxratereconciliation johnsonjohnsonannualreport approximatelybillionofusdeferredtaxexpenserelatingtothegiltideferredtaxliabilityresultingfromthe remeasurementoftheswissdeferredtaxassetsandliabilitiesinthefiscalyearthisbenefithasbeenreflectedas ustaxoninternationalincomeonthecompanyseffectivetaxratereconciliation thecompanydoesnotexpecttoreceivefuturerulingsregardingthetransitionalprovisionsoftraf alsointhefiscalfourthquarterofthecompanyrecognizedacapitallossoncertainusaffiliatesrelatedtothe previouslyimpairedbookvalueofcertainintangibleswhichreducedthetaxratebyapproximatelywhichis reflectedasataxbenefitsoncapitallossontheeffectivetaxratereconciliationinadditioninthefiscalyearthe companyhadlowerincomeinhighertaxjurisdictionsprimarilydrivenby theimpactoftheaccrualoflitigationcostsrelatedtotalcforbillionwhichreducedtheusearningsbefore taxesataneffectivetaxrateof theaccrualofadditionallegalcostsincludinganadditionalbillionassociatedwitharevisedagreementin principletosettleopioidlitigationataneffectivetaxrateof thecompanyalsogeneratedadditionaltaxbenefitsfromstockbasedcompensationthatwereeitherexercisedorveste reducedthecontingentconsiderationliabilityrelatedtotheaurishealthacquisitionseenoteandreversalofsomeof itsunrecognizedtaxbenefitsduetothecompletionofseveralyearsoftaxexaminationsincertainjurisdictionsduringthe fiscalyear thefiscalyeartaxratedecreasedbycomparedtothefiscalyeartaxrateinadditiontotheimpactof trafdiscussedinmoredetailbelowtheprimarydriversofthenetdecreasewereasfollow thecompanyreorganizedtheownershipstructureofcertainwhollyownedinternationalsubsidiariesinthefiscal fourthquarterofwhichresultedinareductionofcertainwithholdingandlocaltaxesthatithadpreviously recognizedaspartoftheprovisionaltaxcutsandjobsacttcjataxchargeinthefiscalyearandfinalizedin thefiscalyearfollowingthecompletionofthisrestructuringandapprovalbytheapplicablelocalauthoritie thecompanyreversedadeferredtaxliabilityofbillionandarelateddeferredtaxassetofbillionforus foreigntaxcreditsforanetdeferredtaxbenefitofbilliondecreasingtheannualeffectivetaxratebythis benefithasbeenreflectedastcjaandrelatedimpactsonthecompanyseffectivetaxratereconciliation theimpactoftheagreementinprincipletosettleopioidlitigationforbillionseenotetotheconsolidate financialstatementswhichreducedtheusearningsbeforetaxesataneffectivetaxrateofanddecrease thecompanysannualeffectivetaxratebyapproximately indecemberoffiscalyeartheustreasuryissuedfinalforeigntaxcreditregulationswhichresultedinthe companyrevisingtheamountofforeigntaxcreditsthatwereinitiallyrecordedinthefiscalyearaspartofthe provisionaltcjataxchargeasaresultthecompanyrecordedanincreaseddeferredtaxassetrelatedtothese foreigntaxcreditsofapproximatelybillionortotheannualeffectivetaxratethisbenefithasbeen reflectedastcjaandrelatedimpactsonthecompanyseffectivetaxratereconciliation thecompanyreassesseditsuncertaintaxpositionsrelatedtothecurrentirsauditandincreaseditsunrecognize taxbenefitbybillionliabilitywhichincreasedtheannualeffectivetaxratebyapproximatelyseesectionon unrecognizedtaxbenefitsforadditionalinformationasthesepositionswererelatedtouncertaintaxregarding internationaltransferpricingthisexpensehasbeenclassifiedasinternationaloperationsonthecompany effectivetaxratereconciliationsubsequenttodecemberthecompanyreceivedandagreedtonoticesof proposedadjustmentsnopasfromtheirsthecompanybelievesitisadequatelyreservedforpotential exposure therewereseveralonetimetaximpactsthatresultedinacumulativenettaxbenefittotheannualeffectivetax rateoftheseitemsincludedthelifescandivestituretheadjustmenttotheprovisionaltcjataxcharge andtheaccelerationofcertaintaxdeductionsaspartofthetaxreturn moreincomeinhighertaxjurisdictionsrelativetolowertaxjurisdictionsascomparedto asdescribedabovefortheswisstaxlegislationinthefiscalyearthecompanyrecordedanettaxexpenseof billionwhichincreasedtheeffectivetaxrateforthefiscalyearbyapproximatelythisnettaxexpense relatedtofederalandcertaincantonalenactmentsinthefiscalyearconsistingofthefollowingprovision approximatelybilliontaxexpenserelatingtotheremeasurementofswissdeferredtaxassetsandliabilitiesfor thechangeinthefederalandcantonaltaxrateswhereenactmentoccurredbydecemberthisexpense hasbeenreflectedasinternationaloperationsonthecompanyseffectivetaxratereconciliation johnsonjohnsonannualreport abilliondeferredtaxassetrelatedtotheestimatedvalueofafederaltaxbasisstepupofthecompanysswiss subsidiariesassetsthisbenefithasbeenreflectedasinternationaloperationsonthecompanyseffectivetaxrate reconciliation approximatelymillionofusdeferredtaxexpenserelatingtothegiltideferredtaxliabilityresultingfromthe remeasurementoftheswissdeferredtaxassetsandliabilitiesandthenewdeferredtaxassetforthefederalstepup thisbenefithasbeenreflectedasustaxoninternationalincomeonthecompanyseffectivetaxrate reconciliation inthefiscalyearthecompanycompleteditsfullassessmentandfinalizedtheaccountingfortheimpactofthe tcjathecompanyrecordednetadjustmentstotheabovecomponentsoftheprovisionalchargeofapproximately billiontheserevisionswerebasedonupdatedestimatesandadditionalanalysisbymanagementaswellasapplye interpretativeguidanceissuedbytheusdepartmentoftreasurytothefactsandcircumstancesthatexistedasofthe tcjaenactmentdatethischargewasprimarilyrelatedtoadditionaldeferredtaxliabilitiesforforeignlocaland withholdingtaxesfortheremainingbalanceofundistributedforeignearningsasofdecemberthatwerenot providedforintheprovisionalcharge asdescribedinnoteinthefiscalyearthecompanyelectedtotreatgiltiasaperiodexpenseunderthe deferredmethodandrecordedadeferredtaxcostofapproximatelybillioninthefiscalyearrelatedtofactsand circumstancesthatexistedonthedateoftcjaenactmentduringthecompanyreorganizedtheownership structureofcertainforeignsubsidiarieswhichresultedinareductionofcertainforeignwithholdingtaxesthatithad recognizedaspartoftheprovisionaltcjataxchargeinthefourthquarteroffollowingthecompletionofthis restructuringandasaresultofclarificationbyswisstaxauthoritiesregardingtheapplicabilityofwithholdingtaxto repatriationofcertainearningsthecompanyreversedadeferredtaxliabilityofbillionandarelateddeferredtax assetofbillionforusforeigntaxcreditsforanetdeferredtaxbenefitofbillionthisbenefithasbeenreflecte astcjaandrelatedimpactsonthecompanyseffectivetaxratereconciliation temporarydifferencesandcarryforwardsattheendoffiscalyearsandwereasfollow deferredtax deferredtax dollarsinmillion asset liability asset liability employeerelatedobligation stockbasedcompensation depreciationamortization nondeductibleintangible internationalrdcapitalizedfortax reservesliabilitie incomereportedfortaxpurpose netoperatinglosscarryforwardinternational undistributedforeignearning globalintangiblelowtaxedincome miscellaneousinternational miscellaneousus totaldeferredincometaxe certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation thecompanyhaswhollyownedinternationalsubsidiariesthathavecumulativenetlossesthecompanybelievesthatitis morelikelythannotthatthesesubsidiarieswillgeneratefuturetaxableincomesufficienttoutilizethesedeferredtaxasset johnsonjohnsonannualreportthefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefit dollarsinmillion beginningofyear increasesrelatedtocurrentyeartaxposition increasesrelatedtopriorperiodtaxposition decreasesrelatedtopriorperiodtaxposition settlement lapseofstatuteoflimitation endofyear theunrecognizedtaxbenefitsofbillionatjanuaryifrecognizedwouldaffectthecompanysannual effectivetaxratethecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxaudits inprogresswithanumberoftaxauthoritieswithrespecttotheunitedstatestheinternalrevenueserviceirsha completeditsauditforthetaxyearsthroughasofdecemberthecompanyclassifiedunrecognizedtax benefitsandrelatedinterestofapproximatelybillionasacurrentliabilityontheaccruedtaxesonincomelineofthe consolidatedbalancesheetinthefiscalyearthecompanymadeitsfinalpaymentsforapproximatelybillion totheustreasuryrelatedtothefinalsettlementoftaxauditliability inothermajorjurisdictionswherethecompanyconductsbusinesstheyearsthatremainopentotaxauditgobacktothe yearthecompanybelievesitispossiblethattaxauditsmaybecompletedoverthenexttwelvemonthsbytaxing authoritiesinsomejurisdictionsoutsideoftheunitedstateshoweverthecompanyisnotabletoprovideareasonably reliableestimateofthetimingofanyotherfuturetaxpaymentsrelatingtouncertaintaxposition thecompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslongtermliabilitie exceptaspreviouslynotedonamountsrelatedtothecurrentunitedstatesirsauditinterestexpenseandpenaltie relatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpensethecompanyrecognizedaftertaxinter expenseofmillionmillionandmillioninfiscalyearsandrespectivelythetotalamountof accruedinterestwasmillionandmillioninfiscalyearsandrespectively employee relate obligation attheendoffiscalandfiscalemployeerelatedobligationsrecordedontheconsolidatedbalancesheet dollarsinmillion pensionbenefit postretirementbenefit postemploymentbenefit deferredcompensation totalemployeeobligation lesscurrentbenefitspayable employeerelatedobligationsnoncurrent prepaidemployeerelatedobligationsofmillionandmillionforandrespectivelyareincludedin otherassetsontheconsolidatedbalancesheet johnsonjohnsonannualreport pension benefit plan thecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefitdefinedcontributionand terminationindemnityplanswhichcovermostemployeesworldwidethecompanyalsoprovidespostretirement benefitsprimarilyhealthcaretoalleligibleusretiredemployeesandtheirdependent manyinternationalemployeesarecoveredbygovernmentsponsoredprogramsandthecosttothecompanyisnot significant intheusnonunionpensionbenefitsforemployeeshiredbeforejanuaryareprimarilybasedontheemployee compensationduringthelastfiveyearsbeforeretirementandthenumberofyearsofservicethefinalaveragepay formulauspensionbenefitsforemployeeshiredafterarecalculatedusingadifferentformulabasedonemployee compensationovertotalyearsofservicetheretirementvalueformula injanuarythecompanyannouncedthateffectiveonjanuaryalleligibleusnonunionemployee regardlessofhiredatewillearnbenefitsundertheretirementvalueformulathisamendmentdoesnotaffectthebenefit accruedunderthefinalaveragepayformulaforservicebeforejanuarytheimpactofthischangedecreasesthe pboasofjanuarybyapproximatelybillionandisincludedintheamendmentslineinthechangein benefitobligation internationalsubsidiarieshaveplansunderwhichfundsaredepositedwithtrusteesannuitiesarepurchasedundergroup contractsorreservesareprovide thecompanydoesnotfundretireehealthcarebenefitsinadvanceandhastherighttomodifytheseplansinthefuture inandthecompanyuseddecemberanddecemberrespectivelyasthemeasurement dateforallusandinternationalretirementandotherbenefitplans netperiodicbenefitcostsforthecompanysdefinedbenefitretirementplansandotherbenefitplansforand includethefollowingcomponent retirementplan otherbenefitplan dollarsinmillion servicecost interestcost expectedreturnonplanasset amortizationofpriorservicecost recognizedactuariallossesgain curtailmentsandsettlement netperiodicbenefitcost unrecognizedgainsandlossesfortheuspensionplansareamortizedovertheaverageremainingfutureserviceforeach planforplanswithnoactiveemployeestheyareamortizedovertheaveragelifeexpectancytheamortizationofgain andlossesfortheotherusbenefitplansisdeterminedbyusingacorridorofthegreaterofthemarketvalueof assetsortheaccumulatedpostretirementbenefitobligationtotalunamortizedgainsandlossesinexcessofthecorridor areamortizedovertheaverageremainingfutureservice priorservicecostsbenefitsfortheuspensionplansareamortizedovertheaverageremainingfutureserviceofplan participantsatthetimeoftheplanamendmentpriorservicecostbenefitfortheotherusbenefitplansisamortizedover theaverageremainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment johnsonjohnsonannualreportthefollowingtablerepresentstheweightedaverageactuarialassumption retirementplan otherbenefitplan worldwidebenefitplan netperiodicbenefitcost servicecostdiscountrate interestcostdiscountrate rateofincreaseincompensationlevel expectedlongtermrateofreturnonplanasset benefitobligation discountrate rateofincreaseincompensationlevel thecompanysdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighqualitylongterm fixedincomeinstrumentstheresultingdiscountratesareconsistentwiththedurationofplanliabilitiesthecompanys methodologyindeterminingserviceandinterestcostusesdurationspecificspotratesalongthatyieldcurvetotheplans liabilitycashflow theexpectedratesofreturnonplanassetassumptionsrepresentthecompanysassessmentoflongtermreturnson diversifiedinvestmentportfoliosgloballytheassessmentisdeterminedusingprojectionsfromexternalfinancialsource longtermhistoricalaveragesactualreturnsbyassetclassandthevariousassetclassallocationsbymarket thefollowingtabledisplaystheassumedhealthcarecosttrendratesforallindividual healthcareplan healthcarecosttrendrateassumedfornextyear ratetowhichthecosttrendrateisassumedtodeclineultimatetrend yeartheratereachestheultimatetrendrate johnsonjohnsonannualreport thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatfiscalyearend andforthecompanysdefinedbenefitretirementplansandotherpostretirementplan otherbenefit retirementplan plan dollarsinmillion changeinbenefitobligation projectedbenefitobligationbeginningofyear servicecost interestcost planparticipantcontribution amendment actuarialgainslosse divestituresacquisition curtailmentssettlementsrestructure benefitspaidfromplan effectofexchangerate projectedbenefitobligationendofyear changeinplanasset planassetsatfairvaluebeginningofyear actualreturnonplanasset companycontribution planparticipantcontribution settlement divestituresacquisition benefitspaidfromplanasset effectofexchangerate planassetsatfairvalueendofyear fundedstatusendofyear amountsrecognizedinthecompanysbalancesheetconsistofthefollowe noncurrentasset currentliabilitie noncurrentliabilitie totalrecognizedintheconsolidatedbalancesheetendofyear amountsrecognizedinaccumulatedothercomprehensiveincomeconsistof thefollowe netactuarialloss priorservicecostcredit unrecognizednettransitionobligation totalbeforetaxeffect accumulatedbenefitobligationsendofyear injanuarythecompanyannouncedthateffectiveonjanuaryalleligibleusnonunionemployeesregardlessofhire datewillearnbenefitsundertheretirementvalueformulathisamendmentdoesnotaffectthebenefitsaccruedunderthefinal averagepayformulaforservicebeforejanuary theactuariallossesforretirementplansinandwasprimarilyrelatedtodecreasesindiscountrate inthecompanyofferedavoluntarylumpsumpaymentoptionforcertaineligibleformeremployeeswhoarevestedparticipant oftheusqualifieddefinedbenefitpensionplanthedistributionofthelumpsumswascompletedbytheendoffiscalthe amountdistributedinwasapproximatelymillion johnsonjohnsonannualreportotherbenefit retirementplan plan dollarsinmillion amountsrecognizedinnetperiodicbenefitcostandothercomprehensive income netperiodicbenefitcost netactuarialgainloss amortizationofnetactuarialloss priorservicecostcredit amortizationofpriorservicecostcredit effectofexchangerate totallossincomerecognizedinothercomprehensiveincomebeforetax totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome thecompanyplanstocontinuetofunditsusqualifiedplanstocomplywiththepensionprotectionactof internationalplansarefundedinaccordancewithlocalregulationsadditionaldiscretionarycontributionsaremadewhen deemedappropriatetomeetthelongtermobligationsoftheplansforcertainplansfundingisnotacommonpracticea fundingprovidesnoeconomicbenefitconsequentlythecompanyhasseveralpensionplansthatarenotfunde inthecompanycontributedmillionandmilliontoitsusandinternationalpensionplansrespectively thefollowingtabledisplaysthefundedstatusofthecompanysusqualifiednonqualifiedpensionplansand internationalfundedandunfundedpensionplansatdecemberanddecemberrespectively usplans internationalplans qualifiedplan nonqualifiedplans fundedplan unfundedplan dollarsinmillion planasset projectedbenefitobligation accumulatedbenefitobligation overunderfundedstatus projectedbenefitobligation accumulatedbenefitobligation planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligationprojected benefitobligationandplanassetsofbillionbillionandbillionrespectivelyattheendofand billionbillionandbillionrespectivelyattheendof thefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromthecompanysretirementandotherbenefitplan dollarsinmillion projectedfuturebenefitpayment retirementplan otherbenefitplan thefollowingtabledisplaystheprojectedfutureminimumcontributionstotheunfundedretirementplanstheseamount donotincludeanydiscretionarycontributionsthatthecompanymayelecttomakeinthefuture dollarsinmillion projectedfuturecontribution eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand investmentofthepensionplansindetermininginvestmentpoliciesstrategiesandgoalseachcommitteeorboard considersfactorsincludinglocalpensionrulesandregulationslocaltaxregulationsavailabilityofinvestmentvehicles johnsonjohnsonannualreport separateaccountscommingledaccountsinsurancefundsetcfundedstatusoftheplansratioofactivestoretiree durationofliabilitiesandotherrelevantfactorsincludingdiversificationliquidityoflocalmarketsandliquidityofbase currencyamajorityofthecompanyspensionfundsareopentonewentrantsandareexpectedtobeongoingplan permittedinvestmentsareprimarilyliquidandorlistedwithlittlerelianceonilliquidandnontraditionalinvestmentssuch ashedgefund thecompanysretirementplanassetallocationattheendofandandtargetallocationsforareasfollow percentof target planasset allocation worldwideretirementplan equitysecuritie debtsecuritie totalplanasset determinationoffairvalueofplanasset theplanhasanestablishedandwelldocumentedprocessfordeterminingfairvaluesfairvalueisbaseduponquote marketpriceswhereavailableiflistedpricesorquotesarenotavailablefairvalueisbaseduponmodelsthatprimarily useasinputsmarketbasedorindependentlysourcedmarketparametersincludingyieldcurvesinterestratesvolatilitie equityordebtpricesforeignexchangeratesandcreditcurve whiletheplanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipantstheuseof differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent estimateoffairvalueatthereportingdate valuationhierarchy theauthoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevel withinthehierarchyaredescribedinthetablebelowwithlevelhavingthehighestpriorityandlevelhavingthelowest thenetassetvaluenavisbasedonthevalueoftheunderlyingassetsownedbythefundminusitsliabilitiesandthen dividedbythenumberofsharesoutstanding afinancialinstrumentscategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis significanttothefairvaluemeasurement followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue shortterminvestmentfundscashandquotedshortterminstrumentsarevaluedattheclosingpriceortheamountheld ondepositbythecustodianbankotherinvestmentsarethroughinvestmentvehiclesvaluedusingthenavprovidedby theadministratorofthefundthenavisaquotedpriceinamarketthatisnotactiveandclassifiedaslevel governmentandagencysecuritiesalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon themajormarketonwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarket theinvestmentsareclassifiedwithinlevelofthevaluationhierarchyifquotedmarketpricesarenotavailableforthe specificsecuritythenfairvaluesareestimatedbyusingpricingmodelsquotedpricesofsecuritieswithsimilar characteristicsordiscountedcashflowswhenquotedmarketpricesforasecurityarenotavailableinanactivemarket theyareclassifiedaslevel debtinstrumentsalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarketon whichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarkettheinvestmentsare classifiedaslevelifquotedmarketpricesarenotavailableforthespecificsecuritythenfairvaluesareestimatedby usingpricingmodelsquotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassifie aslevelleveldebtinstrumentsarepricedbasedonunobservableinput equitysecuritiesequitysecuritiesarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual securitiesaretradedsubstantiallyallequitysecuritiesareclassifiedwithinlevelofthevaluationhierarchy commingledfundstheseinvestmentvehiclesarevaluedusingthenavprovidedbythefundadministratorassetsin thelevelcategoryhaveaquotedmarketprice johnsonjohnsonannualreport otherassetsotherassetsarerepresentedprimarilybylimitedpartnershipstheseinvestmentvehiclesarevalue usingthenavprovidedbythefundadministratorotherassetsthatareexchangelistedandactivelytradedare classifiedaslevelwhileinactivelytradedassetsareclassifiedaslevel thefollowingtablesetsforththeretirementplansinvestmentsmeasuredatfairvalueasofdecemberand december quotedprice significant inactive significant investment marketsfor observable unobservable measuredat identicalasset input input netasset level level level value totalasset dollarsinmillion shortterminvestmentfund governmentandagencysecuritie debtinstrument equitysecuritie commingledfund otherasset investmentsatfairvalue theactivityforthelevelassetsisnotsignificantforallyearspresente thecompanysotherbenefitplansareunfundedexceptforuscommingledfundslevelofmillionand millionatdecemberanddecemberrespectivelyandusshortterminvestmentfundslevel ofmillionatdecember thefairvalueofjohnsonjohnsoncommonstockdirectlyheldinplanassetswasmillionoftotalplan assetsatdecemberandmillionoftotalplanassetsatdecember saving plan thecompanyhasvoluntaryksavingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible employeesthecompanymatchesapercentageofeachemployeescontributionsconsistentwiththeprovisionsofthe planforwhichhesheiseligibletotalcompanymatchingcontributionstotheplansweremillionmillionand millioninfiscalyearsandrespectively capital treasury stock changesintreasurystockwere treasurystock amountsinmillionsexcepttreasurystocksharesinthousand share balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary aggregatesharesofcommonstockissuedwereapproximatelysharesattheendoffiscalyear johnsonjohnsonannualreport cashdividendspaidwerepershareinfiscalyearcomparedwithdividendsofpershareinfiscalyear andpershareinfiscalyear onjanuarytheboardofdirectorsdeclaredaregularcashdividendofpersharepayableonmarch toshareholdersofrecordasoffebruary ondecemberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyssharesofcommonstockthissharerepurchase programwascompletedasofseptember accumulate comprehensive income loss componentsofothercomprehensiveincomelossconsistofthefollowe total gainloss accumulate foreign gainloss employee currency benefit derivative comprehensive dollarsinmillion translation security plan hedge incomeloss december cumulativeadjustmenttoretainedearning netchange december netchange december netchange january pertheadoptionofasufinancialinstruments amountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpactforeigncurrency translationisnotadjustedforincometaxeswhereitrelatestopermanentinvestmentsininternationalsubsidiariesfor additionaldetailsoncomprehensiveincomeseetheconsolidatedstatementsofcomprehensiveincome detailsonreclassificationsoutofaccumulatedothercomprehensiveincome gainlossonsecuritiesreclassificationsreleasedtootherincomeexpensenet employeebenefitplansreclassificationsareincludedinnetperiodicbenefitcostseenoteforadditionaldetail gainlossonderivativeshedgesreclassificationstoearningsarerecordedinthesameaccountasthehedge transactionseenoteforadditionaldetail international currency translation fortranslationofitssubsidiariesoperatinginnonusdollarcurrenciesthecompanyhasdeterminedthatthelocal currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomieswhich aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationoformoreduringthepastthreeyear orwhereasubstantialportionofitscashflowsarenotinthelocalcurrencyforthemajorityofthecompanyssubsidiarie thelocalcurrencyisthefunctionalcurrency inconsolidatinginternationalsubsidiariesbalancesheetcurrencyeffectsarerecordedasacomponentofaccumulate othercomprehensiveincometheothercurrentandnoncurrentassetslinewithinthestatementofcashflowsinclude theimpactofforeigncurrencytranslationthisequityaccountincludestheresultsoftranslatingcertainbalancesheet assetsandliabilitiesatcurrentexchangeratesandsomeaccountsathistoricalratesexceptforthoselocatedinhighly inflationaryeconomiesargentinaandvenezuelathetranslationofbalancesheetaccountsforhighlyinflationary economiesarereflectedintheoperatingresult arollforwardofthechangesduringfiscalyearsandforforeigncurrencytranslationadjustmentsis includedinnote johnsonjohnsonannualreportnetcurrencytransactiongainsandlossesincludedinotherincomeexpensewerelossesofmillionmillion andmillioninfiscalyearsandrespectively earning share thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsende januarydecemberanddecember inmillionsexceptpershareamount basicnetearningspershare averagesharesoutstandingbasic potentialsharesexercisableunderstockoptionplan lesssharesrepurchasedundertreasurystockmethod convertibledebtshare adjustedaveragesharesoutstandingdilute dilutednetearningspershare thedilutednetearningspersharecalculationforfiscalyearexcludedmillionsharesrelatedtostockoptionsa theexercisepriceoftheseoptionswasgreaterthantheiraveragemarketvalueasofjanuarythecompanydid nothaveconvertibledebt thedilutednetearningspersharecalculationforfiscalyearexcludedaninsignificantnumberofsharesrelatedto stockoptionsastheexercisepriceoftheseoptionswasgreaterthantheaveragemarketvalueofthecompanysstock thedilutednetearningspersharecalculationforfiscalyearincludedthedilutiveeffectofconvertibledebtthatwa offsetbytherelatedreductionininterestexpenseofmillionaftertax thedilutednetearningspersharecalculationforfiscalyearincludedallsharesrelatedtostockoptionsasthe exercisepriceofalloptionswaslessthantheaveragemarketvalueofthecompanysstockthedilutednetearningsper sharecalculationforfiscalyearincludedthedilutiveeffectofconvertibledebtthatwasoffsetbytherelate reductionininterestexpenseofmillionaftertax common stock stock option plan stock compensation agreement atjanuarythecompanyhadstockbasedcompensationplansthesharesoutstandingareforcontractsunder thecompanyslongtermincentiveplanandthelongtermincentiveplanthelongtermincentive planexpiredaprilalloptionsandrestrictedsharesgrantedsubsequenttothatdatewereunderthelong termincentiveplanunderthelongtermincentiveplanthecompanymayissueuptomillionsharesof commonstockplusanysharescanceledexpiredforfeitedornotissuedfromthelongtermincentiveplan subsequenttoaprilsharesavailableforfuturegrantsunderthelongtermincentiveplanwere millionattheendoffiscalyear thecompensationcostthathasbeenchargedagainstincomefortheseplanswasmillionmillionand millionforfiscalyearsandrespectivelythetotalincometaxbenefitrecognizedintheincome statementforsharebasedcompensationcostswasmillionmillionandmillionforfiscalyear andrespectivelythecompanyalsorecognizedadditionalincometaxbenefitsofmillionmillion andmillionforfiscalyearsandrespectivelyforwhichoptionswereexercisedorrestrictedshare werevestedthetotalunrecognizedcompensationcostwasmillionmillionandmillionforfiscalyear andrespectivelytheweightedaverageperiodforthiscosttoberecognizedwasyear yearsandyearsforfiscalyearsandrespectivelysharebasedcompensationcost capitalizedaspartofinventorywereinsignificantinallperiod thecompanysettlesemployeebenefitequityissuanceswithtreasurysharestreasurysharesarereplenishedthrough marketpurchasesthroughouttheyearforthenumberofsharesusedtosettleemployeebenefitequityissuance stockoption stockoptionsexpireyearsfromthedateofgrantandvestoverserviceperiodsthatrangefrommonthstoyearsall optionsaregrantedattheaverageofthehighandlowpricesofthecompanyscommonstockonthenewyorkstock exchangeonthedateofgrant johnsonjohnsonannualreport thefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheblackscholesoptionvaluationmodel thatusestheassumptionsnotedinthefollowingtableforandgrantsexpectedvolatilityrepresentsa blendedrateofyearweeklyhistoricaloverallvolatilityrateandaweekaverageimpliedvolatilityratebasedon atthemoneytradedjohnsonjohnsonoptionswithalifeofyearsforallgrantshistoricaldataisusedtodetermine theexpectedlifeoftheoptiontheriskfreeratewasbasedontheustreasuryyieldcurveineffectatthetimeofgrant theaveragefairvalueofoptionsgrantedwasandinfiscalyearsand respectivelythefairvaluewasestimatedbasedontheweightedaverageassumptionsof riskfreerate expectedvolatility expectedlifeinyear expecteddividendyield asummaryofoptionactivityundertheplanasofjanuarydecemberanddecemberand changesduringtheyearsendingonthosedatesispresentedbelow aggregate intrinsic weight value outstanding average dollarsin sharesinthousand share exerciseprice millions sharesatdecember optionsgrante optionsexercised optionscanceledforfeite sharesatdecember optionsgrante optionsexercised optionscanceledforfeite sharesatdecember optionsgrante optionsexercised optionscanceledforfeited sharesatjanuary thetotalintrinsicvalueofoptionsexercisedwasmillionmillionandmillioninfiscalyear andrespectively thefollowingtablesummarizesstockoptionsoutstandingandexercisableatjanuary sharesinthousand outstanding exercisable weighted weight average average average exercise exercise exercisepricerange option life price option price averagecontractualliferemaininginyear johnsonjohnsonannualreportstockoptionsoutstandingatdecemberanddecemberwereandanaveragelifeofyears andandanaveragelifeofyearsrespectivelystockoptionsexercisableatdecemberand decemberwereatanaveragepriceofandatanaveragepriceofrespectively restrictedshareunitsandperformance shareunit thecompanygrantsrestrictedshareunitswhichvestoverserviceperiodsthatrangefrommonthstoyearsthe companyalsograntsperformanceshareunitswhicharepaidinsharesofjohnsonjohnsoncommonstockafterthe endofathreeyearperformanceperiodwhetheranyperformanceshareunitsvestandtheamountthatdoesvestistied tothecompletionofserviceperiodsthatrangefrommonthstoyearsandtheachievementoverathreeyearperiodof threeequallyweightedgoalsthatdirectlyalignwithorhelpdrivelongtermtotalshareholderreturnoperationalsale adjustedoperationalearningspershareandrelativetotalshareholderreturnbeginninginfiscalperformance sharesweregrantedwithtwoequallyweightedgoalsthatdirectlyalignwithorhelpdrivelongtermtotalshareholder returnadjustedoperationalearningspershareandrelativetotalshareholderreturnthenumberofsharesactuallyearned attheendofthethreeyearperiodwillvarybasedonlyonactualperformancefromtoofthetargetnumberof performanceshareunitsgrante asummaryoftherestrictedshareunitsandperformanceshareunitsactivityundertheplansasofjanuaryis presentedbelow outstanding outstanding restricted performance sharesinthousand shareunit shareunit sharesatdecember grant issue canceledforfeitedadjuste sharesatjanuary theaveragefairvalueoftherestrictedshareunitsgrantedwasandinfiscalyear andrespectivelyusingthefairmarketvalueatthedateofgrantthefairvalueofrestrictedshareunitswa discountedfordividendswhicharenotpaidontherestrictedshareunitsduringthevestingperiodthefairvalueof restrictedshareunitsissuedwasmillionmillionandmillioninandrespectively theweightedaveragefairvalueoftheperformanceshareunitsgrantedwasandinfiscal yearsandcalculatedusingtheweightedaveragefairmarketvalueforeachofthecomponentgoalsat thedateofgrant thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenotpaidonthe performanceshareunitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalofeach performanceshareunitwasestimatedonthedateofgrantusingthemontecarlovaluationmodelthefairvalueof performanceshareunitsissuedwasmillionmillionandmillioninfiscalyearsand respectively johnsonjohnsonannualreport segment business geographic area salestocustomer change dollarsinmillion consumerhealth otc international worldwide skinhealthbeauty international worldwide oralcare international worldwide babycare international worldwide womenshealth international worldwide woundcareother international worldwide totalconsumerhealth international worldwide previouslyreferredtoasconsumer previouslyreferredtoasbeauty johnsonjohnsonannualreportsalestocustomer change dollarsinmillion pharmaceutical immunology international worldwide remicade usexport international worldwide simponisimponiaria international worldwide stelara international worldwide tremfya international worldwide otherimmunology international worldwide infectiousdisease international worldwide edurantrilpivirine international worldwide prezistaprezcobixrezolstasymtuza international worldwide otherinfectiousdisease international worldwide johnsonjohnsonannualreport salestocustomer change dollarsinmillion neuroscience international worldwide concertamethylphenidate international worldwide invegasustennaxeplioninvegatrinzatrevicta international worldwide risperdalconsta international worldwide otherneuroscience international worldwide oncology international worldwide darzalex international worldwide erleada international worldwide imbruvica international worldwide velcade international worldwide zytigaabirateroneacetate international worldwide johnsonjohnsonannualreportsalestocustomer change dollarsinmillion otheroncology international worldwide pulmonaryhypertension international worldwide opsumit international worldwide uptravi international worldwide international worldwide cardiovascularmetabolismother international worldwide xarelto international worldwide invokanainvokamet international worldwide procriteprex international worldwide international worldwide totalpharmaceutical international worldwide johnsonjohnsonannualreport salestocustomer change dollarsinmillion medicaldevice diabetescare international worldwide interventionalsolution international worldwide orthopaedic international worldwide hip international worldwide knee international worldwide trauma international worldwide spinesportsother international worldwide surgery international worldwide advance international worldwide general international worldwide vision international johnsonjohnsonannualreportsalestocustomer change dollarsinmillion worldwide contactlensesother international worldwide surgical international worldwide totalmedicaldevice international worldwide worldwide international worldwide previouslyreferredtoasspineother certainprioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation percentagegreaterthanornotmeaningful incomelossbeforetax identifiableasset dollarsinmillion consumerhealth pharmaceutical medicaldevice total lessexpensenotallocatedtosegment generalcorporate worldwidetotal additionstoproperty depreciationand plantequipment amortization dollarsinmillions consumerhealth pharmaceutical medicaldevice segmentstotal generalcorporate worldwidetotal johnsonjohnsonannualreport salestocustomer longlivedasset dollarsinmillion unitedstate europe westernhemisphereexcludingus asiapacificafrica segmentstotal generalcorporate othernonlonglivedasset worldwidetotal seenoteforadescriptionofthesegmentsinwhichthecompanyoperate exportsalesarenotsignificantinfiscalyearthecompanyutilizedthreewholesalersdistributingproductsforall threesegmentsthatrepresentedapproximatelyandofthetotalconsolidatedrevenuesinfiscalyear thecompanyhadthreewholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximately andofthetotalconsolidatedrevenuesinfiscalyearthecompanyhadthreewholesaler distributingproductsforallthreesegmentsthatrepresentedapproximatelyandofthetotal consolidatedrevenue amountsnotallocatedtosegmentsincludeinterestincomeexpenseandgeneralcorporateincomeexpense generalcorporateincludescashcashequivalentsandmarketablesecuritie consumerhealthinclude litigationexpenseofbillionprimarilytalcrelatedreservesandcertainsettlement pharmaceuticalinclude litigationexpenseofbillionprimarilyrelatedtotheagreementinprincipletosettleopioidlitigation anunrealizedgainonsecuritiesofbillion arestructuringrelatedchargeofbillion medicaldevicesinclude acontingentconsiderationreversalofbillionrelatedtothetimingofcertaindevelopmentalmilestones associatedwiththeaurishealthacquisition litigationexpenseofbillion arestructuringrelatedchargeofbillion aninprocessresearchanddevelopmentexpenseofbillion amedicaldeviceregulationchargeofbillion consumerhealthinclude againofbillionrelatedtothecompanyspreviouslyheldequityinvestmentindrcilabo litigationexpenseofbillion arestructuringrelatedchargeofbillion pharmaceuticalinclude litigationexpenseofbillionofwhichbillionisrelatedtotheagreementinprincipletosettleopioidlitigation aninprocessresearchanddevelopmentexpenseofbillionrelatedtothealiosasset aresearchanddevelopmentexpenseofbillionforanupfrontpaymentrelatedtoargenx anunrealizedgainonsecuritiesofbillion actelionacquisitionandintegrationrelatedcostsofbillion arestructuringchargeofbillion medicaldevicesinclude againofbillionfromthedivestitureoftheaspbusiness arestructuringrelatedchargeofbillion johnsonjohnsonannualreport litigationexpenseofbillion aurishealthacquisitionandintegrationrelatedcostsofbillion consumerhealthinclude againofbillionfromthedivestitureofnizoral litigationexpenseofbillion pharmaceuticalinclude aninprocessresearchanddevelopmentchargeofbillionrelatedtothealiosandxoassetsandthe correspondingxocontingentliabilityreversalofbillion actelionacquisitionandintegrationrelatedcostsofbillion anunrealizedlossonsecuritiesofbillion againofbillionfromthedivestitureofcertainnonstrategicpharmaceuticalproduct medicaldevicesinclude litigationexpenseofbillion arestructuringrelatedchargeofbillion amoacquisitionandintegrationrelatedcostsofbillion againofbillionfromthedivestitureofthelifescanbusiness longlivedassetsincludepropertyplantandequipmentnetforfiscalyearsandofand respectivelyandintangibleassetsandgoodwillnetforfiscalyearsandofand respectively acquisition divestiture certainbusinesseswereacquiredforbillionincashandbillionofliabilitiesassumedduringfiscalyear theseacquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeen includedinthefinancialstatementsfromtheirrespectivedatesofacquisition theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtobillionandhas beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwill thefiscalyearacquisitionsprimarilyincludedallrightstotheinvestigationalcompoundbermekimabwhichha multipledermatologicalindicationsalongwithcertainemployeesfromxbiotechincxbiotechmomenta pharmaceuticalsincmomentaacompanythatdiscoversanddevelopsnoveltherapiesforimmunemediateddisease andtheoutstandingsharesinverbsurgicalincacompanywithsignificantroboticsanddatasciencecapabilitie duringthefiscalfirstquarterofthecompanycompletedtheacquisitionofallrightstotheinvestigationalcompound bermekimabwhichhasmultipledermatologicalindicationsalongwithcertainemployeesfromxbiotechincfora purchasepriceofbillionthefairvalueoftheacquisitionwasallocatedprimarilytononamortizableintangibleasset primarilyiprdforbillionapplyingaprobabilityofsuccessfactorthatrangedfromtotoreflectinherent developmentregulatoryandcommercialriskforthedifferentindicationsthediscountrateappliedwasapproximately xbiotechmaybeeligibletoreceiveadditionalpaymentsuponthereceiptofcertaincommercializationauthorizations thetransactionwasaccountedforasabusinesscombinationandincludedinthepharmaceuticalsegment additionallyinthefiscalfirstquarterofthecompanycompletedtheacquisitionofalloutstandingsharesinverb surgicalincacompanywithsignificantroboticsanddatasciencecapabilitiesincludingthosesharespreviouslyheldby verilythetransactionwasaccountedforasabusinesscombinationandincludedinthemedicaldevicessegmentthe fairvalueoftheacquisitionwasallocatedprimarilytononamortizableintangibleassetsprimarilyiprdforbillion goodwillforbillionotherassetsofbillionandliabilitiesassumedofbillionthefairvalueofthecompany previouslyheldequityinvestmentinverbsurgicalincwasbillion onoctoberthecompanycompletedtheacquisitionofmomentaforapurchasepriceofapproximately billionnetofcashacquiredthefairvalueoftheacquisitionwasallocatedprimarilytononamortizableintangible assetsiprdofbilliongoodwillofbillionotherassetsofbillionandliabilitiesofbilliontheasset johnsonjohnsonannualreport acquiredareintendedtoaddresssubstantialunmetmedicalneedinmaternalfetaldisordersneuroinflammatory disordersrheumatologydermatologyandautoimmunehematologydependingontheassetprobabilityofsuccess factorsrangingfromtowereusedinthefairvaluecalculationtoreflectinherentdevelopmentandregulatory riskoftheiprdthediscountrateappliedwasapproximatelythegoodwillisprimarilyattributabletosynergie expectedtoarisefromthebusinessacquisitionandisnotexpectedtobedeductiblefortaxpurposesthetransactionwa accountedforasabusinesscombinationandincludedinthepharmaceuticalsegment duringfiscalyearcertainbusinesseswereacquiredforbillionincashandbillionofliabilitiesassumed theseacquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeen includedinthefinancialstatementsfromtheirrespectivedatesofacquisition theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtobillionandha beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwill thefiscalyearacquisitionsprimarilyincludeddrcilaboajapanesecompanyfocusedonthemarkete developmentanddistributionofabroadrangeofdermocosmeticcosmeticandskincareproductsandaurishealthinca privatelyhelddeveloperofrobotictechnologiesinitiallyfocusedinlungcancerwithanfdaclearedplatformcurrently usedinbronchoscopicdiagnosticandtherapeuticprocedure onjanuarythecompanyacquireddrcilaboajapanesecompanyfocusedonthemarketingdevelopment anddistributionofabroadrangeofdermocosmeticcosmeticandskincareproductsforatotalpurchasepriceof approximatelybillionwhichequatestoapproximatelybillionusingtheexchangerateofjapaneseyen toeachusdollaronjanuaryadditionallyinthefiscalfirstquarterofthecompanyrecognizedapretax gainrecordedinotherincomeexpensenetofapproximatelybillionrelatedtothecompanyspreviouslyheld equityinvestmentindrcilabo thecompanytreatedthistransactionasabusinesscombinationandincludeditintheconsumerhealthsegmentdure thefiscalfirstquarterofthecompanyfinalizedthepurchasepriceallocationthefinalfairvalueoftheacquisition wasallocatedprimarilytoamortizableintangibleassetsforbilliongoodwillforbillionandliabilitiesof billiontheamortizableintangibleassetswerecomprisedofbrandtrademarksandcustomerrelationshipswitha weightedaveragelifeofyearsthegoodwillisprimarilyattributabletosynergiesexpectedtoarisefromthebusiness acquisitionandisnotexpectedtobedeductiblefortaxpurpose onaprilthecompanycompletedtheacquisitionofaurishealthincforapproximatelybillionnetofcash acquiredadditionalcontingentpaymentsofuptobillionintheaggregatemaybepayableuponreachingcertain predeterminedmilestonesaurishealthwasaprivatelyhelddeveloperofrobotictechnologiesinitiallyfocusedinlung cancerwithanfdaclearedplatformcurrentlyusedinbronchoscopicdiagnosticandtherapeuticproceduresthe companytreatedthistransactionasabusinesscombinationandincludeditinthemedicaldevicessegmentthefair valueoftheacquisitionwasallocatedprimarilytoamortizableandnonamortizableintangibleassetsprimarilyiprdfor billiongoodwillforbillionmarketablesecuritiesofbillionandliabilitiesassumedofbillionwhich includesthefairvalueofthecontingentpaymentsmentionedaboveduringthefiscalsecondquarterofthe companyfinalizedthepurchasepriceallocationduringfiscalthecompanyrecordedotherincomeof approximatelybillionforthereversalofallofthecontingentconsiderationrelatedtothetimingofcertain developmentalandcommercialmilestoneswhicharenotexpectedtobemetbasedonthecompanyscurrenttimeline duringthefiscalthirdquarterofthecompanyrecordedapartialiprdimpairmentchargeofbillionrelatedto timingandprogressionofthedigitalsurgeryplatformsaprobabilityofsuccessfactorrangingfromtowa usedinthefairvaluecalculationtoreflectinherentregulatoryandcommercialriskofthecontingentpaymentsandiprd thediscountrateappliedwasapproximatelythegoodwillisprimarilyattributabletosynergiesexpectedtoarise fromthebusinessacquisitionandisnotexpectedtobedeductiblefortaxpurpose duringfiscalyearcertainbusinesseswereacquiredforbillionincashandbillionofliabilitiesassumed theseacquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeen includedinthefinancialstatementsfromtheirrespectivedatesofacquisitiontheexcessofpurchasepriceoverthe estimatedfairvalueoftangibleassetsacquiredamountedtobillionandhasbeenassignedtoidentifiableintangible assetswithanyresidualrecordedtogoodwill inaccordancewithusgaapstandardsrelatedtobusinesscombinationsandgoodwillandotherintangibleasset supplementalproformainformationforfiscalyearsandisnotprovidedastheimpactofthe aforementionedacquisitionsdidnothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancial position johnsonjohnsonannualreportdivestiture subsequenttofiscalinseparatetransactionsthecompanydivestedtwobrandsoutsidetheuswithinthe pharmaceuticalsegmentandreceivedcombinedproceedsofapproximatelybillionthecompanywillreflectthese branddivestituresinitsfinancialresult duringfiscalyearthecompanysoldmillionsharesofidorsialtdidorsiaoritsownershipinthe companythetransactionresultedingrossproceedsofapproximatelychfmillionmillionbasedonasale priceofchfshareandanimmaterialnetlossthecompanycurrentlyhasrightstoatleastanadditional millionsharesorapproximatelyofidorsiaequitythroughaconvertibleloanwithaprincipalamountofchf millionduejuneidorsiaalsohasaccesstoanapproximatechfmillioncreditfacilitywiththecompany asofjanuaryidorsiahasnotmadeanydrawdownsunderthecreditfacility duringfiscalyearthecompanydivesteditsaspbusinesstofortivecorporationforanaggregatevalueof approximatelybillionconsistingofbillionofcashproceedsandbillionofretainednetreceivablesthe companyrecognizedapretaxgainrecordedinotherincomeexpensenetofapproximatelybillion duringfiscalyearthecompanydivestedthelifescanincbusinessforapproximatelybillionandretaine certainnetliabilitiesotherdivestituresinfiscalyearincludednizoralrocandcertainnonstrategic pharmaceuticalproductsinthepretaxgainsonthedivestitureswereapproximatelybillion infiscalyearthecompanyacceptedabindingoffertoformastrategiccollaborationwithjabilinconeofthe worldsleadingmanufacturingservicesprovidersforhealthcareproductsandtechnologyproductsthecompanyis expandingayearrelationshipwithjabiltoproducearangeofproductswithintheethiconendosurgeryanddepuy synthesbusinessesthistransactionincludesthetransferofemployeesandmanufacturingsitesthetransferswere completedinfiscalyearasofjanuarytherewerenoassetsheldforsaleontheconsolidatedbalance sheetasofdecembertheassetsheldforsaleontheconsolidatedbalancesheetwerebillionof inventoryandpropertyplantandequipmentnetforadditionaldetailsontheglobalsupplychainrestructuringseenote totheconsolidatedfinancialstatement legal proceeding johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialsupplierindemnificationandothermattersgovernmentalinvestigationsandotherlegal proceedingsthatarisefromtimetotimeintheordinarycourseoftheirbusinessduetotheongoingimpactsofthe covidpandemiccertaintrialshavebeenrescheduledordelayedthecompanycontinuestomonitoritslegal proceedingsasthesituationevolve thecompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimatedasofjanuarythecompanyhas determinedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimatedthe companyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmight bewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithascfortheseand otherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossiblethecompany isunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsaccruedamountsaccruedforlegal contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon estimatesandassumptionsincludingtimingofrelatedpaymentstheabilitytomakesuchestimatesandjudgmentscanbe affectedbyvariousfactorsincludingamongotherthingswhetherdamagessoughtintheproceedingsare unsubstantiatedorindeterminatescientificandlegaldiscoveryhasnotcommencedorisnotcompleteproceedingsarein earlystagesmatterspresentlegaluncertaintiestherearesignificantfactsindisputeproceduralorjurisdictionalissue theuncertaintyandunpredictabilityofthenumberofpotentialclaimsabilitytoachievecomprehensivemultiparty settlementscomplexityofrelatedcrossclaimsandcounterclaimsandortherearenumerouspartiesinvolvedtothe extentadverseverdictshavebeenrenderedagainstthecompanythecompanydoesnotrecordanaccrualuntilalossis determinedtobeprobableandcanbereasonablyestimate inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutionoforincreaseinaccrualsfor oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod johnsonjohnsonannualreport productliability johnsonjohnsonandcertainofitssubsidiariesareinvolvedinnumerousproductliabilityclaimsandlawsuitsinvolving multipleproductsclaimantsinthesecasesseeksubstantialcompensatoryandwhereavailablepunitivedamageswhile thecompanybelievesithassubstantialdefensesitisnotfeasibletopredicttheultimateoutcomeoflitigationfromtime totimeevenifithassubstantialdefensesthecompanyconsidersisolatedsettlementsbasedonavarietyof circumstancesthecompanyhasestablishedaccrualsforproductliabilityclaimsandlawsuitsincompliancewithasc basedoncurrentlyavailableinformationwhichinsomecasesmaybelimitedthecompanyaccruesanestimate ofthelegaldefensecostsneededtodefendeachmatterwhenthosecostsareprobableandcanbereasonably estimatedforcertainofthesemattersthecompanyhasaccruedadditionalamountssuchasestimatedcostsassociate withsettlementsdamagesandotherlossesproductliabilityaccrualscanrepresentprojectedproductliabilityfor thousandsofclaimsaroundtheworldeachindifferentlitigationenvironmentsandwithdifferentfactpatternschangesto theaccrualsmayberequiredinthefutureasadditionalinformationbecomesavailable themostsignificantofthesecasesincludethedepuyasrxlacetabularsystemanddepuyasrhipresurfacing systemthepinnacleacetabularcupsystempelvicmeshesrisperdalxareltobodypowderscontaine talcprimarilyjohnsonsbabypowderinvokanaandethiconphysiomeshflexiblecompositemeshasof januaryintheunitedstatestherewereapproximatelyplaintiffswithdirectclaimsinpendinglawsuit regardinginjuriesallegedlyduetothedepuyasrxlacetabularsystemanddepuyasrhipresurfacingsystem withrespecttothepinnacleacetabularcupsystemwithrespecttopelvicmesheswith respecttorisperdalwithrespecttoxareltowithrespecttobodypowderscontainingtalc withrespecttoinvokanaandwithrespecttoethiconphysiomeshflexiblecompositemesh inaugustdepuyorthopaedicsincdepuyannouncedaworldwidevoluntaryrecallofitsasrxlacetabular systemanddepuyasrhipresurfacingsystemusedinhipreplacementsurgeryclaimsforpersonalinjuryhavebeen madeagainstdepuyandjohnsonjohnsonthenumberofpendinglawsuitsisexpectedtofluctuateascertainlawsuit aresettledordismissedandadditionallawsuitsarefiledcasesfiledinfederalcourtsintheunitedstateshavebeen organizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthenortherndistrictofohiolitigationha alsobeenfiledincountriesoutsideoftheunitedstatesprimarilyintheunitedkingdomcanadaaustraliaireland germanyindiaanditalyinnovemberdepuyreachedanagreementwithacourtappointedcommitteeoflawyer representingasrhipsystemplaintiffstoestablishaprogramtosettleclaimswitheligibleasrhippatientsintheunite stateswhohadsurgerytoreplacetheirasrhipsknownasrevisionsurgeryasofaugustdepuyreache additionalagreementsinfebruaryandmarchwhichfurtherextendedthesettlementprogramtoincludeasr hippatientswhohadrevisionsurgeriesafteraugustandpriortofebruarythissettlementprogram hasresolvedmorethanclaimsthereforebringingtoresolutionsignificantasrhiplitigationactivityintheunited stateshoweverlawsuitsintheunitedstatesremainandthesettlementprogramdoesnotaddresslitigationoutsideof theunitedstatesinaustraliaaclassactionsettlementwasreachedthatresolvedtheclaimsofthemajorityofasrhip patientsinthatcountryincanadathecompanyhasreachedagreementstosettletheclassactionsfiledinthatcountry thecompanycontinuestoreceiveinformationwithrespecttopotentialadditionalcostsassociatedwiththisrecallona worldwidebasisthecompanyhasestablishedaccrualsforthecostsassociatedwiththeunitedstatessettlement programanddepuyasrhiprelatedproductliabilitylitigation claimsforpersonalinjuryhavealsobeenmadeagainstdepuyorthopaedicsincandjohnsonjohnsoncollectively depuyrelatingtothepinnacleacetabularcupsystemusedinhipreplacementsurgeryproductliabilitylawsuit continuetobefiledandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipate numberofcasescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationinthe unitedstatesdistrictcourtforthenortherndistrictoftexaslitigationhasalsobeenfiledinsomestatecourtsandin countriesoutsideoftheunitedstatesseveraladverseverdictshavebeenrenderedagainstdepuyoneofwhichwas reversedonappealandremandedforretrialduringthefirstquarterofdepuyestablishedaunitedstates settlementprogramtoresolvethesecasesaspartofthesettlementprogramadverseverdictshavebeensettledthe companyhasestablishedanaccrualforproductliabilitylitigationassociatedwiththepinnacleacetabularcup systemandtherelatedsettlementprogram claimsforpersonalinjuryhavebeenmadeagainstethiconincethiconandjohnsonjohnsonarisingoutofethicon pelvicmeshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapsethecompanycontinuesto receiveinformationwithrespecttopotentialcostsandadditionalcasescasesfiledinfederalcourtsintheunitedstate hadbeenorganizedasamultidistrictlitigationmdlintheunitedstatesdistrictcourtforthesoutherndistrictofw virginiathemdlcourtisremandingcasesfortrialtothejurisdictionswherethecasewasoriginallyfiledandadditional pelvicmeshlawsuitshavebeenfiledandremainoutsideofthemdlthecompanyhassettledorotherwiseresolveda johnsonjohnsonannualreportmajorityoftheunitedstatescasesandtheestimatedcostsassociatedwiththesesettlementsandtheremainingcase arereflectedinthecompanysaccrualsinadditionclassactionsandindividualpersonalinjurycasesorclaimshavebeen commencedinvariouscountriesoutsideoftheunitedstatesincludingclaimsandcasesintheunitedkingdomthe netherlandsandclassactionsinisraelaustraliaandcanadaseekingdamagesforallegedinjuryresultingfromethicon pelvicmeshdevicesinnovemberthefederalcourtofaustraliaissuedajudgmentregardingitsfindingswith respecttoliabilityinrelationtothethreeleadapplicantsandgenerallyinrelationtothedesignmanufacturepreand postmarketassessmentsandtestingandsupplyandpromotionofthedevicesinaustraliausedtotreatstressurinary incontinenceandpelvicorganprolapseinmarchthecourtentereddamagesawardstothethreeleadapplicant thecompanyisappealingthedecisionwithrespecttoothergroupmemberstherewillbeanindividualcase assessmentprocesswhichwillrequireproofofuseandcausallyrelatedlosstheformoftheindividualcaseassessment processhasnotyetbeendeterminedbythecourttheclassactionsincanadawerediscontinuedinasaresultof asettlementofagroupofcasesthecompanyhasestablishedaccrualswithrespecttoproductliabilitylitigation associatedwithethiconspelvicmeshproduct followingajuneworldwidemarketwithdrawalofethiconphysiomeshflexiblecompositemeshclaimsfor personalinjuryhavebeenmadeagainstethiconincandjohnsonjohnsonallegingpersonalinjuryarisingoutoftheuse ofthisherniameshdevicecasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrict litigationmdlintheunitedstatesdistrictcourtforthenortherndistrictofgeorgiaamulticountylitigationmclhas alsobeenformedinnewjerseystatecourtandassignedtoatlanticcountyforcasespendinginnewjerseyinaddition tothemattersinthemdlandmclthereareadditionallawsuitspendingintheunitedstatesdistrictcourtforthe southerndistrictofohiowhicharepartofthemdlforpolypropylenemeshdevicesmanufacturedbycrbardincand lawsuitspendingoutsidetheunitedstatesdiscoveryisproceedinginthesecasesandcertainofthecasesarein preparationfortrial claimshavealsobeenfiledagainstethiconandjohnsonjohnsonallegingpersonalinjuriesarisingfromtheproceed meshandproceedventralpatchherniameshproductsinmarchthenewjerseysupremecourtenteredan orderconsolidatingthesecasespendinginnewjerseyasanmclinatlanticcountysuperiorcourtadditionalcase havebeenfiledinvariousfederalandstatecourtsintheusandinjurisdictionsoutsidetheusdiscoveryisunderwayin thesecase inseptemberplaintiffsattorneyfiledanapplicationwiththenewjerseysupremecourtseekingcentralize managementofprolenepolypropyleneherniasystemphscasesthenewjerseysupremecourtgrante plaintiffsapplicationinjanuaryandthosecaseshavealsobeentransferredtoanmclinatlanticcountysuperior courtdiscoveryisunderwayinthesecase thecompanyhasestablishedaccrualswithrespecttoproductliabilitylitigationassociatedwithethicon physiomeshflexiblecompositemeshproceedmeshandproceedventralpatchandprolene polypropyleneherniasystemproduct claimsforpersonalinjuryhavebeenmadeagainstjanssenpharmaceuticalsincandjohnsonjohnsonarisingoutofthe useofrisperdalandrelatedcompoundsindicatedforthetreatmentofschizophreniaacutemanicormixedepisode associatedwithbipolaridisorderandirritabilityassociatedwithautismlawsuitshavebeenprimarilyfiledinstatecourtsin pennsylvaniacaliforniaandmissouriotheractionsarependinginvariouscourtsintheunitedstatesandcanada productliabilitylawsuitscontinuetobefiledandthecompanycontinuestoreceiveinformationwithrespecttopotential costsandtheanticipatednumberofcasesthecompanyhassuccessfullydefendedanumberofthesecasesbutthere havebeenverdictsagainstthecompanyincludingaverdictinoctoberofbillionofpunitivedamagesrelate toonesingleplaintiffwhichwassubsequentlyreducedinjanuarytomillionbythetrialjudgethecompany andplaintiffareeachappealingthisjudgmentthecompanyhassettledorotherwiseresolvedmanyoftheunitedstate casesandthecostsassociatedwiththesesettlementsarereflectedinthecompanysaccrual claimsforpersonalinjuryarisingoutoftheuseofxareltoanoralanticoagulanthavebeenmadeagainstjanssen pharmaceuticalsincjpijohnsonjohnsonjjandjpiscollaborationpartnerforxareltobayeragandcertain ofitsaffiliatescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationinthe unitedstatesdistrictcourtfortheeasterndistrictoflouisianainadditioncaseshavebeenfiledinstatecourtsacrossthe unitedstatesmanyofthesecaseswereconsolidatedintoastatemasstortlitigationinphiladelphiapennsylvaniaandina coordinatedproceedinginlosangelescaliforniaclassactionlawsuitsalsohavebeenfiledincanadainmarchjpi andjjannouncedanagreementinprincipletothesettlethexareltocasesintheunitedstatesthesettlement agreementwasexecutedinmaythesettlementbecamefinalindecemberandthesettlementwasfundedin januarythisresolvedthemajorityofcasespendingintheunitedstatesthecompanyhasestablishedaccrualsfor itscostsassociatedwiththeunitedstatessettlementprogramandxareltorelatedproductliabilitylitigation johnsonjohnsonannualreport personalinjuryclaimsallegingthattalccausescancerhavebeenmadeagainstjohnsonjohnsonconsumerincand johnsonjohnsonarisingoutoftheuseofbodypowderscontainingtalcprimarilyjohnsonsbabypowderthe numberofpendingpersonalinjurylawsuitscontinuestoincreaseandthecompanycontinuestoreceiveinformationwith respecttopotentialcostsandtheanticipatednumberofcaseslawsuitshavebeenprimarilyfiledinstatecourtsin missourinewjerseyandcaliforniaandsuitshavealsobeenfiledoutsidetheunitedstatesthemajorityofcasesare pendinginfederalcourtorganizedintoamultidistrictlitigationmdlintheunitedstatesdistrictcourtforthedistrictof newjerseyinthemdlthepartiessoughttoexcludeexpertsthroughdaubertmotionsinaprilthecourtissue rulingsthatlimitthescopeoftestimonyincludingsometheoriesandtestingmethodsforcertainplaintiffexpertwitnesses anddeniedplaintiffsattempttolimitthescopeoftestimonyofcertainofthecompanyswitnesseswiththisrulingmade casespecificdiscoveryhasbegunperthecourtsdirective intalccasesthathavepreviouslygonetotrialthecompanyhasobtaineddefenseverdictsinanumberofthembutthere havealsobeenverdictsagainstthecompanymanyofwhichhavebeenreversedonappealinjunethemissouri courtofappealsreversedinpartandaffirmedinpartajulyverdictofbillionininghamvjohnsonjohnsonet alnoedmoappreducingtheoverallawardtobillionandwithadditionalinterestasofjanuary asthecompanypursuesfurtherappealiscurrentlybilliontheinghamdecisionanapplicationfortransferof thecasetothemissourisupremecourtwassubsequentlydeniedandthecompanyiscurrentlyseekingreviewbythe unitedstatessupremecourtthecompanycontinuestobelievethatithasstronglegalgroundsfortheappealofthis verdictaswellasotherverdictsthatithasappealednotwithstandingthecompanysconfidenceinthesafetyofitstalc productsincertaincircumstancesthecompanyhasandmaysettlecasesthecompanyhasestablishedanaccrualfor defensecostsandreservesfortheresolutionofcertaincasesandclaimsincludingtheinghamdecisioncurrentlyon appealinconnectionwithproductliabilitylitigationassociatedwithbodypowderscontainingtalc infebruarythecompanystalcsupplierimerystalcamericaincandtwoofitsaffiliatesimerystalcvermontinc andimerystalccanadainccollectivelyimerysfiledavoluntarychapterpetitioncommencingareorganizationunder theunitedstatesbankruptcycodeintheunitedstatesbankruptcycourtforthedistrictofdelawareimerys bankruptcytheimerysbankruptcyrelatestoimeryspotentialliabilityforpersonalinjuryfromexposuretotalcumpowder soldbyimerystalcclaimsinitsbankruptcyfilingimerysnotedcertainclaimsitallegesithasagainstthecompanyfor indemnificationandrightstojointinsuranceproceedsthecompanypreviouslyproposedtoresolveimerysandthe companysobligationsarisingoutofthetalcclaimsbyagreeingtoassumethedefenseoflitigationofalltalcclaims involvingthecompanysproductswaivingthecompanysindemnificationclaimsagainstimerysandliftingtheautomatic staytoenablethetalcclaimstoproceedoutsidethebankruptcyforumwiththecompanyagreeingtosettleorpayany judgmentagainstimerysinmayimerysandtheasbestosclaimantscommitteeplanproponentsfiledtheirplanof reorganizationtheplanandthedisclosurestatementrelatedtheretoagreeingtoputitsnorthamericanoperationsup forauctionwhichwassubsequentlyamendedthecompanyhasobjectedtothedisclosurestatementandintendsto objecttotheplanofreorganizationascurrentlystructuredadditionallyinjunecyprusminescorporationandit parentcyprusfiledanadversaryproceedingagainstthecompanyaswellasimerysseekingadeclarationofindemnity undercertaincontractualagreementsthecompanydeniessuchindemnificationisowedandfiledamotiontodismissthe adversarycomplaintarguingamongotherthingsthatthecourtdoesnothavesubjectmatterjurisdictionovercypruss claimsagainstthecompanytheplanproponentsfilednumerousamendmentstotheplananddisclosurestatementto whichthecompanyobjectedahearingontheplanproponentsdisclosurestatementwasheldinjanuaryandthe courtenteredanorderapprovingthedisclosurestatementfortheninthamendedjointchapterplanof reorganizationofimerystalcamericaincanditsdebtoraffiliatesallowingdebtorstoproceedwithsolicitingvoteson theplanthecompanyintendstocontinuetoobjecttotheplanahearingtoconsiderconfirmationoftheplanhasbeen scheduledforjune infebruaryasecuritiesclassactionlawsuitwasfiledagainstjohnsonjohnsonandcertainnamedofficersinthe unitedstatesdistrictcourtforthedistrictofnewjerseyallegingthatjohnsonjohnsonviolatedthefederalsecurities lawsbyfailingtodiscloseallegedasbestoscontaminationinbodypowderscontainingtalcprimarilyjohnsonsbaby powderandthatpurchasersofjohnsonjohnsonssharessufferedlossesasaresultplaintiffisseekingdamagesin aprilthecompanymovedtodismissthecomplaintandbriefingonthemotionwascompleteasofaugustin decemberthecourtdeniedinpartthemotiontodismissinmarchdefendantsansweredthecomplaint discoveryisunderway injuneashareholderfiledacomplaintinitiatingasummaryproceedinginnewjerseystatecourtforabooksand recordsinspectioninaugustjohnsonjohnsonrespondedtothebooksandrecordscomplaintandfiledacross motiontodismissinseptemberplaintiffrepliedandthecourtheardoralargumentthecourthasnotyetruledin thebooksandrecordsactioninoctoberdecemberandjanuaryfourshareholdersfiledfourseparate derivativelawsuitsagainstjohnsonjohnsonasthenominaldefendantanditscurrentdirectorsandcertainofficersas johnsonjohnsonannualreportdefendantsintheunitedstatesdistrictcourtforthedistrictofnewjerseyallegingabreachoffiduciarydutiesrelatedto theallegedasbestoscontaminationinbodypowderscontainingtalcprimarilyjohnsonsbabypowderandthat johnsonjohnsonhassuffereddamagesasaresultofthoseallegedbreachesinfebruarythefourcaseswere consolidatedintoasingleactionunderthecaptioninrejohnsonjohnsontalcstockholderderivativelitigation injulyareportwasdeliveredtothecompanysboardofdirectorsbyindependentcounselretainedbytheboard toinvestigatetheallegationsinthederivativelawsuitsandinaseriesofshareholderlettersthattheboardreceivedraise similarissuesfouroftheshareholderswhosentdemandsareplaintiffsintheinrejohnsonjohnsontalcstockholder derivativelitigationtheindependentcounselrecommendedthatthecompanyrejecttheshareholderdemandsandtake thestepsthatarenecessaryorappropriatetosecuredismissalofthederivativelawsuitstheboardunanimouslyadopte therecommendationsoftheindependentcounselsreportinoctobertheshareholdersfiledaconsolidate complaintandinjanuaryjohnsonjohnsonmovedtodismisstheconsolidatedcomplaint injanuarytwoerisaclassactionlawsuitswerefiledbyparticipantsinthejohnsonjohnsonsavingsplan againstjohnsonjohnsonitspensionandbenefitscommitteeandcertainnamedofficersintheunitedstatesdistrict courtforthedistrictofnewjerseyallegingthatthedefendantsbreachedtheirfiduciarydutiesbyofferingjohnson johnsonstockasajohnsonjohnsonsavingsplaninvestmentoptionwhenitwasimprudenttodosobecauseof failurestodiscloseallegedasbestoscontaminationinbodypowderscontainingtalcprimarilyjohnsonsbaby powderplaintiffsareseekingdamagesandinjunctivereliefinseptemberdefendantsfiledamotiontodismissin aprilthecourtgranteddefendantsmotionbutgrantedleavetoamendinjuneplaintiffsfiledanamende complaintandinjulydefendantsmovedtodismisstheamendedcomplaintasofoctoberbriefingon defendantsmotionwascomplete alawsuitpendinginthesuperiorcourtofcaliforniaforthecountyofsandiegoallegingviolationsofcalifornias consumerlegalremediesactrelatingtojohnsonsbabypowderhasbeenresolvedinthecompanysfavorinthat lawsuittheplaintiffsallegethatjohnsonjohnsonviolatedtheclrabyfailingtoproviderequiredproposition warningsinjulythecompanyfiledanoticeofremovaltotheunitedstatesdistrictcourtforthesoutherndistrict ofcaliforniaandplaintiffsfiledasecondamendedcomplaintshortlythereafterinoctoberthecompanymovedto dismissthesecondamendedcomplaintforfailuretostateaclaimuponwhichreliefmaybegrantedinresponsetothose motionsplaintiffsfiledathirdamendedcomplaintindecemberthecompanymovedtodismissthethirdamende complaintforfailuretostateaclaimuponwhichreliefmaybegrantedinaprilthecourtgrantedthemotionto dismissbutgrantedleavetoamendinmayplaintiffsfiledafourthamendedcomplaintbutindicatedthatthey wouldbefilingamotionforleavetofileafifthamendedcomplaintplaintiffsfiledafifthamendedcomplaintinaugust thecompanymovedtodismissthefifthamendedcomplaintforfailuretostateaclaimuponwhichreliefmaybe grantedinjanuarythecourtissuedanorderandopinionrulinginthecompanysfavorandgrantingthemotionto dismisswithprejudice injanuarytheabtahilawgroupfiledanactionunderpropositionagainstjohnsonjohnsonandjohnson johnsonconsumerincaswellasanumberofotherallegedtalcumpowdermanufacturersanddistributorsincludingone californiacompanyinthatactiontheplaintiffallegescontaminationoftalcumpowderproductswithunsafelevelsof arsenichexavalentchromiumandleadtheplaintiffseekscivilpenaltiesandinjunctivereliefdefendantsfiledamotionfor summaryjudgmentinjanuaryandahearinghasbeenscheduledforaprillimitedinformaldiscoveryis continue inadditionthecompanyhasreceivedpreliminaryinquiriesandsubpoenastoproducedocumentsregardingthese mattersfromsenatormurrayamemberofthesenatecommitteeonhealtheducationlaborandpensionsthe departmentofjusticethesecuritiesandexchangecommissionsecandtheuscongressionalsubcommitteeon economicandconsumerpolicythecompanyproduceddocumentsasrequiredinresponseandwillcontinueto cooperatewithgovernmentinquiriesinnovemberthesecterminateditsinvestigation claimsforpersonalinjuryhavebeenmadeagainstanumberofjohnsonjohnsoncompaniesincludingjanssen pharmaceuticalsincandjohnsonjohnsonarisingoutoftheuseofinvokanaaprescriptionmedicationindicate toimproveglycemiccontrolinadultswithtypediabetesindecemberlawsuitsfiledinfederalcourtsintheunite stateswereorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthedistrictofnewjerseycase havealsobeenfiledinstatecourtsclassactionlawsuitshavebeenfiledincanadaproductliabilitylawsuitscontinueto befiledandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof casesthecompanyhassettledorotherwiseresolvedmanyofthecasesandclaimsintheunitedstatesandthecost associatedwiththesesettlementsarereflectedinthecompanysaccrual johnsonjohnsonannualreport claimsforpersonalinjuryhavebeenmadeagainstanumberofjohnsonjohnsoncompaniesincludingjanssen pharmaceuticalsincandjohnsonjohnsonarisingoutoftheuseofelmironaprescriptionmedicationindicatedfor thereliefofbladderpainordiscomfortassociatedwithinterstitialcystitistheselawsuitswhichallegethatelmiron contributestothedevelopmentofpermanentretinalinjuryandvisionlosshavebeenfiledinbothstateandfederalcourts acrosstheunitedstatesindecemberthefederalcasesincludingtwoputativeclassactioncasesseekingmedical monitoringwereorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthedistrictofnewjerseyin additionthreeclassactionlawsuitshavebeenfiledincanadaproductliabilitylawsuitscontinuetobefiledandthe companycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberofcasesthe companyhasestablishedaccrualsfordefensecostsassociatedwithelmironrelatedproductliabilitylitigation intellectualproperty certainsubsidiariesofjohnsonjohnsonaresubjectfromtimetotimetolegalproceedingsandclaimsrelatedto patenttrademarkandotherintellectualpropertymattersarisingoutoftheirbusinessesmanyofthesemattersinvolve challengestothecoverageandorvalidityofthepatentsonvariousproductsandallegationsthatcertainofthecompanys productsinfringethepatentsofthirdpartiesalthoughthesesubsidiariesbelievethattheyhavesubstantialdefensesto thesechallengesandallegationswithrespecttoallsignificantpatentstherecanbenoassuranceastotheoutcomeof thesemattersalossinanyofthesecasescouldadverselyaffecttheabilityofthesesubsidiariestoselltheirproduct resultinlossofsalesduetolossofmarketexclusivityrequirethepaymentofpastdamagesandfutureroyaltiesandmay resultinanoncashimpairmentchargeforanyassociatedintangibleassetsignificantmattersaredescribedbelow medicaldevice innovembermedideallcmedideafiledapatentinfringementlawsuitagainstdepuyorthopaedicsincinthe unitedstatesdistrictcourtforthenortherndistrictofillinoisalleginginfringementbytheattunekneesystemin aprilmedideafiledanamendedcomplaintaddingdepuysynthesproductsincanddepuysynthessalesinca nameddefendantscollectivelydepuymedideaallegedinfringementofunitedstatespatentno andrelatingtoposteriorstabilizedkneesystemsspecifically medideaallegesthatthesofcamtmcontactfeatureoftheattuneposteriorstabilizedkneeproductsinfringesthe patentsinsuitmedideaisseekingmonetarydamagesandinjunctivereliefinjunethecasewastransferredtothe unitedstatesdistrictcourtforthedistrictofmassachusettsinnovemberjudgmentwasenteredinfavorof depuyinjanuarytheuscourtofappealsforthefederalcircuitaffirme indecemberdrfordalbrittonsuedacclarentincacclarentinunitedstatesdistrictcourtforthenorthern districtoftexasallegingthatacclarentsrelievaspinandrelieveaspinplusproductsinfringeuspatent nodralbrittonalsoallegesbreachofcontractfraudandthatheisthetrueownerofacclarentsuspatent notrialisscheduledtobegininoctober innovemberboardofregentstheuniversityoftexassystemandtissuegeninccollectivelyutfiledalawsuit intheunitedstatesdistrictcourtforthewesterndistrictoftexasagainstethiconincandethiconusllc collectivelyethiconallegingthemanufactureandsaleofvicrylplusantibacterialsuturesmonocrylplus antibacterialsuturespdsplusantibacterialsuturesstratafixpdsantibacterialsuturesandstratafix monocrylplusantibacterialsuturesinfringeplaintiffsunitedstatespatentnosand directedtoimplantablepolymerdrugreleasingbiodegradablefiberscontainingatherapeuticagentutisseeking damagesandaninjunctionindecemberethiconfiledpetitionswiththeunitedstatespatentandtrademarkoffice usptoseekinginterpartesreviewiprofbothassertedpatentsinjunetheusptodeniedinstitutionofthe patentiprandgrantedinstitutionofthepatentiprutdismissedthepatentfromthesuitandnolonger accusespdsplusantibacterialsuturesorstratafixpdsplusantibacterialsuturesofinfringementthe previouslyscheduleddistrictcourttrialhasbeenpostpone inaugustintuitivesurgicalincandintuitivesurgicaloperationsinccollectivelyintuitivefiledapatent infringementsuitagainstaurishealthincaurisinunitedstatesdistrictcourtforthedistrictofdelawareinthesuit intuitiveallegeswillfulinfringementofuspatentno andbasedonaurismonarchplatform aurisfilediprpetitionswiththeusptoregardingtheandpatentsintuitive subsequentlydroppedtheandpatentsfromthesuitindecembertheusptoinstitutedreviewof thepatentanddeniedreviewofthepatentinfebruaryandmarchtheusptoinstitutedreviewofthe andpatentsanddeniedreviewofthepatentindecembertheusptodeclaredallof johnsonjohnsonannualreportthechallengedclaimsinthepatenttobeinvalidintuitivehasappealedthatdecisionthedistrictcourttrialis scheduledtobegininjune inaugustrsbspinellcrsbspinefiledapatentinfringementsuitagainstdepuysynthesincinunitedstate districtcourtforthedistrictofdelawareinoctoberrsbspineamendedthecomplainttochangethename defendantstodepuysynthessalesincanddepuysynthesproductsincinthesuitrsbspineallegeswillful infringementofunitedstatespatentnosandbyoneormoreofthefollowingproduct zeropvaspacerzeropspacerzeropnaturalplatesynfixlrspacerandsynfixevolution systemrsbspineseeksmonetarydamagesandinjunctivereliefinnovemberthesuitwasconsolidatedfor pretrialpurposeswithotherpatentinfringementsuitsbroughtbyrsbspineintheunitedstatesdistrictcourtforthe districtofdelawareagainstlifespineincmedactausaincandprecisionspineincinjunethecasewas stayedpendingiprproceedingsfiledbytheconsolidateddefendantsinvolvingtheassertedpatent inmarchosteoplasticsllcfiledapatentinfringementsuitagainstdepuysynthesincdepuysynthesproduct incmedicaldevicebusinessservicesincandsynthesinccollectivelydepuysynthesintheunitedstatesdistrict courtforthedistrictofdelawareinthesuitosteoplasticsallegeswillfulinfringementofuspatentno andbasedontheproplancmfvirtual surgicalplanningservicesandthetrumatchcmfpersonalizesolutionsinaprilosteoplasticsfiledanamende complainttosubstituteuspatentnoforuspatentnoosteoplasticsseeksmonetarydamage andinjunctivereliefinjunedepuysynthesfiledamotiontodismissthecomplaintinoctoberthecourt dismissedmedicaldevicebusinessservicesincfromthecasebutotherwisedeniedthemotiontrialisscheduledfor october pharmaceutical litigationagainstfilersofabbreviatednewdrugapplicationsanda thefollowingsummarizeslawsuitspendingagainstgenericcompaniesthathavefiledandaswiththefdaorundertaken similarregulatoryprocessesoutsideoftheunitedstatesseekingtomarketgenericformsofproductssoldbyvarious subsidiariesofjohnsonjohnsonpriortoexpirationoftheapplicablepatentscoveringthoseproductstheseanda typicallyincludeallegationsofnoninfringementandinvalidityoftheapplicablepatentsintheeventthesubsidiariesare notsuccessfulinanactionortheautomaticstatutorystayoftheandasexpiresbeforetheunitedstatesdistrictcourt rulingsareobtainedthethirdpartycompaniesinvolvedwouldhavetheabilityuponapprovalofthefdatointroduce genericversionsoftheirproductstothemarketresultinginthepotentialforsubstantialmarketshareandrevenuelosse fortheapplicableproductsandwhichmayresultinanoncashimpairmentchargeinanyassociatedintangibleassetin additionfromtimetotimesubsidiariesmaysettlethesetypesofactionsandsuchsettlementscaninvolvetheintroduction ofgenericversionsoftheproductsatissuetothemarketpriortotheexpirationoftherelevantpatentstheinterparte reviewiprprocesswiththeusptocreatedundertheamericainventsactisalsobeingusedattimesby genericcompaniesinconjunctionwithandasandlawsuitstochallengetheapplicablepatent zytiga innovemberjanssenincandjanssenoncologyinccollectivelyjansseninitiatedanoticeofapplicationunder sectionofthepatentedmedicinesnoticeofcomplianceregulationsagainstapotexincapotexandtheministerof healthincanadainresponsetoapotexsfilingofanabbreviatednewdrugsubmissionandsseekingapprovalto marketagenericversionofzytigabeforetheexpirationofcanadianpatentnothefinalheare concludedinmayinoctoberthecourtissuedanorderprohibitingthecanadianministerofhealthfrom approvingapotexsandsuntiltheexpirationofthepatentinnovemberapotexfiledanappeal beginninginjanuaryjansseninitiatedstatementsofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsincanadaagainstapotexpharmascienceincpharmascienceanddrreddyslaboratorie ltdanddrreddyslaboratoriesinccollectivelydrlinresponsetothosepartiesfilingofabbreviatednewdrug submissionsandsseekingapprovaltomarketgenericversionsofzytigabeforetheexpirationofthepatent thefinalhearingintheseactionsconcludedinnovemberandthecourtissuedadecisionholdingthepatent invalidinjanuaryinfebruaryjanssenappealedthedecision inaugustjansseninitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstjamppharmacorporationjampincanadainresponsetojampsfilingofanand seekingapprovaltomarketagenericversionofzytigabeforetheexpirationofthepatentthefinalhearingis scheduledtobegininmay johnsonjohnsonannualreport ineachofthesecanadianactionsjanssenisseekinganorderenjoiningthedefendantsfrommarketingtheirgeneric versionsofzytigabeforetheexpirationofthepatent xarelto inaugustjanssenpharmaceuticalsincjpiandbayerintellectualpropertygmbhandbayeragcollectively bayerfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainst drreddyslaboratoriesincanddrreddyslaboratoriesltdcollectivelydrlwhichfiledanandaseekingapproval tomarketagenericversionofxareltobeforeexpirationofuspatentnointhislawsuitjpiand bayerwereseekinganorderenjoiningdrlfrommarketingtheirgenericversionsofxareltobeforetheexpirationof therelevantpatentsinnovemberjpiandbayerenteredintoaconfidentialsettlementagreementwithdrlandthe casewasvoluntarilydismisse invokanainvokametinvokametxr beginninginjulyjanssenpharmaceuticalsincjanssenresearchdevelopmentllccilaggmbhinternational andjanssenpharmaceuticanvcollectivelyjanssenandmitsubishitanabepharmacorporationmtpcfiledpatent infringementlawsuitsintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainstanumberofgeneric companiesthatfiledandasseekingapprovaltomarketgenericversionsofinvokanainvokametandor invokametxrbeforeexpirationofmtpcsunitedstatespatentnosandor relatingtoinvokanainvokametandorinvokametxrjanssenistheexclusivelicenseeoftheasserte patentsnameddefendantsincludemsnlaboratoriesprivateltdandmsnpharmaceuticalsincmsnzydus pharmaceuticalsusainczydussandozincsandozandlupinltdandlupinpharmaceuticalsinclupinthese caseswereconsolidatedintooneactionpolymorphmainactionwhichhasbeenscheduledfortrialstartinginapril indecemberjanssenandmtpcenteredintoaconfidentialsettlementwithsandozandinjanuary janssenandmtpcenteredintoaconfidentialsettlementwithlupinthecasesagainstsandozandlupinwerevoluntarily dismiss injulyjanssenandmtpcfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof newjerseyagainstzyduswhichfiledandasseekingapprovaltomarketgenericversionsofinvokanaand ivokametbeforeexpirationofmtpcsunitedstatespatentnoandor relatingtoinvokanainvokametandorinvokametxrcompoundsmainactionjanssenis theexclusivelicenseeoftheassertedpatentstrialconcludedinoctober injulyjanssenandmtpcfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof newjerseyagainstmsnwhichfiledanandaseekingapprovaltomarketagenericversionofinvokametxrbefore expirationofthepatentandpatentrelatingtoinvokametxrinoctoberjanssenandmtpcinitiate apatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainstmsnwhichfile andasseekingapprovaltomarketgenericversionsofinvokanaandinvokametxrbeforeexpirationofthe patentinoctoberjanssenandmtpcinitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtfor thedistrictofnewjerseyagainstdrreddyslaboratoriesincanddrreddyslaboratoriesltddrlwhofiledan andaseekingapprovaltomarketagenericversionofinvokametbeforeexpirationofthepatentinjanuary janssenandmtpcfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnew jerseyagainstmacleodspharmaceuticalsltdandmacleodspharmausaincmacleodswhichfiledanandaseeke approvaltomarketagenericversionofinvokametxrbeforeexpirationofthepatentandpatentrelatingto invokametxrinfebruaryjanssenfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofnewjerseyagainstmacleodspharmaceuticalsltdandmacleodspharmausaincmacleodswhichfiledan andaseekingapprovaltomarketagenericversionofinvokanabeforeexpirationofunitedstatespatent norelatingtoinvokanatheselawsuitshavenotbeenconsolidatedwiththemainaction ineachoftheseuslawsuitsjanssenandmtpcareseekinganorderenjoiningthedefendantfrommarketingtheir genericversionsofinvokanainvokametandorinvokametxrbeforetheexpirationoftherelevantpatent inoctoberjanssenincjanssenpharmaceuticanvandmtpcinitiatedastatementofclaimundersectionof thepatentedmedicinesnoticeofcomplianceregulationsagainstsandozcanadaincsandozincanadainresponse tosandozsfilingofanandsseekingapprovaltomarketagenericversionofinvokanabeforetheexpirationofthe canadianpatentnosandthefinalhearingisscheduledtobegininaugust janssenincjanssenpharmaceuticanvandmtpcareseekinganorderenjoiningsandozfrommarketingitsgeneric versionofinvokanabeforetheexpirationoftherelevantpatent johnsonjohnsonannualreportopsumit inoctoberactelionpharmaceuticalsltdactelioninitiatedapatentinfringementlawsuitintheunitedstate districtcourtforthedistrictofnewjerseyagainstlauruslabslimitedandpharmaqinccollectivelylauruswhich filedanandaseekingapprovaltomarketgenericversionsofopsumitbeforetheexpirationofuspatent noactelionwasseekinganorderenjoininglaurusfrommarketinggenericversionsofopsumit beforetheexpirationofthepatentinjanuaryactelionenteredintoasettlementagreementwithlaurus inmayjanssenincjanssenandactelioninitiatedastatementofclaimundersectionofthepatente medicinesnoticeofcomplianceregulationsagainstsandozcanadaincsandozincanadainresponsetosandozs filingofanandsseekingapprovaltomarketagenericversionofopsumitmgbeforetheexpirationofcanadian patentnotrialisscheduledtobegininjanuary inmayjanssenandactelioninitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstapotexincapotexincanadainresponsetoapotexsfilingofanandsseeke approvaltomarketagenericversionofopsumitmgbeforetheexpirationofthepatenttrialisscheduledto begininfebruary injulyjanssenandactelioninitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstjamppharmacorporationjampincanadainresponsetojampsfilingofanands seekingapprovaltomarketagenericversionofopsumitmgbeforetheexpirationofthepatentandcanadian patentnotrialisscheduledtobegininapril ineachofthesecanadianactionsjanssenandactelionareseekinganorderenjoiningthedefendantsfrommarkete theirgenericversionsofopsumitbeforetheexpirationoftherelevantpatent invegasustenna injanuaryjanssenpharmaceuticanvandjanssenpharmaceuticalsinccollectivelyjansseninitiatedapatent infringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainsttevapharmaceuticalsusa inctevawhichfiledanandaseekingapprovaltomarketagenericversionofinvegasustennabeforethe expirationofunitedstatespatentnotrialconcludedinoctober inaugustjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnew jerseyagainstmylanlaboratorieslimitedmylanwhichfiledanandaseekingapprovaltomarketagenericversionof invegasustennabeforetheexpirationofthepatentinfebruarymylanfiledapetitionforinterpartes reviewwiththeusptoseekingtoinvalidatethepatenttheusptodeniedthepetitioninseptemberand mylanappeale indecemberjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtsforthedistrictsof newjerseyanddelawareagainstpharmascienceincmallinckrodtplcandspecgxllccollectivelypharmascience whichfiledanandaseekingapprovaltomarketagenericversionofinvegasustennabeforetheexpirationofthe patent ineachoftheseuslawsuitsjanssenisseekinganorderenjoiningthedefendantfrommarketingagenericversionof invegasustennabeforetheexpirationoftherelevantpatent infebruaryjanssenincandjanssenpharmaceuticanvcollectivelyjanssencanadainitiatedastatementofclaim undersectionofthepatentedmedicinesnoticeofcomplianceregulationsagainsttevacanadalimitedteva canadainresponsetotevasfilingofanandsseekingapprovaltomarketagenericversionofinvegasustenna beforetheexpirationofcanadianpatentnosandjanssensubsequentlydiscontinue theportionofthelawsuitrelatingtothepatentinmaythecanadianfederalcourtissuedapublicjudgment andreasonsdeclaringthattevacanadasgenericversionofinvegasustennaifapprovedwouldinfringeclaimsof thepatentandthattheclaimsofthepatentarenotinvalidforobviousnesstevacanadaappeale innovemberjanssencanadainitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstpharmascienceincinresponsetopharmascienceincsfilingofanandsseeke approvaltomarketagenericversionofinvegasustennabeforetheexpirationofthepatentthefinalheare isscheduledtobegininjuly johnsonjohnsonannualreport injanuaryjanssencanadainitiatedastatementofclaimundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstapotexincapotexinresponsetoapotexsfilingofanandsseekingapprovalto marketagenericversionofinvegasustennabeforetheexpirationofthepatentthefinalhearingisschedule tobegininseptember ineachofthesecanadianlawsuitsjanssencanadaisseekinganorderenjoiningthedefendantfrommarketingageneric versionofinvegasustennabeforetheexpirationoftherelevantpatent imbruvica beginninginjanuarypharmacyclicsllcpharmacyclicsandjanssenbiotechincjbifiledpatentinfringement lawsuitsintheunitedstatesdistrictcourtforthedistrictofdelawareagainstanumberofgenericcompaniesthatfile andasseekingapprovaltomarketgenericversionsofimbruvicamgcapsulesbeforeexpirationof pharmacyclicsunitedstatespatentnos andorrelatingtoimbruvicajbiistheexclusivelicenseeof theassertedpatentsthenameddefendantsincludethefollowinggenericcompaniesciplalimitedandciplausainc collectivelyciplasandozincandlekpharmaceuticalsddcollectivelysandoz injanuarypharmacyclicsandjbiamendedtheircomplaintagainstsandoztoallegeinfringementofunitedstates patentnosand infebruarypharmacyclicsandjbiamendedtheircomplaintagainstciplatoallegeinfringementofunitedstate patentnosand inmarchpharmacyclicsandjbifiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrict ofdelawareagainstalvogenpinebrookllcandnatcopharmaltdcollectivelyalvogenwhichfiledanandaseeke approvaltomarketgenericversionsofimbruvicatabletsassertinginfringementofunitedstatespatentno inmaypharmacyclicsandjbiamendedtheircomplaintagainstciplatofurtherallegeinfringementofunitedstate patentnoinjunepharmacyclicsandjbiamendedtheircomplaintagainstalvogentofurtherallege infringementofunitedstatespatentno inaugustpharmacyclicsandjbiamendedtheircomplaintsagainstciplaandsandoztofurtherallegeinfringement ofuspatentnosandinaugustthecourtgrantedajointstipulationtostaythelitigation againstcipla trialintheactionsagainstsandozandalvogentookplaceinoctober inmarchsandozfiledaniprpetitionwiththeusptoseekingtoinvalidateunitedstatespatentnoin septembertheusptoissuedafinaldecisionintheiprinvalidatingcertainclaimsofthepatentand upholdingthevalidityofcertainclaimsinthepatentthefinaldecisionwasnotappealedbythepartie inmarchpharmacyclicsandjbifiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrict ofdelawareagainstalvogenandsandozassertinginfringementofunitedstatespatentnoinapril pharmacyclicsandjbiamendedtheircomplaintagainstsandoztofurtherallegeinfringementofuspatent noinoctoberpharmacyclicsandjbiamendedtheircomplaintagainstsandoztofurtherallege infringementofuspatentnosandandamendedtheircomplaintagainstalvogentofurther allegeinfringementofuspatentnoindecemberthecourtenteredajointstipulationdismissingthe complaintagainstsandoz inaprilpharmacyclicsandjbifiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrict ofdelawareagainstzydusworldwidedmccandcadilahealthcarelimitedcollectivelyzyduswhichfiledananda seekingapprovaltomarketgenericversionsofimbruvicatabletsassertinginfringementofunitedstatespatentnos trialsintheactionsagainstalvogenandzydusarescheduledtobegininmarch ineachofthelawsuitspharmacyclicsandjbiareseekinganorderenjoiningthedefendantsfrommarketinggeneric versionsofimbruvicabeforetheexpirationoftherelevantpatent johnsonjohnsonannualreportuptravi inaprilactelionpharmaceuticalsltdactelionandnipponshinyakucoltdnipponshinyakuinitiatedapatent infringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainstanumberofgeneric companiesthatfiledandasseekingapprovaltomarketgenericversionsofuptravibeforeexpirationofnippon shinyakusunitedstatespatentnosandrelatingtouptraviactelionisthe exclusivelicenseeoftheassertedpatentsthedefendantsincludealembicpharmaceuticalslimitedandalembic pharmaceuticalsinccollectivelyalembicmsnlaboratoriesprivatelimitedandmsnpharmaceuticalsinccollectively msnvgyaanpharmaceuticalsllcvgyaanandzyduspharmaceuticalsusaincandzydusworldwidedmcc collectivelyzydusinjanuarythecourtenteredjointstipulationsdismissingvgyaanandmsnfromsuit actelionandnipponshinyakuareseekinganorderenjoiningthedefendantsfrommarketinggenericversionsof uptravibeforetheexpirationoftherelevantpatent invegatrinza inseptemberjanssenpharmaceuticalsincjanssenpharmaceuticanvandjanssenresearchdevelopment lcccollectivelyjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnew jerseyagainstmylanlaboratorieslimitedmylanpharmaceuticalsincandmylaninstitutionalllccollectivelymylan mylanfiledanandaseekingapprovaltomarketgenericversionsofinvegatrinzabeforeexpirationofunitedstate patentnorelatingtoinvegatrinzajanssenisseekinganorderenjoiningmylanfrommarketinga genericversionofinvegatrinzabeforetheexpirationoftherelevantpatent governmentproceeding likeothercompaniesinthepharmaceuticalconsumerhealthandmedicaldevicesindustriesjohnsonjohnsonand certainofitssubsidiariesaresubjecttoextensiveregulationbynationalstateandlocalgovernmentagenciesintheunite statesandothercountriesinwhichtheyoperatesuchregulationhasbeenthebasisofgovernmentinvestigationsand litigationsthemostsignificantlitigationbroughtbyandinvestigationsconductedbygovernmentagenciesareliste belowitispossiblethatcriminalchargesandsubstantialfinesandorcivilpenaltiesordamagescouldresultfrom governmentinvestigationsorlitigation averagewholesalepriceawplitigation johnsonjohnsonandseveralofitspharmaceuticalsubsidiariesthejjawpdefendantsalongwithnumerousother pharmaceuticalcompanieswerenamedasdefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolve allegationsthatthepricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwise actionableconductbecauseamongotherthingsthecompaniesallegedlyreportedaninflatedaveragewholesaleprice awpforthedrugsatissuepayorsallegedthattheyusedthoseawpsincalculatingproviderreimbursementlevelsthe plaintiffsinthesecasesincludedthreeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchaseof thedrugsatissuebasedonawpandstategovernmententitiesthatmademedicaidpaymentsforthedrugsatissue basedonawpmanyofthesecasesbothfederalactionsandstateactionsremovedtofederalcourtwereconsolidate forpretrialpurposesinamultidistrictlitigationintheunitedstatesdistrictcourtforthedistrictofmassachusettswhere allclaimsagainstthejjawpdefendantswereultimatelydismissedthejjawpdefendantsalsoprevailedinacase broughtbythecommonwealthofpennsylvaniaotherawpcaseshavebeenresolvedthroughcourtorderorsettlement thecasebroughtbyillinoiswassettledaftertrialinnewjerseyaputativeclassactionbaseduponawpallegationsis pendingagainstcentocorincandorthobiotechincbothnowjanssenbiotechincjohnsonjohnsonandalza corporationallothercaseshavebeenresolve opioidlitigation beginninginandcontinuingtothepresentjohnsonjohnsonandjanssenpharmaceuticalsincjpialongwith otherpharmaceuticalcompanieshavebeennamedinmorethanlawsuitsrelatedtothemarketingofopioid includingduragesicnucyntaandnucyntaerthesuitsalsoraiseallegationsrelatedtopreviouslyowne activepharmaceuticalingredientsuppliersubsidiariestasmanianalkaloidsptyltdandnoramcoincbothsubsidiarie weredivestedinthemajorityofthecaseshavebeenfiledbystateandlocalgovernmentssimilarlawsuitshavealso beenfiledbyprivateplaintiffsandorganizationsincludingbutnotlimitedtothefollowingindividualplaintiffsonbehalfof childrensufferingfromneonatalabstinencesyndromehospitalsandhealthinsurerspayorstodatecomplaintsagainst pharmaceuticalcompaniesincludingjohnsonjohnsonandjpihavebeenfiledbythestateattorneysgeneralin johnsonjohnsonannualreport arkansasfloridaidahoillinoiskentuckylouisianamississippimissourinewhampshirenewjerseynewmexiconew yorkohiooklahomasouthdakotatexaswashingtonandwestvirginiacomplaintsagainstthemanufacturersalso havebeenfiledinstateorfederalcourtbycitycountyandlocalgovernmentagenciesinthefollowingstatesalabama arizonaarkansascaliforniaconnecticutfloridageorgiaillinoiskentuckylouisianamainemarylandmassachusetts mississippimissourinevadanewhampshirenewjerseynewmexiconewyorknorthcarolinaohiooklahoma oregonpennsylvaniarhodeislandsouthcarolinasouthdakotatennesseetexasutahvirginiawashingtonwest virginiaandwisconsinthegovernmentofpuertoricofiledsuitinsuperiorcourtofsanjuantherearemorethan casespendinginvariousstatecourtsthereareoverfederalcasescoordinatedinafederalmultidistrictlitigation mdlpendingintheusdistrictcourtforthenortherndistrictofohiomdlnoinadditiontheprovinceof britishcolumbiafiledsuitincanadainoctoberanantitrustcomplaintwasfiledbyprivateplaintiffsinfederalcourt intennesseeandispendingtransfertothemdltheseactionsallegeavarietyofclaimsrelatedtoopioidmarkete practicesincludingfalseadvertisingunfaircompetitionpublicnuisanceconsumerfraudviolationsdeceptiveactsand practicesfalseclaimsandunjustenrichmentthesuitsgenerallyseekpenaltiesandorinjunctiveandmonetaryreliefandin someofthesuitstheplaintiffsareseekingjointandseveralliabilityamongthedefendantsanadversejudgmentinanyof theselawsuitscouldresultintheimpositionoflargemonetarypenaltiesandsignificantdamagesincludingpunitive damagescostofabatementsubstantialfinesequitableremediesandothersanction thetrialinthematterfiledbytheoklahomaattorneygeneralresultedinajudgmentagainstjohnsonjohnsonandjpiin theamountofmillionsubjecttoafinalordertobeissuedbythecourtthecourtissuedafinaljudgmentreduce theamounttomillionjohnsonjohnsonandjpihaveappealedthejudgmentthecompanybelievesthatithas stronggroundstooverturnthisjudgmentinoctoberjohnsonjohnsonandjpiannouncedasettlementofthefirst casesetfortrialinthemdlwithtwocountiesinohio johnsonjohnsonjpiandotherpharmaceuticalcompanieshavealsoreceivedsubpoenasorrequestsforinformation relatedtoopioidsmarketingpracticesfromthefollowingstateattorneysgeneralalaskaindianamontananew hampshiresouthcarolinatennesseetexasandwashingtoninseptemberjohnsonjohnsonandjpiwere contactedbythetexasandcoloradoattorneygeneralsofficesonbehalfofapproximatelystatesregardingamulti stateattorneygeneralinvestigationinoctoberthecompanyannouncedaproposedagreementinprinciplethat wouldincludethecompanypayingbillionassettlementofthesemattersinoctoberthecompanyagreedto contributeuptoanadditionalbilliontoanallinsettlementamountthatwouldresolveopioidlawsuitsfiledandfuture claimsbystatescitiescountiesandtribalgovernmentsforatotalofbillionwhichhasbeenaccruedsubjectto variousconditionsandanagreementbeingfinalizedthisagreementinprincipleisnotanadmissionofliabilityorwrong doingandwouldresolveopioidlawsuitsfiledandfutureclaimsbystatescitiesandcountiesthecompanycannotpredict iforwhentheagreementwillbefinalizedandindividualcasesareongoe inaugustjohnsonjohnsonreceivedagrandjurysubpoenafromtheunitedstatesattorneysofficeforthe easterndistrictofnewyorkfordocumentsrelatedtothecompanysantidiversionpoliciesandproceduresand distributionofitsopioidmedicationsinwhatthecompanyunderstandstobepartofabroaderinvestigationinto manufacturersanddistributorsmonitoringprogramsandreportingunderthecontrolledsubstancesactinseptember johnsonjohnsonreceivedsubpoenasfromthenewyorkstatedepartmentoffinancialservicesnydfsas partofanindustrywideinquiryintotheeffectofopioidprescriptionsonnewyorkhealthinsurancepremiumsin septemberthecompanylearnedthatnydfsfiledastatementofchargesrelatedtothisinvestigation fromjunethroughdecemberthecompanysboardofdirectorsreceivedaseriesofshareholderdemand lettersallegingbreachesoffiduciarydutiesrelatedtothemarketingofopioidstheboardretainedindependentcounselto investigatetheallegationsinthedemandsandinaprilindependentcounseldeliveredareporttotheboard recommendingthatthecompanyrejecttheshareholderdemandsandtakethestepsthatarenecessaryorappropriateto securedismissalofrelatedderivativelitigationtheboardunanimouslyadoptedtherecommendationsoftheindependent counselsreport innovemberoneoftheshareholderswhosentademandfiledaderivativecomplaintagainstjohnsonjohnsona thenominaldefendantandcertaincurrentandformerdirectorsandofficersasdefendantsinthesuperiorcourtofnew jerseythecomplaintallegesbreachesoffiduciarydutiesrelatedtothemarketingofopioidsandthatjohnsonjohnson hassuffereddamagesasaresultofthoseallegedbreachesinmaytheshareholderfiledanamendedcomplaint challengingtheboardsrejectionofhisdemandinaugustjohnsonjohnsonmovedtodismisstheamended complaintandasofdecemberthatmotionwasfullybriefedinaugustanothershareholderwhosenta demandfiledaseparatederivativecomplaintinthesamecourtmakingsimilarallegationsinoctoberthecourt granteddefendantsrequesttoreassignthesecondfiledcasetothedivisionwherethefirstfiledcaseispende johnsonjohnsonannualreportindecembertwoadditionalshareholderswhosentdemandsfiledtwoseparatederivativecomplaintsmakingsimilar allegationsagainstjohnsonjohnsonasthenominaldefendantandcertaincurrentandformerdirectorsandofficersas defendantsintheunitedstatesdistrictforthedistrictofnewjerseyinaprilthetwofederalcaseswere consolidatedintoasingleactioncaptionedinrejohnsonjohnsonopioidstockholderderivativelitigationinjuly theshareholdersfiledaconsolidatedcomplaintinseptemberjohnsonjohnsonmovedtodismissthe consolidatedcomplaintandindecembertheshareholdersopposedjohnsonjohnsonsmotionjohnson johnsonfileditsreplyinfebruaryinjulyanadditionalshareholderwhosentademandfiledaderivative complaintinthesamefederalcourtmakingsimilarallegationsagainstthesamedefendantsnamedintheconsolidate actioninjanuarypursuanttoanorderintheconsolidatedactionthethirdcasewasconsolidatedintothe consolidatedactioninfebruarytheshareholdersintheconsolidatedactionfiledamotionforvoluntarydismissal inaugustdepuyorthopaedicsincdepuyincnowknownasdepuysynthesincandjohnsonjohnson servicesinccollectivelydepuyreceivedaninformalrequestfromtheunitedstatesattorneysofficeforthedistrictof massachusettsandthecivildivisionoftheunitedstatesdepartmentofjusticetheunitedstatesfortheproductionof materialsrelatingtothedepuyasrxlhipdeviceinjulytheunitedstatesnotifiedtheunitedstatesdistrict courtforthedistrictofmassachusettsthatithaddeclinedtointerveneinaquitamcasefiledpursuanttothefalseclaim actagainstthecompaniesinfebruarythedistrictcourtgrantedthecompaniesmotiontodismisswithprejudice unsealedthequitamcomplaintanddeniedthequitamrelatorsrequestforleavetofileafurtheramendedcomplaintthe quitamrelatorsappealedthecasetotheunitedstatescourtofappealsforthefirstcircuitinjulythefirstcircuit affirmedthedistrictcourtsdismissalinpartreversedinpartandaffirmedthedecisiontodenytherelatorsrequesttofile athirdamendedcomplainttherelatorsremainingclaimsarenowpendingbeforethedistrictcourtinjulythe courtorderedtherelatorstocompletediscoverybyaugusttherelatorshaverequestedanextensionoftheaugust deadlinethatdepuyopposedandadditionaldiscoveryrelatedmotionshavebeenfiledbybothpartiesadditionally depuyhasrequestedascheduleforthefilingofamotiontostrikeandtodismisstherelatorssecondamendedcomplaint inoctoberjohnsonjohnsonwascontactedbythecaliforniaattorneygeneralsofficeregardingamultistate attorneygeneralinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesby johnsonjohnsonssubsidiaryethiconincethiconinmaycaliforniaandwashingtonfiledcivilcomplaint againstjohnsonjohnsonethiconandethiconusllcallegingviolationsoftheirconsumerprotectionstatutessimilar complaintswerefiledagainstthecompaniesbythefollowingstateskentuckymississippiwestvirginiaandoregonin apriljohnsonjohnsonandethiconsettledthewashingtoncasethecaliforniacasestartedtrialinjuly andconcludedinseptemberthetrialdateforthekentuckycasewasscheduledforseptemberbuthasbeen adjournedandnonewtrialdatehasbeenscheduledinoctoberjohnsonjohnsonandethiconsettledthemulti stateinvestigationwithotherstatesandthedistrictofcolumbiainjanuarythecourtincaliforniaissueda statementofdecisionfindinginfavorofthestateofcaliforniaandawardedcivilpenaltiesintheamountofmillion inaprilthecourtincaliforniadeniedthecompanysmotionforanewtrialinaugustthecourtentere judgmentwithrespecttothepenaltiesofmillionbutdeniedtheattorneygeneralsrequestforinjunctivereliefthe companyisappealingthepenaltyjudgmentinaprilthecompanysettledthewestvirginiainoctoberthe companysettledwiththeattorneygeneraloforegoninnovemberthecompanysettledwiththeattorney generalofmississippi indecembertherakosinctherakosformerlyasubsidiaryofjohnsonjohnsonandpartoftheorthoclinical diagnosticsincocdfranchisereceivedaletterfromthecivildivisionoftheunitedstatesattorneysofficeforthe easterndistrictofpennsylvaniainformingtherakosthattheunitedstatesattorneysofficewasinvestigatingthesales andmarketingofuvadexmethoxsalenandtheuvarxtsandcellexsystemsduringtheperiodtothepresent theunitedstatesattorneysofficerequestedthatocdandjohnsonjohnsonpreservedocumentsthatcouldrelateto theinvestigationtherakoswassubsequentlyacquiredbyanaffiliateofgorescapitalpartnersiiilpinjanuary andocdwasdivestedinjunefollowingthedivestitureofocdjohnsonjohnsonretainedocdsportionofany liabilityresultingfromtheinvestigationforactivitythatoccurredpriortothesaleoftherakosfollowingproductionof documentstoandsettlementdiscussionswiththeusattorneysofficejjaffiliatemedicaldevicebusinessservice incagreedtoresolveclaimsunderthefederalfalseclaimsactandanalogousstatelawsinasettlementannouncedin novemberinthesettlementagreementmedicaldevicebusinessservicesexpresslydeniedanywrongfulconduct asaresultofthesettlementaquitamcomplaintfiledbytworelatorspendingintheusdistrictcourtfortheeastern districtofpennsylvaniawillbedismissedseparatesettlementagreementswiththestatesparticipatinginthesettlement areintheprocessofbeingfinalize johnsonjohnsonannualreport injunethemississippiattorneygeneralfiledacomplaintinchancerycourtofthefirstjudicialdistrictofhind countymississippiagainstjohnsonjohnsonandjohnsonjohnsonconsumercompaniesincnowknownas johnsonjohnsonconsumerincjjcithecomplaintallegesthatdefendantsviolatedthemississippiconsumer protectionactbyfailingtodiscloseallegedhealthrisksassociatedwithfemaleconsumersuseoftalccontainedin johnsonsbabypowderandjohnsonsshowertoshoweraproductdivestedinandseeksinjunctive andmonetaryreliefthematterisstayedpendinginterlocutoryappealofadecemberdenialofjohnsonjohnson andjjcismotionforsummaryjudgmentthemississippisupremecourtgrantedjjandjjcisrequesttofilean interlocutoryappealofthedenialofthemotionforsummaryjudgmentinlatebriefingiscompleteandoralargument washeldinfebruary injanuarythestateofnewmexicofiledaconsumerprotectioncaseallegingthatthecompanydeceptively marketedandsolditstalcumpowderproductsbymakingmisrepresentationsaboutthesafetyoftheproductsandthe presenceofcarcinogensincludingasbestosthestateofnewmexicofiledanamendedcomplaintinmarchthe companymovedtodismisscertainoftheclaimsintheamendedcomplaintwhichwasgrantedthecompanythenfile amotionforpartialjudgmentonthepleadingsindecember fortyonestateshavecommencedajointinvestigationintothecompanysmarketingofitstalcumpowderproductsat thistimethemultistategrouphasnotassertedanyclaimsagainstthecompanyseveralstateshaveissuedcivil investigativedemandsseekingdocumentsandotherinformation inmarchjanssenpharmaceuticalsincjpireceivedacivilinvestigativedemandfromtheunitedstate attorneysofficeforthesoutherndistrictofnewyorkrelatedtojpiscontractualrelationshipswithpharmacybenefit managersovertheperiodfromjanuarytothepresentwithregardtocertainofjpispharmaceuticalproductsthe demandwasissuedinconnectionwithaninvestigationunderthefalseclaimsactthecompanyhasprovide documentsinresponsetothedemand injulyjohnsonjohnsonandjanssenproductslpwereservedwithaquitamcomplaintpursuanttothefalse claimsactfiledintheunitedstatesdistrictcourtforthedistrictofnewjerseyallegingtheofflabelpromotionoftwo hivproductsprezistaandintelenceandantikickbackviolationsinconnectionwiththepromotionofthese productsthecomplaintwasfiledundersealindecemberthefederalandstategovernmentshavedeclinedto interveneandthelawsuitisbeingprosecutedbytherelatorsinfebruarythecourtstayedthecaseandordere mediation inmarchjanssenbiotechincreceivedacivilinvestigativedemandfromtheunitedstatesdepartmentofjustice regardingafalseclaimsactinvestigationconcerningmanagementandadvisoryservicesprovidedtorheumatologyand gastroenterologypracticesthatpurchasedremicadeorsimponiariainaugusttheunitesstate departmentofjusticenotifiedjanssenbiotechincthatitwasclosingtheinvestigationsubsequentlytheunitedstate districtcourtforthedistrictofmassachusettsunsealedaquitamfalseclaimsactcomplaintwhichwasservedonthe companythedepartmentofjusticehaddeclinedtointerveneinthequitamlawsuitinaugustthecompanyfile amotiontodismisswhichwasgrantedinpartanddeniedinpartdiscoveryisunderway inaprilandseptemberjohnsonjohnsonreceivedsubpoenasfromtheunitedstatesattorneyforthedistrictof massachusettsseekingdocumentsbroadlyrelatingtopharmaceuticalcopaymentsupportprogramsfordarzalex olysioremicadesimponistelaraandzytigathesubpoenasalsoseekdocumentsrelatingtoaverage manufacturerpriceandbestpricereportingtothecenterformedicareandmedicaidservicesrelatedtothoseproduct aswellasrebatepaymentstostatemedicaidagenciesthecompanyhasprovideddocumentsinresponsetothe subpoenas injunejohnsonjohnsonreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsseekinginformationregardingpracticespertainingtothesterilizationofdepuysynthesincspinal implantsatthreehospitalsinbostonaswellasinteractionsofemployeesofcompanysubsidiarieswithphysiciansat thesehospitalsjohnsonjohnsonanddepuysynthesinchaveproduceddocumentsinresponsetothesubpoenaand arefullycooperatingwiththegovernmentsinvestigation injulythepublicprosecutionserviceinriodejaneiroandrepresentativesfromthebrazilianantitrustauthority cadeinspectedtheofficesofmorethancompaniesincludingjohnsonjohnsondobrasilindstriaecomrciode produtosparasadeltdatheauthoritiesappeartobeinvestigatingallegationsofpossibleanticompetitivebehaviorand possibleimproperpaymentsinthemedicaldeviceindustrywecontinuetoactivelyrespondtoinquiriesregardingthe foreigncorruptpracticesactfromtheunitedstatesdepartmentofjusticeandtheunitedstatessecuritiesand exchangecommission johnsonjohnsonannualreportfromtimetotimethecompanyhasreceivedrequestsfromavarietyofunitedstatescongressionalcommitteesto produceinformationrelevanttoongoingcongressionalinquiriesitisthepolicyofjohnsonjohnsontocooperatewith theseinquiriesbyproducingtherequestedinformation generallitigation inmarchapurportedclassactionwasfiledinthecircuitcourtthirdjudicialdistrictmadisoncountyillinois againstjohnsonjohnsonconsumerincjjciallegingviolationsofstateconsumerfraudstatutesbasedon nondisclosureofallegedhealthrisksassociatedwithtalccontainedinjohnsonsbabypowderthecomplaintseeks damagesbutdoesnotallegepersonalinjuryinoctoberjjcimovedtodismissthecomplaint inaugustunitedstatescustomsandborderprotectionuscbpissuedapenaltynoticeagainstjanssenortho llcjanssenorthoassessingpenaltiesfortheallegedimproperclassificationofdarunavirethanolatetheactive pharmaceuticalingredientinprezistainconnectionwithitsimportationintotheunitedstatesinaugustus cbpformallyrejectedjanssenssupplementalpetitionchallengingthepenaltiesassessmentanddemandedpaymentof themitigatedpenaltyinoctoberuscbpagreedtonotreferthemattertotheofficeofchiefcounselatthistime pendingresolutionoftherelatedclassificationlitigationindecemberjanssenorthosuedtheunitedstatesinthe unitedstatescourtofinternationaltradetheclassificationlitigationseekingadeterminationthatdarunavirethanolate isexemptfromdutiesuponimportationintotheunitedstatesinfebruarythecourtruledthatdarunavirethanolate iseligiblefordutyfreetreatmentinapriltheunitedstatesappealedtotheunitedstatescourtofappealsforthe federalcircuit inseptembergenmabasbroughtanarbitrationagainstjanssenbiotechincpursuanttoalicense agreementbetweenthepartiesthearbitrationrelatestoroyaltiesforcertainjanssendaratumumabproduct inmarchandapriloverputativeclassactioncomplaintswerefiledbycontactlenspatientsinanumberofcourt aroundtheunitedstatesagainstjohnsonjohnsonvisioncareincjjvciandothercontactlensmanufacturer distributorsandretailersallegingverticalandhorizontalconspiraciestofixtheretailpricesofcontactlensesthe complaintsallegethatthemanufacturersreachedagreementswitheachotherandcertaindistributorsandretailer concerningthepricesatwhichsomecontactlensescouldbesoldtoconsumerstheplaintiffsareseekingdamagesand injunctivereliefalloftheclassactioncasesweretransferredtotheunitedstatesdistrictcourtforthemiddledistrictof floridainjunetheplaintiffsfiledaconsolidatedclassactioncomplaintinnovemberdiscoveryandpretrial motionpracticeiscompletenotrialdatehasbeenset inaugusttwothirdpartypayorsfiledapurportedclassactionintheunitedstatesdistrictcourtfortheeastern districtoflouisianaagainstjanssenresearchdevelopmentllcjanssenorthollcjanssenpharmaceuticalsinc orthomcneiljanssenpharmaceuticalsincandjohnsonjohnsonaswellascertainbayerentitiesallegingthatthe defendantsimproperlymarketedandpromotedxareltoassaferandmoreeffectivethanlessexpensivealternative medicationswhilefailingtofullydiscloseitsrisksthecomplaintseeksdamagesinnovemberdefendantsmove todismissthecomplaint inseptemberpfizerincpfizerfiledanantitrustcomplaintagainstjohnsonjohnsonandjanssenbiotechinc collectivelyjansseninunitedstatesdistrictcourtfortheeasterndistrictofpennsylvaniapfizerallegesthatjanssen hasviolatedfederalantitrustlawsthroughitscontractingstrategiesforremicadethecomplaintseeksdamagesand injunctivereliefdiscoveryisongoe beginninginseptembermultiplepurportedclassactionswerefiledonbehalfofindirectpurchasersof remicadeagainstjohnsonjohnsonandjanssenbiotechinccollectivelyjanssenallegingthatjanssenha violatedfederalantitrustlawsthroughitscontractingstrategiesforremicadethecaseswereconsolidatedforpretrial purposesasinreremicadeantitrustlitigationinunitedstatesdistrictcourtfortheeasterndistrictofpennsylvania theconsolidatedcomplaintseeksdamagesandinjunctivereliefdiscoveryisongoing injunewalgreencoandkrogercofiledanantitrustcomplaintagainstjohnsonjohnsonandjanssenbiotech inccollectivelyjanssenintheunitedstatesdistrictcourtfortheeasterndistrictofpennsylvaniathecomplaint allegesthatjanssenhasviolatedfederalantitrustlawsthroughitscontractingstrategiesforremicadethecomplaint seeksdamagesandinjunctivereliefinmarchsummaryjudgmentwasgrantedinfavorofjansseninfebruary theunitedstatescourtofappealsforthethirdcircuitreversedthedistrictcourtsdecisiondiscoveryis ongoing johnsonjohnsonannualreport injunetheunitedstatesfederaltradecommissionftcissuedacivilinvestigativedemandtojohnson johnsoninconnectionwithitsinvestigationofwhetherjanssensremicadecontractingpracticesviolatefederal antitrustlawsthecompanyproduceddocumentsandinformationresponsivetothecivilinvestigativedemand inoctobercertainunitedstatesservicemembersandtheirfamiliesbroughtacomplaintagainstanumberof pharmaceuticalandmedicaldevicescompaniesincludingjohnsonjohnsonandcertainofitssubsidiariesinunite statesdistrictcourtforthedistrictofcolumbiaallegingthatthedefendantsviolatedtheunitedstatesantiterrorism actthecomplaintallegesthatthedefendantsprovidedfundingforterroristorganizationsthroughtheirsalespractice pursuanttopharmaceuticalandmedicaldevicecontractswiththeiraqiministryofhealthinjulythedistrictcourt dismissedthecomplaintinjanuaryplaintiffsappealedthedistrictcourtsdecisiontotheunitedstatescourtof appealsforthedistrictofcolumbiacircuit inoctobertwoseparateputativeclassactionswerefiledagainstactelionpharmaceuticalltdactelion pharmaceuticalsusincandactelionclinicalresearchinccollectivelyactelioninunitedstatesdistrictcourtforthe districtofmarylandandunitedstatesdistrictcourtforthedistrictofcolumbiathecomplaintsallegethatactelion violatedstateandfederalantitrustandunfaircompetitionlawsbyallegedlyrefusingtosupplygenericpharmaceutical manufacturerswithsamplesoftracleertracleerissubjecttoariskevaluationandmitigationstrategyrequire bythefoodanddrugadministrationwhichimposesrestrictionsondistributionoftheproductinjanuarythe plaintiffsdismissedthedistrictofcolumbiacaseandfiledaconsolidatedcomplaintintheunitedstatesdistrictcourtfor thedistrictofmarylandinoctoberthecourtgrantedactelionsmotiontodismisstheamendedcomplaint plaintiffshaveappealedthedecisiontotheunitedstatescourtofappealsforthefourthcircuit indecemberjanssenbiotechincjanssenoncologyincjanssenresearchdevelopmentllcandjohnson johnsoncollectivelyjanssenwereservedwithaquitamcomplaintfiledonbehalfoftheunitedstatesstatesand thedistrictofcolumbiathecomplaintwhichwasfiledindecemberinunitedstatesdistrictcourtforthenorthern districtofcaliforniaallegesthatjanssenviolatedthefederalfalseclaimsactandstatelawwhenprovidingprice informationforzytigatothegovernmentinconnectionwithdirectgovernmentsalesandgovernmentfundeddrug reimbursementprogramsatthistimethefederalandstategovernmentshavedeclinedtointervenethecasehasbeen transferredtounitedstatesdistrictcourtforthedistrictofnewjerseyinseptemberjanssenmovedtodismiss thecomplaint inaprilbluecrossblueshieldoflouisianaandhmolouisianaincfiledaclassactioncomplaintagainst janssenbiotechincjanssenoncologyincjanssenresearchdevelopmentllcandbtginternationallimitedinthe unitedstatesdistrictcourtfortheeasterndistrictofvirginiaonbehalfofindirectpurchasersofzytigaseveral additionalcomplaintswerefiledthereafterinvirginiaandnewjerseytheindirectpurchasercomplaintsgenerallyallege thatthedefendantsviolatedtheantitrustandconsumerprotectionslawsofseveralstatesandtheshermanactby pursuingpatentlitigationrelatingtozytigainordertodelaygenericentryandseekdamagesthevirginiacaseshave beentransferredtotheunitedstatesdistrictcourtforthedistrictofnewjerseyandconsolidatedwiththenewjersey caseforpretrialpurposesinmayaclassactioncomplaintwasfiledagainstjanssenbiotechincjanssen oncologyincjanssenresearchdevelopmentllcandbtginternationallimitedintheunitedstatesdistrictcourt forthedistrictofnewjerseyonbehalfofdirectpurchasersofzytigathedirectpurchasercomplaintallegesthat defendantsviolatedtheshermanactbypursuingpatentlitigationrelatingtozytigainordertodelaygenericentryand seekdamagesandinjunctiverelief inmayaclassactionantitrustcomplaintwasfiledagainstjanssenrdirelandjanssenandjohnsonjohnsonin theunitedstatesdistrictcourtforthenortherndistrictofcaliforniathecomplaintallegesthatjanssenviolatedfederal andstateantitrustandconsumerprotectionlawsbyagreeingtoexclusivityprovisionsinitsagreementswithgilead concerningthedevelopmentandmarketingofcombinationantiretroviraltherapiescarttotreathivthecomplaintalso allegesthatgileadenteredintosimilaragreementswithbristolmyerssquibbandjapantobaccoinmarchthe courtgrantedinpartanddeniedinpartdefendantsmotionstodismissplaintiffsfiledanamendedcomplaintinapril defendantsmovedtodismisstheamendedcomplaintinjulythecourtgrantedinpartanddeniedinpartthe renewedmotiontodismissdiscoveryisongoing inoctoberinnovativehealthllcfiledacomplaintagainstbiosensewebsterincbwiintheunitedstate districtcourtforthemiddledistrictofcaliforniathecomplaintallegesthatcertainofbwisbusinesspracticesand contractualtermsviolatetheantitrustlawsoftheunitedstatesandthestateofcaliforniabyrestrictingcompetitioninthe saleofhighdensitymappingcathetersandultrasoundcathetersinjanuarybwifiledamotiontodismissthe complaintinaugustthecourtgrantedinpartanddeniedinpartbwismotiontodismissdiscoveryisongoing johnsonjohnsonannualreportinnovemberjohnsonjohnsonreceivedademandforindemnificationfrompfizerincpursuanttothestock andassetpurchaseagreementbetweenthecompanyandpfizeralsoinnovemberjohnsonjohnsoninc receivedademandforindemnificationfromsanoficonsumerhealthincpursuanttotheassetpurchase agreementbetweenjjincandsanofiinjanuaryjohnsonjohnsonreceivedademandforindemnificationfrom boehringeringelheimpharmaceuticalsincpursuanttotheassetpurchaseagreementamongthecompany pfizerandboehringeringelheimthenoticesseekindemnificationforlegalclaimsrelatedtooverthecounterzantac ranitidineproductsplaintiffsintheunderlyingactionsallegethatzantacandotheroverthecounterranitidine medicationscontainunsafelevelsofndmannitrosodimethylamineandcancauseandorhavecausedvariouscancer inpatientsusingtheproductsandseekinjunctiveandmonetaryrelief inoctoberfortisadvisorsllcfortisinitscapacityasrepresentativeoftheformerstockholdersofaurishealth incaurisfiledacomplaintagainstjohnsonjohnsonethiconincandcertainnamedofficersandemployee collectivelyethiconinthecourtofchanceryofthestateofdelawarethecomplaintallegesbreachofcontractfraud andothercausesofactionagainstethiconinconnectionwithethiconsacquisitionofaurisinthecomplaintseek damagesandotherreliefindecemberethiconmovedtodismisscertaincausesofactioninthecomplaint johnsonjohnsonoritssubsidiariesarealsopartiestoanumberofproceedingsbroughtunderthecomprehensive environmentalresponsecompensationandliabilityactcommonlyknownassuperfundandcomparablestatelocalor foreignlawsinwhichtheprimaryreliefsoughtisthecostofpastandorfutureremediation johnsonjohnsonannualreport restructure inthefiscalsecondquarterofthecompanyannouncedplanstoimplementaseriesofactionsacrossitsglobal supplychainthatareintendedtofocusresourcesandincreaseinvestmentsinthecriticalcapabilitiestechnologiesand solutionsnecessarytomanufactureandsupplyitsproductportfolioenhanceagilityanddrivegrowththeglobalsupply chainactionsincludeexpandingtheuseofstrategiccollaborationsandbolsteringinitiativestoreducecomplexityimprove costcompetitivenessenhancecapabilitiesandoptimizethesupplychainnetworkforadditionaldetailsontheglobal supplychainrestructuringstrategiccollaborationsseenotetotheconsolidatedfinancialstatementsinfiscalyear thecompanyrecordedapretaxchargeofbillionwhichisincludedonthefollowinglinesoftheconsolidate statementofearningsbillioninrestructuringbillioninotherincomeexpenseandbillionincostof productssoldtotalprojectcostsofapproximatelybillionhavebeenrecordedsincetherestructuringwas announcedseethefollowingtableforadditionaldetailsontherestructuringprogram intotalthecompanyexpectstheglobalsupplychainactionstogenerateapproximatelybilliontobillionin annualpretaxcostsavingsthatwillbesubstantiallydeliveredbythecompanyexpectstorecordpretax restructuringchargesofapproximatelybilliontobillionoverthetoyearperiodofthisactivitythesecost areassociatedwithnetworkoptimizationsexitcostsandaccelerateddepreciationandamortization thefollowingtablesummarizestheseverancechargesandtheassociatedspendingundertheseinitiativesthroughthe fiscalyearended dollarsinmillion severance assetwriteoffssale total reservebalancedecember activity reservebalancedecember currentyearactivity charge cashsettlement settlednoncash reservebalancejanuary cashoutlaysforseveranceareexpectedtobesubstantiallypaidoutoverthenextyearsinaccordancewiththecompanysplan andlocallaw otherincludesprojectexpensesuchassalariesforemployeessupportingtheseinitiativesandconsultingexpense relatestopensionrelatednetactuariallossesassociatedwiththetransferofemployeestojabilincaspartofthestrategic collaboration representsgainonsaleofanasset thecompanycontinuouslyreevaluatesitsseverancereservesrelatedtorestructuringandthetimingofpaymentsdueto theplannedreleaseofassociatesregardingseverallongertermprojectsthecompanybelievesthattheexiste severancereservesaresufficienttocovertheglobalsupplychainplansgiventheperiodoverwhichtheactionswilltake placethecompanywillcontinuetoassessandmakeadjustmentsasnecessaryifadditionalamountsbecomeprobable andestimable johnsonjohnsonannualreportreport independent register public accounting firm totheboardofdirectorsandshareholdersofjohnsonjohnson opinionsonthefinancialstatementsandinternalcontroloverfinancialreporte wehaveauditedtheaccompanyingconsolidatedbalancesheetsofjohnsonjohnsonanditssubsidiariesthe companyasofjanuaryanddecemberandtherelatedconsolidatedstatementsofearningsof comprehensiveincomeofequityandofcashflowsforeachofthethreefiscalyearsintheperiodendedjanuary includingtherelatednotescollectivelyreferredtoastheconsolidatedfinancialstatementswealsohaveauditedthe companysinternalcontroloverfinancialreportingasofjanuarybasedoncriteriaestablishedininternalcontrol integratedframeworkissuedbythecommitteeofsponsoringorganizationsofthetreadwaycommission coso inouropiniontheconsolidatedfinancialstatementsreferredtoabovepresentfairlyinallmaterialrespectsthefinancial positionofthecompanyasofjanuaryanddecemberandtheresultsofitsoperationsanditscash flowsforeachofthethreefiscalyearsintheperiodendedjanuaryinconformitywithaccountingprinciple generallyacceptedintheunitedstatesofamericaalsoinouropinionthecompanymaintainedinallmaterialrespect effectiveinternalcontroloverfinancialreportingasofjanuarybasedoncriteriaestablishedininternalcontrol integratedframeworkissuedbythecoso basisforopinion thecompanysmanagementisresponsiblefortheseconsolidatedfinancialstatementsformaintainingeffectiveinternal controloverfinancialreportingandforitsassessmentoftheeffectivenessofinternalcontroloverfinancialreporte includedintheaccompanyingmanagementsreportoninternalcontroloverfinancialreportingourresponsibilityisto expressopinionsonthecompanysconsolidatedfinancialstatementsandonthecompanysinternalcontroloverfinancial reportingbasedonourauditsweareapublicaccountingfirmregisteredwiththepubliccompanyaccountingoversight boardunitedstatespcaobandarerequiredtobeindependentwithrespecttothecompanyinaccordancewiththe usfederalsecuritieslawsandtheapplicablerulesandregulationsofthesecuritiesandexchangecommissionandthe pcaob weconductedourauditsinaccordancewiththestandardsofthepcaobthosestandardsrequirethatweplanand performtheauditstoobtainreasonableassuranceaboutwhethertheconsolidatedfinancialstatementsarefreeofmaterial misstatementwhetherduetoerrororfraudandwhethereffectiveinternalcontroloverfinancialreportingwasmaintaine inallmaterialrespect ourauditsoftheconsolidatedfinancialstatementsincludedperformingprocedurestoassesstherisksofmaterial misstatementoftheconsolidatedfinancialstatementswhetherduetoerrororfraudandperformingproceduresthat respondtothoseriskssuchproceduresincludedexaminingonatestbasisevidenceregardingtheamountsand disclosuresintheconsolidatedfinancialstatementsourauditsalsoincludedevaluatingtheaccountingprinciplesused andsignificantestimatesmadebymanagementaswellasevaluatingtheoverallpresentationoftheconsolidatedfinancial statementsourauditofinternalcontroloverfinancialreportingincludedobtaininganunderstandingofinternalcontrol overfinancialreportingassessingtheriskthatamaterialweaknessexistsandtestingandevaluatingthedesignand operatingeffectivenessofinternalcontrolbasedontheassessedriskourauditsalsoincludedperformingsuchother proceduresasweconsiderednecessaryinthecircumstanceswebelievethatourauditsprovideareasonablebasisfor ouropinion definitionandlimitationsofinternalcontroloverfinancialreporte acompanysinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith generallyacceptedaccountingprinciplesacompanysinternalcontroloverfinancialreportingincludesthosepoliciesand proceduresthatipertaintothemaintenanceofrecordsthatinreasonabledetailaccuratelyandfairlyreflectthe transactionsanddispositionsoftheassetsofthecompanyiiprovidereasonableassurancethattransactionsare johnsonjohnsonannualreport recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounte principlesandthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof managementanddirectorsofthecompanyandiiiprovidereasonableassuranceregardingpreventionortimelydetection ofunauthorizedacquisitionuseordispositionofthecompanysassetsthatcouldhaveamaterialeffectonthefinancial statement becauseofitsinherentlimitationsinternalcontroloverfinancialreportingmaynotpreventordetectmisstatementsalso projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate becauseofchangesinconditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate criticalauditmatter thecriticalauditmatterscommunicatedbelowaremattersarisingfromthecurrentperiodauditoftheconsolidate financialstatementsthatwerecommunicatedorrequiredtobecommunicatedtotheauditcommitteeandthatirelateto accountsordisclosuresthatarematerialtotheconsolidatedfinancialstatementsandiiinvolvedourespecially challengingsubjectiveorcomplexjudgmentsthecommunicationofcriticalauditmattersdoesnotalterinanywayour opinionontheconsolidatedfinancialstatementstakenasawholeandwearenotbycommunicatingthecriticalaudit mattersbelowprovidingseparateopinionsonthecriticalauditmattersorontheaccountsordisclosurestowhichthey relate uspharmaceuticalrebatereservesmanagedcaremedicareandmedicaid asdescribedinnotetotheconsolidatedfinancialstatementsthecompanyrecognizesrevenuefromproductsales whenobligationsunderthetermsofacontractwiththecustomeraresatisfiedrebatesanddiscountsprovidedto customersareaccountedforasvariableconsiderationandrecordedasareductioninsalestheliabilityforsuchrebates anddiscountsisrecognizedwithinaccruedrebatesreturnsandpromotionsontheconsolidatedbalancesheeta significantportionoftheliabilityrelatedtorebatesisfromthesaleofpharmaceuticalgoodswithintheusprimarilythe managedcaremedicareandmedicaidprogramswhichamountedtobillionasofjanuaryforsignificant rebateprogramswhichincludetheusmanagedcaremedicareandmedicaidrebateprogramsrebatesanddiscounts estimatedbymanagementarebasedoncontractualtermshistoricalexperiencepatientoutcomestrendanalysisand projectedmarketconditionsintheuspharmaceuticalmarket theprincipalconsiderationsforourdeterminationthatperformingproceduresrelatingtouspharmaceuticalrebate reservesmanagedcaremedicareandmedicaidisacriticalauditmatterarethesignificantjudgmentbymanagement duetothesignificantmeasurementuncertaintyinvolvedindevelopingthesereservesandthehighdegreeofauditor judgmentsubjectivityandauditeffortinperformingproceduresandevaluatingtheassumptionsrelatedtocontractual termshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsintheuspharmaceutical market addressingthematterinvolvedperformingproceduresandevaluatingauditevidenceinconnectionwithformingour overallopinionontheconsolidatedfinancialstatementstheseproceduresincludedtestingtheeffectivenessofcontrols relatingtouspharmaceuticalrebatereservesmanagedcaremedicareandmedicaidincludingcontrolsoverthe assumptionsusedtoestimatetheserebatestheseproceduresalsoincludedamongothersidevelopingan independentestimateoftherebatesbyutilizingthirdpartyinformationonpriceandmarketconditionsintheus pharmaceuticalmarketthetermsofthespecificrebateprogramsandthehistoricalexperienceandtrendanalysisof actualrebateclaimspaidiitestingrebateclaimsprocessedbythecompanyincludingevaluatingthoseclaimsfor consistencywiththecontractualandmandatedtermsofthecompanysrebatearrangementsandiiicomparingthe independentestimatestomanagementsestimate litigationcontingenciestalc asdescribedinnotesandtotheconsolidatedfinancialstatementsthecompanyrecordsaccrualsforloss contingenciesassociatedwithlegalmattersincludingtalcwhenitisprobablethataliabilitywillbeincurredandthe amountofthelosscanbereasonablyestimatedtotheextentadverseverdictshavebeenrenderedagainstthecompany managementdoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimatedfor thesemattersmanagementisunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccrue amountsaccruedforlegalcontingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsand uncertaintiesthatrelyheavilyonestimatesandassumptionsincludingtimingofrelatedpaymentstheabilitytomakesuch estimatesandjudgmentscanbeaffectedbyvariousfactorsincludingamongotherthingswhetherdamagessoughtin johnsonjohnsonannualreporttheproceedingsareunsubstantiatedorindeterminatescientificandlegaldiscoveryhasnotcommencedorisnot completeproceedingsareinearlystagesmatterspresentlegaluncertaintiestherearesignificantfactsindispute proceduralorjurisdictionalissuestheuncertaintyandunpredictabilityofthenumberofpotentialclaimsabilitytoachieve comprehensivemultipartysettlementscomplexityofrelatedcrossclaimsandcounterclaimsandortherearenumerous partiesinvolvedtherehavebeenverdictsagainstthecompanyforthismatterincludingaverdictinjulyof billionwhichwasreversedinpartandaffirmedinpartbythemissouricourtofappealsinjunereducingthe overallawardtobillionandwithadditionalinterestasofjanuaryasthecompanypursuesfurtherappealis currentlybillionanapplicationfortransferofthecasetothemissourisupremecourtwassubsequentlydeniedand thecompanyiscurrentlyseekingreviewbytheunitedstatessupremecourtasdescribedbymanagementthe companycontinuestobelievethatithasstronglegalgroundsfortheappealofthisverdictaswellasotherverdictsithas appealednotwithstandingthecompanysconfidenceinthesafetyofitstalcproductsincertaincircumstancesthe companyhasandmaysettlecasesthecompanyhasestablishedanaccrualfordefensecostsandreservesfor settlementofcertaincasesandclaimsaswellasonecasecurrentlyonappealinconnectionwithproductliability litigationassociatedwithbodypowderscontainingtalc theprincipalconsiderationsforourdeterminationthatperformingproceduresrelatingtothetalclitigationisacriticalaudit matterarethesignificantjudgmentbymanagementwhenassessingthelikelihoodofalossbeingincurredandwhen determiningwhetherareasonableestimateofthelossorrangeoflossforeachclaimcanbemadewhichinturnledtoa highdegreeofauditorjudgmentsubjectivityandeffortinperformingproceduresandevaluatingmanagement assessmentofthelosscontingenciesassociatedwiththislitigation addressingthematterinvolvedperformingproceduresandevaluatingauditevidenceinconnectionwithformingour overallopinionontheconsolidatedfinancialstatementstheseproceduresincludedtestingtheeffectivenessofcontrol relatingtomanagementsevaluationofthetalclitigationincludingcontrolsoverdeterminingwhetheralossisprobable andwhethertheamountoflosscanbereasonablyestimatedaswellasfinancialstatementdisclosuresthese proceduresalsoincludedamongothersigaininganunderstandingofthecompanysprocessaroundtheaccounting andreportingforthetalclitigationiidiscussingthestatusofsignificantknownactualandpotentiallitigationwiththe companysinhouselegalcounselaswellasexternalcounselwhendeemednecessaryiiiobtainingandevaluatingthe lettersofauditinquirywithinternalandexternallegalcounselforsignificantlitigationivevaluatingthereasonablenessof managementsassessmentregardingwhetheranunfavorableoutcomeisreasonablypossibleorprobableandreasonably estimableandvevaluatingthesufficiencyofthecompanyslitigationcontingenciesdisclosure litigationopioids asdescribedinnotesandtotheconsolidatedfinancialstatementsthecompanyrecordsaccrualsforloss contingenciesassociatedwithlegalmattersincludingopioidswhenitisprobablethataliabilitywillbeincurredandthe amountofthelosscanbereasonablyestimatedtotheextentadverseverdictshavebeenrenderedagainstthecompany managementdoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimatedfor thesemattersmanagementisunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccrue amountsaccruedforlegalcontingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsand uncertaintiesthatrelyheavilyonestimatesandassumptionsincludingtimingofrelatedpaymentstheabilitytomakesuch estimatesandjudgmentscanbeaffectedbyvariousfactorsincludingamongotherthingswhetherdamagessoughtin theproceedingsareunsubstantiatedorindeterminatematterspresentlegaluncertaintiestherearesignificantfactsin disputeproceduralorjurisdictionalissuestheuncertaintyandunpredictabilityofthenumberofpotentialclaimsabilityto achievecomprehensivemultipartysettlementscomplexityofrelatedcrossclaimsandcounterclaimsandorthereare numerouspartiesinvolvedthecompanyhasbeennamedinnumerouslawsuitsbroughtbycertainstateandlocal governmentsrelatedtoopioidsmattersthetrialinthematterfiledbytheoklahomaattorneygeneralresultedina judgmentagainstthecompanyintheamountofmillionwhichwassubsequentlyreducedtomillionthe companyhasappealedthejudgmentandasdescribedbymanagementbelievesthatithasstronggroundstooverturn thisjudgmentseparatelyinoctoberthecompanyannouncedaproposedagreementinprinciplethatwould includethecompanypayingbillionassettlementofthelawsuitsinoctoberthecompanyagreedtocontribute uptoanadditionalbilliontoanallinsettlementamountthatwouldresolveopioidlawsuitsfiledandfutureclaimsby statescitiescountiesandtribalgovernmentsforatotalofbillionwhichhasbeenaccruedsubjecttovarious conditionsandanagreementbeingfinalizedasdescribedbymanagementthisagreementinprincipleisnotanadmission ofliabilityorwrongdoingandwouldresolveopioidlawsuitsfiledandfutureclaimsbystatescitiesandcountie theprincipalconsiderationsforourdeterminationthatperformingproceduresrelatingtotheopioidslitigationisacritical auditmatterarethesignificantjudgmentbymanagementwhenassessingthelikelihoodofalossbeingincurredforthe judgmentagainstthecompanyinoklahomaandwhendeterminingwhetherareasonableestimateoftherangeoflossfor johnsonjohnsonannualreport theproposedagreementinprincipletosettleopioidslitigationcanbemadewhichinturnledtoahighdegreeofauditor judgmentsubjectivityandeffortinperformingproceduresandevaluatingmanagementsassessmentoftheloss contingenciesassociatedwiththislitigation addressingthematterinvolvedperformingproceduresandevaluatingauditevidenceinconnectionwithformingour overallopinionontheconsolidatedfinancialstatementstheseproceduresincludedtestingtheeffectivenessofcontrols relatingtomanagementsevaluationoftheopioidlitigationincludingcontrolsoverdeterminingwhetheralossisprobable andwhethertheamountoflosscanbereasonablyestimatedaswellasfinancialstatementdisclosuresthese proceduresalsoincludedamongothersigaininganunderstandingofthecompanysprocessaroundtheaccounting andreportingfortheopioidslitigationiidiscussingthestatusofsignificantknownactualandpotentiallitigationand ongoingsettlementnegotiationswiththecompanysinhouselegalcounselaswellasexternalcounselwhendeeme necessaryiiiobtainingandevaluatingthelettersofauditinquirywithinternalandexternallegalcounselforsignificant litigationivevaluatingthereasonablenessofmanagementsassessmentregardingwhetheranunfavorableoutcomeis reasonablypossibleorprobableandreasonablyestimableandvevaluatingthesufficiencyofthecompanyslitigation contingenciesdisclosure spricewaterhousecoopersllp florhamparknewjersey february wehaveservedasthecompanysauditorsinceatleastwehavenotbeenabletodeterminethespecificyearwe beganservingasauditorofthecompany johnsonjohnsonannualreportmanagement report internal control financial reporting undersectionofthesarbanesoxleyactofmanagementisrequiredtoassesstheeffectivenessofthe companysinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreportbasedonthatassessment whetherthecompanysinternalcontroloverfinancialreportingiseffective managementofthecompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial reportingthecompanysinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe reliabilityofthecompanysfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith generallyacceptedaccountingprinciple internalcontrolsoverfinancialreportingnomatterhowwelldesignedhaveinherentlimitationsthereforeinternalcontrol overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial statementpreparationandmaynotpreventordetectallmisstatementsmoreoverprojectionsofanyevaluationof effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin conditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate thecompanysmanagementhasassessedtheeffectivenessofthecompanysinternalcontroloverfinancialreportingas ofjanuaryinmakingthisassessmentthecompanyusedthecriteriaestablishedbythecommitteeof sponsoringorganizationsofthetreadwaycommissioncosoininternalcontrolintegratedframework thesecriteriaareintheareasofcontrolenvironmentriskassessmentcontrolactivitiesinformationandcommunication andmonitoringthecompanysassessmentincludedextensivedocumentingevaluatingandtestingthedesignand operatingeffectivenessofitsinternalcontrolsoverfinancialreporting basedonthecompanysprocessesandassessmentasdescribedabovemanagementhasconcludedthatasof januarythecompanysinternalcontroloverfinancialreportingwaseffective theeffectivenessofthecompanysinternalcontroloverfinancialreportingasofjanuaryhasbeenauditedby pricewaterhousecoopersllpanindependentregisteredpublicaccountingfirmasstatedintheirreportwhichappear salexgorsky sjosephjwolk alexgorsky josephjwolk chairmanboardofdirector executivevicepresident chiefexecutiveofficer chieffinancialofficer johnsonjohnsonannualreport shareholder return performance graph setforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnonthecompanyscommonstockfor periodsoffiveyearsandtenyearsendingjanuaryagainstthecumulativetotalreturnofthestandardpoor stockindexthestandardpoorspharmaceuticalindexandthestandardpoorshealthcareequipmentindex thegraphsandtablesassumethatwasinvestedondecemberanddecemberineachofthe companyscommonstockthestandardpoorsstockindexthestandardpoorspharmaceuticalindexandthe standardpoorshealthcareequipmentindexandthatalldividendswerereinvested yearshareholderreturn performancejjvsindice johnson johnson index pharmaceucidcal index healthcare equipment index year cagr pharm equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex yearshareholderreturn performancejjvsindice johnson johnson index pharmaceucidcal index healthcare equipment index year cagr pharm equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex johnsonjohnsonannualreportitem change disagreement accountant account financial disclosure notapplicable item control procedure disclosurecontrolsandproceduresattheendoftheperiodcoveredbythisreportthecompanyevaluatedthe effectivenessofthedesignandoperationofitsdisclosurecontrolsandproceduresthecompanysdisclosurecontrols andproceduresaredesignedtoensurethatinformationrequiredtobedisclosedbythecompanyinthereportsthatit filesorsubmitsundertheexchangeactisrecordedprocessedsummarizedandreportedwithinthetimeperiods specifiedinthesecsrulesandformsdisclosurecontrolsandproceduresincludewithoutlimitationcontrolsand proceduresdesignedtoensurethatinformationrequiredtobedisclosedbythecompanyinthereportsthatitfilesor submitsundertheexchangeactisaccumulatedandcommunicatedtothecompanysmanagementincludingitsprincipal executiveandprincipalfinancialofficersorpersonsperformingsimilarfunctionsasappropriatetoallowtimelydecision regardingrequireddisclosurealexgorskychairmanandchiefexecutiveofficerandjosephjwolkexecutivevice presidentchieffinancialofficerreviewedandparticipatedinthisevaluationbasedonthisevaluationmessrsgorsky andwolkconcludedthatasoftheendoftheperiodcoveredbythisreportthecompanysdisclosurecontrolsand procedureswereeffective reportsoninternalcontroloverfinancialreportingtheinformationcalledforbythisitemisincorporatedhereinby referencetomanagementsreportoninternalcontroloverfinancialreportingandtheattestationregardinginternal controlsoverfinancialreportingincludedinthereportofindependentregisteredpublicaccountingfirmincludedin itemofthisreport changesininternalcontroloverfinancialreportingduringthefiscalquarterendedjanuarytherewereno changesinthecompanysinternalcontroloverfinancialreportingidentifiedinconnectionwiththeevaluationrequire underrulesaanddundertheexchangeactthathavemateriallyaffectedorarereasonablylikelyto materiallyaffectthecompanysinternalcontroloverfinancialreportingthecompanyhasnotexperiencedanymaterial impacttoitsinternalcontrolsoverfinancialreportingdespitethefactthatmostofitsemployeesareworkingremotelydue tothecovidpandemicthecompanyproactivelytookactionstoreevaluateandrefineitsfinancialreportingprocess throughadditionalmonitoringcontrolstoprovidereasonableassurancethatthefinancialresultsarereportedaccurately andtimelythecompanycontinuestomonitorandassesstheeffectivenessofthedesignandoperationofitsdisclosure controlsandprocedure thecompanyisimplementingamultiyearenterprisewideinitiativetointegratesimplifyandstandardizeprocessesand systemsforthehumanresourcesinformationtechnologyprocurementsupplychainandfinancefunctionstheseare enhancementstosupportthegrowthofthecompanysfinancialsharedservicecapabilitiesandstandardizefinancial systemsthisinitiativeisnotinresponsetoanyidentifieddeficiencyorweaknessinthecompanysinternalcontrolover financialreportinginresponsetothisinitiativethecompanyhasandwillcontinuetoalignandstreamlinethedesignand operationofitsfinancialcontrolenvironment item information notapplicable johnsonjohnsonannualreport iii item director executive officer corporate governance theinformationcalledforbythisitemisincorporatedhereinbyreferencetothediscussionoftheauditcommitteeunder thecaptionitemelectionofdirectorsboardcommitteesandthematerialunderthecaptionsitemelectionof directorsandifapplicablestockownershipandsectioncompliancedelinquentsectionareportsinthe proxystatementandthematerialunderthecaptionexecutiveofficersoftheregistrantinpartiofthisreport thecompanyscodeofbusinessconductwhichcoversallemployeesincludingthechiefexecutiveofficerchief financialofficerandcontrollermeetstherequirementsofthesecrulespromulgatedundersectionofthe sarbanesoxleyactofthecodeofbusinessconductisavailableonthecompanyswebsiteatwwwjnjcom codeofbusinessconductandcopiesareavailabletoshareholderswithoutchargeuponwrittenrequesttothesecretary atthecompanysprincipalexecutiveofficesanysubstantiveamendmenttothecodeofbusinessconductoranywaiver ofthecodegrantedtothechiefexecutiveofficerthechieffinancialofficerorthecontrollerwillbepostedonthe companyswebsiteatwwwinvestorjnjcomgovcfmwithinfivebusinessdaysandretainedonthewebsiteforatleastone year inadditionthecompanyhasadoptedacodeofbusinessconductethicsformembersoftheboardofdirectorsand executiveofficersthecodeofbusinessconductethicsformembersoftheboardofdirectorsandexecutiveofficer isavailableonthecompanyswebsiteatwwwinvestorjnjcomgovboardconductcfmandcopiesareavailableto shareholderswithoutchargeuponwrittenrequesttothesecretaryatthecompanysprincipalexecutiveofficesany substantiveamendmenttothecodeoranywaiverofthecodegrantedtoanymemberoftheboardofdirectorsorany executiveofficerwillbepostedonthecompanyswebsiteatwwwinvestorjnjcomgovcfmwithinfivebusinessdaysand retainedonthewebsiteforatleastoneyear item executive compensation theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionsitem electionofdirectorsdirectorcompensationanditemcompensationcommitteereportcompensation discussionandanalysisandexecutivecompensationtablesintheproxystatement thematerialincorporatedhereinbyreferencetothematerialunderthecaptioncompensationcommitteereportinthe proxystatementshallbedeemedfurnishedandnotfiledinthisreportandshallnotbedeemedincorporatedby referenceintoanyfilingunderthesecuritiesactofasamendedorthesecuritiesexchangeactofas amendedasaresultofthisfurnishingexcepttotheextentthatthecompanyspecificallyincorporatesitbyreference item security ownership certain beneficial owner management relate stockholder matter theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionitemstock ownershipandsectioncomplianceintheproxystatementandnotecommonstockstockoptionplansand stockcompensationagreementsofthenotestoconsolidatedfinancialstatementsinitemofthisreport johnsonjohnsonannualreportequity compensation plan information thefollowingtableprovidescertaininformationasofjanuaryconcerningthesharesofthecompanyscommon stockthatmaybeissuedunderexistingequitycompensationplans numberof securitiesto beissuedupon weightedaverage numberofsecuritie exerciseof exercisepriceof remainingavailablefor outstanding outstanding futureissuanceunderequity plancategory optionsandright optionsandright compensationplan equitycompensationplansapprovedbysecurity holder equitycompensationplansnotapprovedbysecurity holder total includedinthiscategoryarethefollowingequitycompensationplanswhichhavebeenapprovedbythecompanysshareholder longtermincentiveplanandlongtermincentiveplan thiscolumnexcludessharesreflectedunderthecolumnnumberofsecuritiestobeissueduponexerciseofoutstandingoption andright thelongtermincentiveplanexpiredaprilalloptionsandrestrictedsharesgrantedsubsequenttothatdatewere underthelongtermincentiveplan item certain relationship relate transaction director independence theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionsitem electionofdirectorsdirectorindependenceandrelatedpersontransactionsintheproxystatement item principal accountant fee service theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionitem ratificationofappointmentofindependentregisteredpublicaccountingfirmintheproxystatement johnsonjohnsonannualreport item exhibit financial statement schedule thefollowingdocumentsarefiledaspartofthisreport financialstatement consolidatedbalancesheetsatendoffiscalyearsand consolidatedstatementsofearningsforfiscalyearsand consolidatedstatementsofcomprehensiveincomeforfiscalyearsand consolidatedstatementsofequityforfiscalyearsand consolidatedstatementsofcashflowsforfiscalyearsand notestoconsolidatedfinancialstatement reportofindependentregisteredpublicaccountingfirm allschedulesareomittedbecausetheyarenotapplicableortherequiredinformationisincludedinthefinancial statementsornote exhibitsrequiredtobefiledbyitemlofregulationsk theinformationcalledforbythisitemisincorporatedhereinbyreferencetotheexhibitindexinthisreport item summary registrantsmayvoluntarilyincludeasummaryofinformationrequiredbyformkunderthisitemthecompanyha electednottoincludesuchsummaryinformation johnsonjohnsonannualreportsignature pursuanttotherequirementsofsectionofthesecuritiesexchangeactoftheregistranthasdulycausedthis reporttobesignedonitsbehalfbytheundersignedthereuntodulyauthorized datefebruary johnsonjohnson registrant sagorsky agorskychairmanboardofdirector andchiefexecutiveofficer pursuanttotherequirementsofthesecuritiesexchangeactofthisreporthasbeensignedbelowbythefollowe personsonbehalfoftheregistrantandinthecapacitiesandonthedatesindicate signature title date sagorsky chairmanboardofdirector february agorsky chiefexecutiveofficer principalexecutiveofficer sjjwolk chieffinancialofficer february jjwolk principalfinancialofficer srjdeckerjr controllerandchiefaccountingofficer february rjdeckerjr principalaccountingofficer smcbeckerle director february mcbeckerle sdsdavis director february dsdavis sieldavis director february ieldavis sjadoudna director february jadoudna smahewson director february mahewson shjoly director february hjoly smbmcclellan director february mbmcclellan sammulcahy director february ammulcahy johnsonjohnsonannualreport signature title date scprince director february cprince saewashington director february aewashington smaweinberger director february maweinberger snywest director february nywest srawilliams director february rawilliams johnsonjohnsonannualreportexhibit index regsk exhibittable itemno descriptionofexhibit restatedcertificateofincorporationeffectivefebruaryincorporatedhereinbyreferencetoexhibitiofthe registrantsformkannualreportforthefiscalyearendedjanuary certificateofamendmenttothecertificateofincorporationofjohnsonjohnsoneffectiveaprilincorporatedherein byreferencetoexhibitoftheregistrantsformkcurrentreportfiledapril iii bylawsofthecompanyasamendedeffectivejuneincorporatedhereinbyreferencetoexhibitofthe registrantsformkcurrentreportfiledjune upontherequestofthesecuritiesandexchangecommissiontheregistrantwillfurnishacopyofallinstrumentsdefiningthe rightsofholdersoflongtermdebtoftheregistrant descriptionofsecuritiesregisteredpursuanttosectionofthesecuritiesexchangeactofincorporatedhereinby referencetoexhibitoftheregistrantsformkcurrentreportfiledaugust longtermincentiveplanincorporatedhereinbyreferencetoexhibitoftheregistrantssregistrationstatement filedonmayfileno formofstockoptioncertificateunderthelongtermincentiveplanincorporatedhereinbyreferencetoexhibitof theregistrantsformkcurrentreportfiledjanuary longtermincentiveplanincorporatedhereinbyreferencetoappendixaoftheregistrantsproxystatementfiledon march formofstockoptioncertificaterestrictedshareunitcertificateandperformanceshareunitcertificateunderthe longtermincentiveplanincorporatedhereinbyreferencetoexhibitsandoftheregistrantsformq quarterlyreportforthequarterendedapril globalnonqualifiedstockoptionawardagreementglobalrestrictedshareunitawardagreementandglobalperformance shareunitawardagreementunderthelongtermincentiveplanincorporatedhereinbyreferencetoexhibits andoftheregistrantsformqquarterlyreportforthequarterendedapril johnsonjohnsonexecutiveincentiveplanamendedasofnovemberincorporatedhereinbyreferencetoexhibit aoftheregistrantsformqquarterlyreportforthequarterendedmarch domesticdeferredcompensationcertificateofextracompensationplanincorporatedhereinbyreferencetoexhibitg oftheregistrantsformkannualreportfortheyearendeddecember amendmentstothecertificateofextracompensationplaneffectiveasofjanuaryincorporatedhereinbyreferenceto exhibitjoftheregistrantsformkannualreportfortheyearendeddecember certificatesoflongtermperformanceplanincorporatedhereinbyreferencetoexhibitoftheregistrantsform qquarterlyreportforthequarterendedseptember amendedandrestateddeferredfeeplanfordirectorsamendedasofjanuaryincorporatedhereinbyreference toexhibitkoftheregistrantsformkannualreportforthefiscalyearendedjanuary thejohnsonjohnsonexecutiveincomedeferralplanamendedandrestatedeffectivejanuaryincorporatedherein byreferencetoexhibitoftheregistrantsformqquarterlyreportforthequarterendedseptember excesssavingsplaneffectiveasofjanuaryincorporatedhereinbyreferencetoexhibitjoftheregistrant formkannualreportforthefiscalyearendeddecember amendmentstothejohnsonjohnsonexcesssavingsplaneffectiveasofjanuaryincorporatedhereinbyreference toexhibitpoftheregistrantsformkannualreportforthefiscalyearendeddecember amendedandrestatedexcessbenefitplanofjohnsonjohnsonandaffiliatedcompaniesamendedandrestatedeffective januaryexceptasotherwiseprovidedfiledwiththisdocument executivelifeplanagreementincorporatedhereinbyreferencetoexhibitioftheregistrantsformkannualreport forthefiscalyearendedjanuary executivelifeplanagreementclosureletterincorporatedhereinbyreferencetoexhibitoftheregistrantsformq quarterlyreportforthequarterendedmarch employmentagreementfordrpaulusstoffelsincorporatedhereinbyreferencetoexhibitoftheregistrantsformq quarterlyreportforthequarterendedseptember johnsonjohnsonannualreport severancepayplanofjohnsonjohnsonandusaffiliatedcompaniesamendedandrestatedasofoctober incorporatedhereinbyreferencetoexhibitoftheregistrantsformqquarterlyreportforthequarterende september firstamendmenttotheseverancepayplanofjohnsonjohnsonandusaffiliatedcompaniesasamendedandrestate effectiveoctoberincorporatedhereinbyreferencetoexhibitoftheregistrantsformqquarterlyreport forthequarterendedjune secondamendmenttotheseverancepayplanofjohnsonjohnsonandusaffiliatedcompaniesasamendedandrestate effectiveoctoberincorporatedhereinbyreferencetoexhibitxoftheregistrantsformkannualreportfor thefiscalyearendedjanuary subsidiariesfiledwiththisdocument consentofindependentregisteredpublicaccountingfirmfiledwiththisdocument certificationofchiefexecutiveofficerpursuanttosectionofthesarbanesoxleyactfiledwiththisdocument certificationofchieffinancialofficerpursuanttosectionofthesarbanesoxleyactfiledwiththisdocument certificationofchiefexecutiveofficerpursuanttosectionofthesarbanesoxleyactfurnishedwiththisdocument certificationofchieffinancialofficerpursuanttosectionofthesarbanesoxleyactfurnishedwiththisdocument exhibit exin instancedocumenttheinstancedocumentdoesnotappearintheinteractivedatafilebecauseitsxbrltagsareembedde withintheinlinexbrldocument exsch inlinexbrltaxonomyextensionschema excal inlinexbrltaxonomyextensioncalculationlinkbase exlab inlinexbrltaxonomyextensionlabellinkbase expre inlinexbrltaxonomyextensionpresentationlinkbase exdef inlinexbrltaxonomyextensiondefinitiondocument exhibit coverpageinteractivedatafilethecoverpageinteractivedatafiledoesnotappearintheinteractivedatafilebecauseit xbrltagsareembeddedwithintheinlinexbrldocument managementcontractorcompensatoryplan paperfiling acopyofanyoftheexhibitslistedabovewillbeprovidedwithoutchargetoanyshareholdersubmittingawrittenrequ specifyingthedesiredexhibitstothesecretaryattheprincipalexecutiveofficesofthecompanypursuanttoitem biiiaofregulationskthecompanyhasnotfiledasexhibitstothisformkcertainlongtermdebt instrumentsincludingindenturesunderwhichthetotalamountofsecuritiesauthorizeddoesnotexceedofthetotal assetsofthecompanyanditssubsidiariesonaconsolidatedbasisthecompanyherebyagreestofurnishacopyofany suchinstrumenttothesecuponrequ thefollowingexhibitsindicatedasbeingfiledwiththisdocumentareomittedfromtheprintedversionofthis annualreport exhibitn exhibit exhibit johnsonjohnsonannualreportexhibit certificationofchiefexecutiveofficer pursuanttosectionofthesarbanesoxleyact ialexgorskycertifythat ihavereviewedthisannualreportonformkforthefiscalyearendedjanuarythereportof johnsonjohnsonthecompany basedonmyknowledgethisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea materialfactnecessarytomakethestatementsmadeinlightofthecircumstancesunderwhichsuchstatementswere madenotmisleadingwithrespecttotheperiodcoveredbythisreport basedonmyknowledgethefinancialstatementsandotherfinancialinformationincludedinthisreportfairly presentinallmaterialrespectsthefinancialconditionresultsofoperationsandcashflowsofthecompanyasofand fortheperiodspresentedinthisreport thecompanysothercertifyingofficersandiareresponsibleforestablishingandmaintainingdisclosurecontrol andproceduresasdefinedinexchangeactrulesaeanddeandinternalcontroloverfinancial reportingasdefinedinexchangeactrulesafanddfforthecompanyandhave adesignedsuchdisclosurecontrolsandproceduresorcausedsuchdisclosurecontrolsandprocedure tobedesignedunderoursupervisiontoensurethatmaterialinformationrelatingtothecompanyincludingit consolidatedsubsidiariesismadeknowntousbyotherswithinthoseentitiesparticularlyduringtheperiodin whichthisreportisbeingprepare bdesignedsuchinternalcontroloverfinancialreportingorcausedsuchinternalcontroloverfinancial reportingtobedesignedunderoursupervisiontoprovidereasonableassuranceregardingthereliabilityof financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally acceptedaccountingprinciple cevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresandpresentedinthis reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandproceduresasoftheendofthe periodcoveredbythisreportbasedonsuchevaluationand ddisclosedinthisreportanychangeinthecompanysinternalcontroloverfinancialreportingthat occurredduringthecompanysmostrecentfiscalquarterthecompanysfourthfiscalquarterinthecaseofan annualreportthathasmateriallyaffectedorisreasonablylikelytomateriallyaffectthecompanysinternalcontrol overfinancialreportingand thecompanysothercertifyingofficersandihavedisclosedbasedonourmostrecentevaluationofinternal controloverfinancialreportingtothecompanysauditorsandtheauditcommitteeofthecompanysboardof directorsorpersonsperformingtheequivalentfunction aallsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover financialreportingwhicharereasonablylikelytoadverselyaffectthecompanysabilitytorecordprocess summarizeandreportfinancialinformationand banyfraudwhetherornotmaterialthatinvolvesmanagementorotheremployeeswhohaveasignificant roleinthecompanysinternalcontroloverfinancialreporte salexgorsky alexgorsky chiefexecutiveofficer datefebruary johnsonjohnsonannualreportexhibit certificationofchieffinancialofficer pursuanttosectionofthesarbanesoxleyact ijosephjwolkcertifythat ihavereviewedthisannualreportonformkforthefiscalyearendedjanuarythereportof johnsonjohnsonthecompany basedonmyknowledgethisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea materialfactnecessarytomakethestatementsmadeinlightofthecircumstancesunderwhichsuchstatementswere madenotmisleadingwithrespecttotheperiodcoveredbythisreport basedonmyknowledgethefinancialstatementsandotherfinancialinformationincludedinthisreportfairly presentinallmaterialrespectsthefinancialconditionresultsofoperationsandcashflowsofthecompanyasofand fortheperiodspresentedinthisreport thecompanysothercertifyingofficersandiareresponsibleforestablishingandmaintainingdisclosurecontrol andproceduresasdefinedinexchangeactrulesaeanddeandinternalcontroloverfinancial reportingasdefinedinexchangeactrulesafanddfforthecompanyandhave adesignedsuchdisclosurecontrolsandproceduresorcausedsuchdisclosurecontrolsandprocedure tobedesignedunderoursupervisiontoensurethatmaterialinformationrelatingtothecompanyincludingit consolidatedsubsidiariesismadeknowntousbyotherswithinthoseentitiesparticularlyduringtheperiodin whichthisreportisbeingprepare bdesignedsuchinternalcontroloverfinancialreportingorcausedsuchinternalcontroloverfinancial reportingtobedesignedunderoursupervisiontoprovidereasonableassuranceregardingthereliabilityof financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally acceptedaccountingprinciple cevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresandpresentedinthis reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandproceduresasoftheendofthe periodcoveredbythisreportbasedonsuchevaluationand ddisclosedinthisreportanychangeinthecompanysinternalcontroloverfinancialreportingthat occurredduringthecompanysmostrecentfiscalquarterthecompanysfourthfiscalquarterinthecaseofan annualreportthathasmateriallyaffectedorisreasonablylikelytomateriallyaffectthecompanysinternalcontrol overfinancialreportingand thecompanysothercertifyingofficersandihavedisclosedbasedonourmostrecentevaluationofinternal controloverfinancialreportingtothecompanysauditorsandtheauditcommitteeofthecompanysboardof directorsorpersonsperformingtheequivalentfunction aallsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover financialreportingwhicharereasonablylikelytoadverselyaffectthecompanysabilitytorecordprocess summarizeandreportfinancialinformationand banyfraudwhetherornotmaterialthatinvolvesmanagementorotheremployeeswhohaveasignificant roleinthecompanysinternalcontroloverfinancialreporte sjosephjwolk josephjwolk chieffinancialofficer datefebruary johnsonjohnsonannualreportexhibit certificationofchiefexecutiveofficer pursuanttosectionofthesarbanesoxleyact theundersignedalexgorskythechiefexecutiveofficerofjohnsonjohnsonanewjerseycorporationthe companypursuanttouscasadoptedpursuanttosectionofthesarbanesoxleyactof herebycertifiesthattothebestofmyknowledge thecompanysannualreportonformkforthefiscalyearendedjanuarythereportfully complieswiththerequirementsofsectionaofthesecuritiesexchangeactofand theinformationcontainedinthereportfairlypresentsinallmaterialrespectsthefinancialconditionand resultsofoperationsofthecompany salexgorsky alexgorsky chiefexecutiveofficer datedfebruary thiscertificationisbeingfurnishedtothesecwiththisreportonformkpursuanttosectionofthe sarbanesoxleyactofandshallnotexcepttotheextentrequiredbysuchactbedeemedfiledbythecompany forpurposesofsectionofthesecuritiesexchangeactofasamendedorotherwisesubjecttotheliabilityof thatsection johnsonjohnsonannualreportexhibit certificationofchieffinancialofficer pursuanttosectionofthesarbanesoxleyact theundersignedjosephjwolkthechieffinancialofficerofjohnsonjohnsonanewjerseycorporationthe companypursuanttouscasadoptedpursuanttosectionofthesarbanesoxleyactof herebycertifiesthattothebestofmyknowledge thecompanysannualreportonformkforthefiscalyearendedjanuarythereportfully complieswiththerequirementsofsectionaofthesecuritiesexchangeactofand theinformationcontainedinthereportfairlypresentsinallmaterialrespectsthefinancialconditionand resultsofoperationsofthecompany sjosephjwolk josephjwolk chieffinancialofficer datedfebruary thiscertificationisbeingfurnishedtothesecwiththisreportonformkpursuanttosectionofthe sarbanesoxleyactofandshallnotexcepttotheextentrequiredbysuchactbedeemedfiledbythecompany forpurposesofsectionofthesecuritiesexchangeactofasamendedorotherwisesubjecttotheliabilityof thatsection johnsonjohnsonannualreportthispageintentionallyleftblankthispageintentionallyleftblankthispageintentionallyleftblankboard director senior management alexgorsky chairmanboardofdirector alexgorsky chiefexecutiveofficer marycbeckerle chairmanexecutivecommittee chiefexecutiveofficerhuntsmancancerinstitute attheuniversityofutah joaquinduato distinguishedprofessorofbiology vicechairmanexecutivecommittee collegeofscienceuniversityofutah paulusstoffel dscottdavis vicechairmanexecutivecommitteechiefscientificofficer formerchairmanandchiefexecutiveofficer unitedparcelserviceinc robertjdeckerjr ianeldavis corporatecontrollerchiefaccountingofficer nonexecutivechairmanrollsroyceholdingsplc petermfasolo formerchairmanandworldwidemanagingdirector executivevicepresidentchiefhumanresourcesofficer mckinseycompany jenniferadoudna ashleymcevoy professorofchemistryprofessorofbiochemistry executivevicepresidentworldwidechairman molecularbiology medicaldevice likashingchancellorsprofessorinbiomedical andhealthuniversityofcaliforniaberkeley thibautmongon executivevicepresidentworldwidechairman marillynahewson consumerhealth executivechairmanformerchairmanandchief executiveofficer mattheworlando lockheedmartincorporation corporatesecretary worldwidevicepresidentcorporategovernance hubertjoly formerchairmanandchiefexecutiveofficerb michellerryan buycoinc treasurer markbmcclellan directordukerobertjmargolismd michaelesneed centerforhealthpolicydukeuniversity executivevicepresidentglobalcorporateaffair chiefcommunicationsofficer annemmulcahy formerchairmanandchiefexecutiveofficer jennifertaubert xeroxcorporation executivevicepresidentworldwidechairman pharmaceutical charlesprince formerchairmanandchiefexecutiveofficer michaelhullmann citigroupinc executivevicepresidentgeneralcounsel aeugenewashington dukeuniversityschancellorforhealthaffair kathrynewengel presidentandchiefexecutiveofficer executivevicepresidentchiefglobalsupplychainofficer dukeuniversityhealthsystem josephjwolk markaweinberger executivevicepresidentchieffinancialofficer formerchairmanandchiefexecutiveofficerey memberexecutivecommittee nadjaywest formerlieutenantgeneralusarmy ronaldawilliams formerchairmanandchiefexecutiveofficer aetnainc johnsonjohnsonannualreportprincipaloffice stockliste johnsonjohnsononline onejohnsonjohnsonplaza johnsonjohnsoncommonstock newbrunswicknewjersey listedonnewyorkstockexchange ourwebsitewwwjnjcom stocksymboljnj httpwwwjnjcommediacenter annualmeetingofshareholder shareholderrelationscontact thursdayapril mattheworlando corporatesecretary wwwfacebookcomjnj ameastern meetingwillbeheldvirtuallyat wwwtwittercomjnjnews wwwvirtualshareholdermeetingcomjnj investorrelationscontact wwwyoutubecomjnj allshareholdersasoftherecorddateof christopherdelorefice februaryareinvitedtoattend vicepresidentinvestorrelation httpwwwlinkedincomcompany aformalnoticeofannualmeetingand johnsonjohnson proxystatementandproxycardhavebeen madeavailabletoshareholder investorrelationswebsite wwwinvestorjnjcom thejohnsonjohnsonyearin annualreportonformkand proxystatement stocktransferagentandregistrar reviewisavailableonourwebsiteat johnsonjohnsonsannualreportonformk questionsregardingstockholding httpswwwjnjcomyearinreview forthefiscalyearendedjanuaryis certificatereplacementtransferdividend theinformationonthesewebsitesshould includedinthisannualreportinitsentiretywith andaddresschangesshouldbedirectedto notbedeemedtobepartofthisannual theexceptionofcertainexhibitstheformk ourstocktransferagentandregistrarat report completewithallofitsexhibitsisavailableonour computersharetrustcompanyna websiteatwwwinvestorjnjcomseccfmandthe pobox secswebsiteatwwwsecgov louisvilleky shareholdersmayalsoobtaincopiesofthe overnightmail computersharetrustcompanyna exhibitsourannualreporton souththstreetsuite formkandourproxystatement louisvilleky withoutchargeuponwrittenrequesttothe officeofthecorporatesecretaryatour principalofficeaddressorbycalle shareholderwebsite wwwcomputersharecominvestor electronicdeliverynotification dividendreinvestmentplan theproxystatementandourannual theplanallowsforfullorpartialdividend reportareavailableonourwebsiteat reinvestmentandadditionalweeklycash wwwinvestorjnjcomgov investmentsuptoperyearin annualmeetingmaterialscfmshareholderswho johnsonjohnsoncommonstockwithout receivepapercopiesofourproxystatementand pershareorservicechargesonstock annualreportbymailcanelecttoreceiveinstead purchasesifyouareinterestedin anemailmessagewithalinktothosedocument participatingintheplanandneedan ontheinternetregisteredshareholdersmay enrollmentformandormoreinformation enrollinelectronicdeliveryat pleasecalltheplanadministrator thejohnsonjohnsonannualreport wwwcomputersharenacomgreenbeneficial computersharetrustcompanynaat containsmanyofthevaluabletrademark shareholderswhoholdsharesofjohnson andtradenamesownedandusedbythe johnsoncommonstockthroughabankbrokeror outsidetheusoraccessonlineat johnsonjohnsonfamilyofcompaniesin otherholderofrecordgenerallycanenrollfor wwwcomputersharecominvestor theunitedstatesandinternationallyto electronicdeliveryatenrollicsdeliverycomjnj distinguishproductsandservicesof hearingimpaire outstandingquality shareholderswhohaveinquiriesregarde johnsonjohnson stockrelatedmatterscancommunicate directlywithcomputersharetrustcompany naviaatelecommunicationsdevicetdd thetelephonenumberforthisserviceis outsidetheus